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ABSTRACT OF DISSERTATION

MITOCHONDRIAL TRANSPLANTATION AFTER SPINAL CORD
INJURY: EFFECTS ON TISSUE BIOENERGETICS AND FUNCTIONAL
NEUROPROTECTION
Contusion spinal cord injury (SCI) results in devastating life-long debilitation
in which there are currently no effective treatments. The primary injury site
presents a complex environment marked by subsequent secondary
pathophysiological cascades involving excessive reactive oxygen and nitrogen
species (ROS/RNS) production, glutamate-induced excitotoxicity, calcium
dysregulation, and delayed neuronal apoptosis. Many of these cascades involve
mitochondrial dysfunction, thus a single mitochondrial-centric therapy that targets
a variety of these factors could be far reaching in its potential benefits after SCI.
As such, this dissertation examines whether transplantation of exogenous
mitochondria after SCI can attenuate secondary injury cascades to decrease the
spread and severity of the injury.
Our first experiment tested the dose-dependent effects of mitochondrial
transplantation on the ability to maintain acute overall bioenergetics after SCI. We
compared transplantation of mitochondria originating from two different sourcescultured PC12 cells or rat soleus leg muscle. 24 hours after injury, State III oxygen
consumption rates were maintained to over 80% of sham levels when 100ug of
mitochondria was transplanted, regardless of the origin of the mitochondria.
Complex I enzyme activity assays corroborated our findings that the 100ug dosage
gave optimal benefits compared to vehicle injection.
We also analyzed the rostral-caudal distribution and cell-type colocalization
of transplanted transgenically-labeled tGFP mitochondria after SCI. There were
greater volumes and rostral-caudal spread of tGFP mitochondria at the 24 hour
time point compared to 7 days post injection. tGFP mitochondria had the greatest
propensity to colocalize with macrophages and pericytes. Colocalization was
evident in endothelial cells, oligodendrocytes and astrocytes, though no such colabeling was present in neurons. Further, colocalization of tGFP was always
greater at the 24 hour time compared to 48 hour or 7days post injection time points.
These data indicate that there is a cell-type difference in incorporation potential of
exogenous mitochondria which changes over time.

Finally, we tested the effects of mitochondrial transplantation on long term
functional recovery. Animals were injected with either vehicle, 100ug cell-derived
mitochondria, or 100ug muscle-derived mitochondria immediately after contusion
SCI. Functional analyses including BBB overground locomotor scale and von Frey
mechanical sensitivity tests did not show any differences between treatment
groups. Likewise, there were no differences in tissue sparing when mitochondria
were transplanted compared to vehicle injections, though there were higher
neuronal cell counts in tGFP mitochondria injected groups caudal of the injury site.
These studies present the potential of mitochondrial transplantation for
therapeutic intervention after SCI. While our acute measures do not correspond
into long term recovery, we show that at 24 hours transplanted mitochondria do
have an effect on bioenergetics and that they are taken into host cells. We believe
that further investigation into caveats and technical refinement is necessary at this
time to translate the evident acute bioenergetic recovery into long term functional
recovery.
KEYWORDS: PC-12 mitochondria, central pattern generators, co-localization,
transgenic labeling, oxidative phosphorylation
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CHAPTER 1
INTRODUCTION AND HYPOTHESIS

1. Introduction to Mitochondria
Mitochondria are located in the cell cytoplasm and often referred to as the
powerhouse of the cell, as they produce most of the cell’s energy in the form of
adenosine triphosphate (ATP). However, they are also referred to as the nuclear
power plant of the cell as they can efficiently make ATP while simultaneously
producing a small but manageable amount of destructive oxidative agents known
as reactive oxygen species (ROS). When mitochondria are damaged they can
become extremely reactive and damaging to themselves and surrounding
mitochondria, unleashing numerous pathways that can lead to both apoptosis
and necrosis. Therefore, a delicate balance must be maintained for these
organelles to function at optimal efficiency without devastating consequences.

1.1.1 Mitochondrial DNA
It is theorized that mitochondria were once bacteria that became engulfed
by a cell and utilized for its respiratory capabilities. Evidence of this theory lies in
the fact that mitochondria have two lipid membranes and their own circular
mitochondrial DNA (mtDNA) (Nass & Nass 1963), which allows them to make
their own proteins (Mc et al 1958). As evolution progressed, cells became more
dependent on mitochondria for their energy supply, even integrating the coding
for key mitochondrial proteins within the nuclear DNA. mtDNA only encodes for
13 mitochondrial proteins and needs the cell’s nuclear DNA to provide the rest of
the mitochondrial proteins.
mtDNA replication and transcription occurs in the S and G2 phases of the
cell cycle (Pica-Mattoccia & Attardi 1971, Pica-Mattoccia & Attardi 1972), but
mitochondrial protein synthesis doubles during interphase and remains relatively
constant during the cell cycle (England & Attardi 1974).
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Mitochondria have a distinct DNA polymerase separate from that of nuclear DNA
(Ch'ih & Kalf 1969, Meyer & Simpson 1970). mtDNA lacks exons and histones,
which protect nuclear DNA by creating a tighter structural formation. Because of
this and their proximity to the electron transport chain (ETC) which is prone to
release oxidative molecules, mtDNA undergo mutations at a higher rate than
nuclear DNA (Brown et al 1979).
Mitochondria are inherited maternally (Hutchison et al 1974), meaning that
each offspring will have mtDNA identical to their mother’s with no input from the
father’s mtDNA, making it possible to track familial lineage using the maternal
mitochondria. This also implicates maternal inheritance of mtDNA mutations and
disorders. It has been suggested that there are no recombinant abilities in
mtDNA; when creating mouse x rat somatic cell hybrids and rat cytoplasmic
hybrids, Hayashi et al (1985) found that there was no mtDNA recombination even
when chloramphenicol (CAP) resistant mtDNA was incorporated into a CAPsensitive cell. The cell remained resistant to CAP, but the mtDNA was
unchanged. The group theorized that since mtDNA is inherited completely
maternally, there is no necessity for recombination of mtDNA, and thus it has lost
the ability to do so (Hayashi et al 1985). However, the amount of mutated mtDNA
in an egg can vary, known as heteroplasmy (Lightowlers et al 1997), resulting in
differing phenotypes creating inheritance patterns that may not be obvious.
Interestingly, mitochondrial replacement has been attempted in fertilization
techniques to replace defective mtDNA with healthy mtDNA from a donor (Cohen
et al 1998, Cohen et al 1997). Mouse models demonstrating the synchronous
transfer of cytoplasts from a donor oocyte to a recipient oocyte which led to the
development of a healthy zygote (Levron et al 1996) furthered the research
efforts of human ooplasmic donation. Clinical studies testing injection of a small
portion of cytoplasm which includes mRNA, protein, and mitochondria from a
healthy donor oocyte into a compromised oocyte with subsequent fertilization
and implantation resulted in successful pregnancy (Cohen et al 1998, Cohen et
al 1997). The developing embryo thus contained nuclear DNA from the mother
and father, along with mtDNA from the donor egg. While cytoplasmic transfer
2

therapy resulted in successful births, it was banned in the United States in 2001
for ethical reasons; however the practice is still being performed legally in other
countries (Ishii 2014). A similar therapy aimed at avoiding mtDNA mutation
inheritance by providing three biological parents uses a nuclear transfer
technique- a mother and father providing the nuclear DNA, and a separate donor
for the mtDNA (Reardon 2016). The nucleus is removed from the mother’s egg
(containing unhealthy mitochondria) and implanted into a donor egg (containing
healthy mitochondria) in which the nucleus and genetic material has been
removed. The resulting egg contains donor mitochondria (with mtDNA) and
cytoplasm, and the mother’s nucleus (with nuclear DNA). The egg is then
fertilized with the father’s sperm and an embryo develops with three distinct
genetic parents. This therapy has been shown in non-human primates to
circumvent the genetic inheritance of mitochondrial disease when the mother’s
mitochondria carry DNA mutations (Tachibana et al 2009).

1.1.2 Oxidative Phosphorylation
Mitochondria provide for most of the cell’s energy needs in the form of
ATP (Figure 1.1A-1). In the process of oxidative phosphorylation mitochondria
use substrates produced by the Kreb’s cycle in the mitochondrial matrix, namely
reduced nicotinamide adenine dinucleotide (NADH) and flavin adenine
dinucleotide (FADH), to power the electron transport system (ETS) located in the
inner mitochondrial membrane (IMM). NADH donates an electron to complex I of
ETC, an exchange that results in hydrogen atoms being pumped against a
concentration gradient from the matrix into the intermembrane space. The
electron then passes across the other complexes of the ETC in a series of
oxidation/reduction reactions, each time releasing energy and pumping hydrogen
from the matrix to the intermembrane space (for comprehensive review see
Nicholls & Ferguson 2013). This creates a membrane potential (between 140
and 180 mV) across the inner mitochondrial membrane, which is used by
complex V to form ATP from adenosine diphosphate (ADP) with simultaneous
passage of hydrogen back into the mitochondrial matrix (Reid et al 1966). When
3

the electron reaches complex IV, it is released back into the matrix where it joins
with oxygen. The oxygen is held at complex IV until enough electrons are present
to allow it to form two water molecules. During oxidative phosphorylation, some
ROS are created but are in small amounts that can be counteracted by
endogenous antioxidant mechanisms within the mitochondria (see Cheeseman &
Slater 1993, Droge 2002).

Figure 1.1. Schematic depiction of how mitochondrial transplantation after
injury may promote cell survival. A. During normal cellular function,
mitochondria sequester and store calcium in their matrix and produce ATP (1)
while NMDA receptors remain closed (2). B. After traumatic injury, the cell is
subjected to glutamate excitotoxicity mediated by activated NMDA receptors (3)
which allow massive calcium influx into cells (4) and subsequent uptake into
mitochondria. This causes a loss of membrane potential across the inner
mitochondrial membrane leading to MPTP formation and subsequent swelling of
mitochondria (5). Consequent bursting of the outer mitochondrial membrane then
releases calcium, ROS, and apoptotic factors (6). ROS damages membrane
lipids, mtDNA, electron transport chain proteins, and nuclear DNA (7), which
leads to death of adjacent mitochondria (8). C. After healthy mitochondria,
depicted in green, are transplanted into damaged cells they can increase
antioxidants to combat ROS release (9) and provide new sources of mtDNA (10).
Further, these mitochondria increase ATP production (11) and overall calcium
buffering capacity (12) in the compromised cells.
4

1.1.3 Endogenous Antioxidant Systems
During oxidative phosphorylation, electron flow leads to a small amount of
ROS production, namely in the form of superoxide radicals. Electrons released
from the ETC can reduce oxygen molecules to superoxides (O2-). Manganese
superoxide dismutase (MnSOD) localized within the mitochondria (Weisiger &
Fridovich 1973) can oxidize superoxides into less reactive hydrogen peroxide
(McCord & Fridovich 1969). Hydrogen peroxide, however, can undergo the
Fenton reaction, creating hydroxyl radicals (OH-) that can damage lipids,
proteins, and nucleic acids (Winterbourn 1995). Alternatively, glutathione
peroxidase can convert hydrogen peroxide into water and is present in the
intermembrane space of mitochondria (Arai et al 1999). Damage to mitochondria
can be countered by an increase of the endogenous antioxidant systems
activities. For example, complex I deficiencies increase the expression of
MnSOD which turns superoxide into hydrogen peroxide in cultured fibroblasts
(Pitkanen & Robinson 1996).

1.1.4 Calcium Buffering
The mitochondrial matrix holds a negative charge of around -240mV, (see
Michelakis 2008) allowing the mitochondria to actively sequester positively
charged calcium ions into their matrix (Figure 1.1A-1). This is important as
calcium is involved in various intracellular signaling pathways. Under normal
conditions, concentration of cytoplasmic calcium is 0.1µM and extracellular
calcium concentration is 1mM, favoring calcium movement into the cytoplasm
(see Bianchi et al 2004). The IMM has a potential of -180mV, favoring calcium
influx into the matrix through the calcium uniporter (Bygrave & Ash 1977), with
equilibrium being reached when the calcium concentration within the
mitochondrial matrix reaches 106 higher than the cytosol (Bianchi et al 2004).
Once inside the matrix, energy is required to export calcium back out of the
matrix to overcome the electrochemical force driving calcium influx. It is found
that the energy released from ATP hydrolysis (34.1kJ/mol) is sufficient to allow
movement of 1 mol of calcium (33kJ) across the inner mitochondrial membrane
5

and into the intermembrane space (Bianchi et al 2004). Importantly, calcium is
required for the activation of different metabolic enzymes such as pyruvate
dehydrogenase, α-ketoglutaratedehydrogenase, and isocitrate dehydrogenase.
Calcium influx into the mitochondrial matrix leads to increased metabolism
through interaction with these metabolic enzymes, increasing ATP production for
the cell (Jouaville et al 1999).

1.1.5 Mitochondrial Fusion and Fission
It is not uncommon to see mitochondria depicted in textbooks as small,
bean-shaped organelles. To the contrary, mitochondrion are very dynamic
organelles that constantly undergo fusion and fission, creating an ever-changing
network contained within the cytoplasm. In healthy cells, these fusion/fission
events are well-balanced for the turnover of mitochondria and serves multiple
purposes pertaining to the health of both the mitochondria and the cell. Fusion
can allow for segregation of damaged areas of the mitochondria with subsequent
fission and mitophagy (a mitochondrial specific form of autophagy) of this
section, serving to maintain a healthy membrane potential of the remaining
mitochondria (Twig et al 2008a). This group also found that loss of membrane
potential decreased the probability for the mitochondrion to undergo fusion,
which could be a protective mechanism keeping damaged mitochondria from
joining and affecting the mitochondrial network. Depolarized mitochondria are
then targeted for autophagy (Priault et al 2005). Mitochondria will undergo
increased levels of fission before apoptosis (Suen et al 2008). Stressed or
starved mitochondria can undergo a process known as hyperfusion, in which the
mitochondria produce higher amounts of ATP (Tondera et al 2009). Fused
mitochondria can share their components such as metabolites, proteins and
mtDNA, known as complementation (Arimura et al 2004, Chen et al 2005).
Fusion of mitochondria containing mutated mtDNA with mitochondria containing
healthy mtDNA could allow a cell to overcome the effects of having mutant
mtDNA (Nakada et al 2001). Each of these mechanisms is adapted for
maintaining the healthiest possible mitochondrial network for the cell.
6

1.1.6 Mitochondria Act as a Death Switch
Cell death is a physiologically important and normal occurrence that is
used to keep an organism in homeostasis. Without cell death, there would be no
opportunities for newer, healthier cells to take over vital functions of the tissue.
However, excessive cell death can be detrimental. An early feature of cellular
apoptosis is disruption of the ETS. Mitochondrial function is necessary for cells to
undergo apoptosis, as this form of controlled cellular death requires energy (see
Kroemer et al 1998). Cytochrome c, a protein in the electron transport chain, can
act as a signal for apoptosis; when released into the cytosol it can bind to
activating factor-1 causing formation of an apoptosome complex that then
activates caspases necessary to signal the induction of apoptosis (see Riedl &
Salvesen 2007). A consequence of damaged ETS is a drop in ATP production; in
cases of extreme ATP depletion the cell undergoes necrosis which is typically
detrimental to nearby cells (Ankarcrona et al 1995, Eguchi et al 1997). Acute
insult in vitro using high concentrations of N-methyl-D-aspartate (NMDA) or free
radicals result in necrosis, but the apoptotic pathway is favored when less
concentrated NMDA and free radicals are present. Further, NMDA-induced cell
death can be prevented with the use of NMDA receptor antagonists, but not
when free radicals are simultaneously present (Bonfoco et al 1995).

1.1.7 Mitochondrial Dysfunction
There is an important stability necessary for mitochondria to optimally
carry out their biological functions essential to cell survival. Damage to
mitochondria can be exponentially devastating as they not only fail to provide
these vital biological functions, but they can be extremely hazardous and
damaging to nearby mitochondria and cells. Mitochondrial dysfunction is
implicated in many disease states such as Parkinson’s Disease (Mizuno et al
1989, Winklhofer & Haass 2010), Alzheimer’s Disease (Swerdlow & Khan 2004),
muscular dystrophy (Onopiuk et al 2009), macular degeneration (Burdon 1995),
and ageing-related neurodegeneration (Lin & Beal 2006). Importantly,
mitochondria dysfunction is also involved in pathologies seen after many
7

traumatic insults including cardiac infarctions (Braunwald & Kloner 1985, Ide et al
2001), stroke (Bolanos et al 2009, Krajewski et al 1999, Sims & Muyderman
2010), traumatic brain injury (Aygok et al 2008, Singh et al 2006, Xiong et al
1997), and spinal cord injury (Huang et al 2012, Sullivan et al 2007).
Our lab, in collaboration with others, have shown there is substantial
mitochondrial dysfunction after traumatic spinal cord injury (SCI). Studies have
shown that mitochondrial ETC functions are compromised and there is increased
mitochondrial oxidative stress as soon as 6 hours after injury (Jin et al 2004,
McEwen et al 2007, Patel et al 2010, Patel et al 2009b, Sullivan et al 2007).
Mitochondrial respiration is significantly decreased as early as 6 hours post
injury, with further progressive decline in respiration over 24 hours post injury
(Sullivan et al 2007). This group also showed significant increases in markers of
oxidation at 24 hours post injury. A different group studying a rat model of spinal
contusion injury found that glutathione, an endogenous antioxidant, and ATP
levels were significantly decreased as early as 2 hours after injury and that this
decrease continued to progress over 24 hours post injury (Jia et al 2016).
Interestingly, this group also reported mitochondrial fusion increases immediately
after injury, followed by a turn to mitochondrial fission corresponding to
decreased ATP and glutathione and increased apoptosis signaling cytochrome c
and caspase 3 release. There is evidence that mitochondrial function drastically
changes after SCI, thus the next sections will explore the pathophysiology
following SCI with emphasis on the role that dysfunctional mitochondria play.
1.2 Introduction to Spinal Cord Injury
Spinal cord injury is a devastating condition with life-long consequences
and there are currently no effective treatments for reversing the pathophysiology
after injury. In the United States there are approximately 17,000 new cases of
SCI each year (Center 2016). There are different types of SCI such as
transection, ischemia, and penetration, though a contusion type of injury is most
common, where there is a physical compression and bruising of the spinal cord
by the bones of the spinal column. Injury progression following the initial
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mechanical insult can be separated into two phases commonly referred to as the
primary injury and the secondary injury (Norenberg et al 2004). The immediate
time point after injury is the primary injury phase and represents the physical
destruction and necrosis of tissue (Baptiste & Fehlings 2006, Dumont et al 2001).
Even at this early time point, glutamate excitotoxicity and microglial activation are
present (Donnelly & Popovich 2008, Wrathall et al 1996). Additionally, vascular
hemorrhaging and vasospasms occur resulting in ischemia of the spinal cord
(Ducker & Assenmacher 1969). The pathophysiological events at this immediate
time point is important, though typically not clinically accessible for treatment
interventions. Accordingly, many current treatments aim to address the
secondary injury phase.

1.2.1 Secondary Pathophysiological Cascades Following SCI
The secondary injury phase contributes to the spread and severity of
tissue damage over time. The progression of the secondary injury phase has
been further separated into different sub-phases (Rowland et al 2008). The
immediate phase comprises the first 2 hours after injury. The acute phase
follows; it is separated into the early acute phase which is 2-48 hours after injury,
and the subacute phase which is 2 days to 2 weeks after injury. The early acute
phase includes free radical production, delayed cellular apoptosis, excitotoxicity,
calcium dysregulation, axonal degeneration, ischemia, and inflammation
(Cuzzocrea et al 2001, Faden et al 1988, Fiskum 2000, Lewen et al 2000, Tator
& Fehlings 1991). The subsequent intermediate phase is 2 weeks to 6 months
post-injury, and the chronic phase begins at 6 after injury. The average time it
takes to diagnose a patient after injury is 3.2 hours, which makes the early acute
secondary injury phase the earliest clinically feasible target for therapeutic
intervention (Bracken et al 1997).

1.2.1.1 Ionic Dysregulation and Excitotoxicity
Ionic imbalance and excitatory molecule release are prevalent
manifestations in the secondary injury phase after SCI that potentiate further
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damage (Agrawal & Fehlings 1996, Allen 1914, Hall et al 1989, Young & Koreh
1986). Glutamate is an excitatory neurotransmitter that can be neurotoxic in the
brain during occurrences of overwhelming exposure (Olney & Sharpe 1969).
After SCI, glutamate is released from damaged cells and binds to NMDA and αamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors located
on the membrane of nearby cells (Figure 1.1A-2). This causes channel opening
and unregulated influx of excessive sodium and calcium into cells, known as
excitotoxicity (Hume et al 1991, Lucas & Newhouse 1957, MacDermott et al
1986, Manev et al 1989, Olney 1969, Tator 1991) (Figure 1.1B-3,4).
Calcium ionic dysregulation can cause disruptions in cellular signaling
processes, mitochondrial function, and increase initiation of apoptotic pathways
and neuronal death (Choi 1988, Senter & Venes 1978, Tymianski & Tator 1996).
Importantly, mitochondria can sequester large amounts of positively charged
calcium ions within their negatively charged matrix. In cases of extreme
intracellular calcium concentrations, increased calcium sequestration in the
mitochondrial matrix results in a loss of membrane potential across the IMM as
the matrix becomes more positively charged (Rottenberg & Scarpa 1974).
Loss of membrane potential then results in decreased calcium buffering
capacity with subsequent calcium dysregulation within the cell such as activation
of calpains and phospholipases that induce the release of apoptosis inducing
factor (AIF) from mitochondria (Polster et al 2005), downstream release of
cytochrome c, and formation of the mitochondrial membrane permeability
transition pore (MPTP) (Krajewska et al 2004). Formation of the MPTP (Figure
1.1B-5) is a phenomenon in which a mega channel forms allowing water, ions,
and molecules up to 1500 Daltons to move freely across the inner mitochondrial
membrane (Hunter & Haworth 1979, Hunter et al 1976). Upon MPTP formation
water will follow its osmotic gradient and pass into the highly concentrated matrix
causing swelling of the mitochondria and bursting of the outer mitochondrial
membrane (Figure 1.1B-6), consequently releasing ROS, reactive nitrogen
species (RNS), calcium, and cytochrome c into the cell. Cyclophilin D is a
component of the MPTP that interacts with mitochondrial amyloid-beta protein in
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Alzheimer’s disease (Du et al 2008). This group showed that an Alzheimer’s
mouse model deficient in cyclophilin D had increased mitochondrial Ca2+
buffering capacity and memory and spatial learning scores compared to mice
with cyclophilin D. Using a small molecule inhibitor that binds to cyclophilin D
such as C-9 decreases the detrimental effects of Aβ and calcium-induced MPTP
opening (Valasani et al 2016, Valasani et al 2014), further indicating MPTP as a
therapeutic target for neuronal disease states.
In addition to causing potential mitochondrial swelling and MPTP, NMDA
receptor activation and calcium influx also leads to activation of nitric oxide
synthase, resulting in production of nitric oxide, a powerful oxidant (Dawson et al
1991). Overstimulation of NMDA receptors can also result in ROS production
including the formation of superoxide radicals (Lafon-Cazal et al 1993).
Superoxide radicals react with nitric oxide to form peroxynitrite (Beckman et al
1990), an oxidant which reacts with lipid membranes, proteins, and DNA and
may further cause release of calcium by mitochondria which can be inhibited by
cyclosporin A (Packer & Murphy 1994).
Increased glutamate levels in the presence of extracellular calcium in vitro
causes neuronal degeneration (Choi 1985) that can be inhibited by using NMDA
antagonists (Choi 1988). Thus, blockade of excitatory NMDA or AMPA receptors
has been a therapeutic target for neuroprotection with promising results (Agrawal
& Fehlings 1996, Gill & Lodge 1997, Hall & Braughler 1982, Young & Koreh
1986).

1.2.1.2 Free Radical Release
Free radical production is an important implication after traumatic injury to
central nervous system tissue. ROS/RNS are released, oxidizing nearby
proteins, lipids, DNA and mtDNA, propagating subsequent reactive species
production and increasing the spread of damage (Hall & Braughler 1993).
Neurons in the spinal cord are especially vulnerable to oxidative damage. They
have a relatively high concentration of polyunsaturated fatty acids in their lipid
membrane that contain double bonds easily broken by ROS. Resident microglia
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can increase ROS production when activated, and neurons have relatively little
endogenous antioxidant mechanisms (for review of CNS tissue vulnerability to
ROS, see Friedman 2011). ROS and RNS release from mitochondria may further
damage nearby proteins and lipids in the mitochondrial membranes, as well as
mtDNA (Figure 1.1B-7). When mitochondria undergo oxidative damage they
release higher amounts of ROS, and when the ROS overload becomes too much
for the endogenous antioxidant systems to handle, these mitochondria will also
undergo MPTP. This illustrates how one damaged mitochondria can cause a
domino effect resulting in widespread mitochondrial damage within the cell until a
threshold is passed to signal the cell to undergo apoptosis or necrosis (Figure
1.1B-8).
Xu et al (2005) used a superoxide dismutase (SOD1) overexpressing
transgenic mouse model of compression spinal cord injury to investigate ROSmediated motor neuron death (Xu et al 2005). They found that there was less
ROS production and motor neuron cell death in animals overexpressing SOD1
compared to wild type animals. The use of antioxidants such as tirilazad
mesylate (Hall 1995) and methylprednisolone have been tested to counter the
detrimental effects of reactive species after nervous system trauma (Hall &
Braughler 1982, Hall et al 1989, Saunders et al 1987). Clinical trials were
performed using methylprednisolone after contusion SCI (Bracken et al 1985,
Bracken et al 1997). Importantly, this study found that timing of treatment is
crucial, with benefits after treatment more profound with shorter times between
injury and treatment. Initial results were promising, though these studies have
come under scrutiny for possible side effects leading to controversy and the
discontinued clinical use of methylprednisolone.

1.2.1.3 Inflammatory Response
After injury there are remarkable and complex inflammatory responses
that can contribute to the escalation of secondary pathophysiology (Blight 1985,
Blight 1992, Carlson et al 1998, Fehlings & Nguyen 2010, Fleming et al 2006).
The immediate inflammatory response after injury includes neutrophil invasion
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and resident microglial activation. Breakdown of the blood brain barrier, coupled
with invasion of peripheral immune cells and cytokine activation, causes intricate
inflammatory responses in the injured tissue that are both injury-severity and
time-dependent (Popovich et al 1996). There is controversy as to the benefits vs
detriments afforded by the inflammatory response after SCI. Macrophages can
have multiple phenotypes depending on the injury environment and signaling
cues. For instance, M1 macrophages produce cytokines and ROS that augment
inflammation of the injury site. Inflammation can cause demyelination (Cammer
et al 1978, Selmaj & Raine 1988, Wisniewski & Bloom 1975), inhibit axonal
growth (Berry & Riches 1974), release ROS/RNS (Griot et al 1989, Merrill et al
1993), release cytokines and increase the progression of injury and cell death
(Means & Anderson 1983). Blocking macrophage migration to the injury site
helps alleviate some of the secondary injury pathophysiology and improve
functional recovery after SCI (Popovich et al 1999). Additionally,
immunosuppressants have been used to fight the inflammatory response as a
therapeutic treatment after SCI (Bethea et al 1999, Blight 1994, Taoka et al
1997). However, it needs to be noted that the inflammatory response does serve
a purpose in tissue healing. M2 phenotype macrophages have anti-inflammatory
actions and promote wound healing- for review on macrophage subtypes (see
Murray & Wynn 2011). For instance, macrophages can create a permissive
environment for neuronal regeneration in a model of optic nerve injury (David et
al 1990, Hirschberg et al 1994, Perry et al 1987). Therefore, it is important to
understand the complexity of the inflammatory response so that targets can be
specifically identified based on the therapeutic goals to counter inflammation but
encourage healing.
It is apparent that mitochondria are of bacterial in origin, as evident by
common morphological properties including circular DNA, double membranes
including cardiolipin, lack of histones, and the ability to form N-formyl peptides.
Because these properties are also recognized by the body’s immune system as
bacterial and thus non-self, or something to be eradicated, the mitochondria can
stimulate an immune response similar to that induced by a bacterial infection
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(Lotze et al 2007). Damage-associated molecular patterns (DAMPs) are located
on the cell surface, secreted into the extracellular matrix, or produced as a
byproduct of degradation (Garg et al 2010). Pattern recognition receptors are
expressed on dendritic cells and macrophages that recognize DAMPs and cause
upregulation of proinflammatory cytokine production (Krysko et al 2011,
Rubartelli & Lotze 2007). Some DAMPs associated with mitochondria include
mtDNA (Collins et al 2004, Zhang et al 2010b), N-formylmethionyl proteins (Carp
1982), Cytochrome c, ATP (Ghiringhelli et al 2009, Iyer et al 2009), cardiolipin
(Sorice et al 2004), carbamoyl phosphate synthase (Struck et al 2005), and ROS
(Kazama et al 2008). ATP released from cells into the extracellular matrix acts to
recruit monocytes and neutrophils in a model of human neutrophil chemotaxis in
vitro (Chen et al 2006, Elliott et al 2009) as well as activation of inflammasomes
(Schroder & Tschopp 2010). In cases of severe tissue trauma, cellular necrosis
can release massive quantities of mitochondrial particles, including mtDNA,
which have been found to activate neutrophils and create an immune response in
a rat model of trauma/hemorrhagic shock (Zhang et al 2010a, Zhang et al
2010b). Thus, the presence of mitochondria or mitochondrial-derived particles in
the extracellular matrix after traumatic tissue damage such as SCI can increase
immune and inflammatory responses including macrophage infiltration.

1.2.1.4 Vasculature Changes
Primary injury causes direct mechanical damage to the spinal cord
vasculature and subsequent disruption of blood flow within the cord leading to
progressive tissue loss (Wolman 1965) which is followed by later reperfusion of
the vessels (Senter & Venes 1978). Hemorrhaging after injury can cause
prolonged pressure on the spinal cord and cell death (Allen 1914). Damage to
vessels results in a breakdown of the blood spinal cord barrier, allowing for
unrestricted access of small molecules to the central nervous system (CNS)
tissue. There is some disagreement on the length of time between SCI and the
reestablishment of the blood spinal cord barrier, which may be due to the
different methods of measuring permeability (Matsushita et al 2015).
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Reestablishment of the blood spinal cord barrier in a rat model of SCI has been
reported as early as 14 days post injury (Noble & Wrathall 1989), though it has
been reported that the blood spinal cord barrier is still compromised up 28 days
(Popovich et al 1996) or 56 days post injury (Cohen et al 2009). Microvascular
damage is thought to exacerbate the secondary injury cascades, and could be a
target for early treatment after SCI (Tator 1991, Tator & Fehlings 1991). Gray
matter has higher metabolic needs than white matter and is more vulnerable to
damage induced by hypoxia and ischemia (Dumont 2001). Ischemia with
subsequent reperfusion injury has been shown to increase the production of free
radicals such as ROS from complex I of mitochondria (Tompkins et al 2006), and
oxidation of lipids and proteins that compromises the integrity of membranes,
DNA, and enzymes among other cellular components including mitochondria
(Cuzzocrea et al 2001).
1.3 Therapeutic Methods of Targeting Mitochondrial Dysfunction after SCI
As described in the previous section (Chapter 1.2), many of the
secondary pathophysiological cascades following SCI are closely associated with
mitochondrial dysfunction, making these organelles a popular therapeutic target.
Accordingly, different treatments for restoring or maintaining mitochondrial
function following neurotrauma such as uncoupling agents, antioxidant addition,
and biofuel addition have been tested, with varying degrees of effectiveness.

1.3.1 Mild Uncoupling
Drugs that uncouple the mitochondrial ETS have been investigated for
their potential benefits in retaining mitochondrial function after different models of
traumatic nervous tissue damage in vivo (Jin et al 2004, Patel et al 2009b,
Rodriguez-Jimnez et al 2012, Sullivan et al 2004). Using drugs to mildly uncouple
the ETC from complex V allows hydrogen atoms to diffuse freely from the
intermembrane space back into the matrix (see Skulachev 1998). This allows for
maximal transport of electrons through the ETC, without conversion of ADP to
ATP. When the uncoupling is mild, there can be a buildup and maintenance of
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membrane potential across the IMM. This maintenance of membrane potential is
beneficial in that the mitochondria are less likely to go through MPTP. Using mild
uncoupling proteins (UCP2 and UCP3) has been shown to reduce ROS
production and may be beneficial in treating neurodegenerative diseases (see
Brand & Esteves 2005). One group found addition of the uncoupler 2,4dinitrophenol resulted in neuroprotection in a rat model of quinolinic acid- induced
Huntington’s disease (Maragos et al 2003). Importantly, intraperitoneal injection
of 2,4-dinitrophenol was found to maintain mitochondrial bioenergetics and
reduce oxidative markers to sham levels when given 15 or 30 min after contusion
SCI (Patel et al 2009b).

1.3.2 Antioxidants
The use of antioxidants to supplement the endogenous mitochondrial
antioxidant systems have been used to combat free radicals such as ROS and
RNS (see Bains & Hall 2012, Smith et al 2008). Reactive species can attack and
damage mitochondrial electron transport complexes and mtDNA, further
increasing mitochondrial dysfunction. Administration of antioxidants or precursors
to antioxidants has been shown to have beneficial effects for Parkinson’s disease
(Jin et al 2014) and traumatic brain injury (Hall et al 2010). Intraperitoneal
injections of N-acetylcysteine amide, a precursor to glutathione, in a rat model of
SCI significanlty maintained both mitochondrial respiration and hindlimb
functional recovery compared to vehicle (Patel et al 2014). Dietary administration
of the antioxidant resveratrol has been shown to increase mitochondrial
antioxidant enzyme activity (MnSOD) in mouse brains (Robb et al 2008) and
reduce oxidative stress in cultured coronary endothelial cells (Ungvari et al
2009). Tempol treatment is shown to decrease oxidative stress and mitochondrial
dysfunction while increasing cell survival and ATP production in a mouse model
of nephrotoxicity (Ahmed et al 2014), and partially restore mitochondrial
respiration in a model of rat SCI (Xiong & Hall 2009). Intraperitoneal injections of
tempol maintained nonsynaptic, but not synaptic, mitochondrial bioenergetics
when administered 15 minutes after contusion SCI, and reduced peroxynitrite16

derived 3-nitrotyrosine and protein oxidation (Patel et al 2009b). Further, modified
antioxidants can be specifically delivered to mitochondria for optimal
effectiveness (see Sheu et al 2006).

1.3.3 Substrate Addition
Substrates that feed into the ETC have also been utilized as mitochondrial
therapy. Increasing the amount of substrates such as NADH, acetyl-CoA, and
succinate can increase mitochondrial bioenergetics. The subsequent increase in
ATP production not only provides more energy to the cell, but helps to maintain a
healthy membrane potential across the IMM (for review see Pettegrew et al
2000). Biofuels such as pyruvate and beta-hydroxybutyrate have been found to
restore mitochondrial respiration when delivered to cultured neurons after
glucose deprivation (Laird et al 2013). Other alternative substrates that can be
used by mitochondria for respiration, such as acetyl-L-carnitine, have beneficial
effects in clinical trials for Alzheimer’s and Parkinson’s disease (Carta & Calvani
1991, Puca et al 1990), and it lowers oxidative damage and restores
mitochondrial function in rat models of aging (Liu et al 2002, Petruzzella et al
1992). Not only did acetyl-L-carnitine significantly restore mitochondrial
bioenergetics compared to vehicle, it also provided significant hindlimb functional
recovery and tissue sparing in a rat model of severe SCI (Patel et al 2012, Patel
et al 2010).
1.4 Mitochondrial Transplantation
A burgeoning approach used in mitochondrial medicine (Armstrong 2007,
Luft 1994) is transplanting mitochondria from a healthy, exogenous source into
damaged tissues in the effort to rescue cells or tissues from death. Various
models of mitochondrial transplantation have been investigated, each with their
own caveats and insights, which is discussed in Chapter 2. Many of the
‘mitochondrial medicines’ that have been explored, such as antioxidants and
alternative substrates (biofuels), have a short therapeutic time window in which to
treat damaged mitochondria before the oxidative and energy depletion damage
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becomes overwhelming. Importantly, they cannot replace mitochondria that are
already lost. With transplantation methods to replace damaged mitochondria it
may be possible to decrease ROS production within the cell (Figure 1.1C-9),
provide a new pool of exogenous mtDNA damaged from oxidative processes
(Figure 1.1C-10), increase energy production (Figure 1.1C-11), and increase
calcium buffering capacity (Figure 1.1C-12). By providing new mitochondria to
the cell it will retain enough energy-producing capacity for survival, thus allowing
damaged mitochondria to undergo mitophagy, a form of mitochondria-specific
targeted autophagy (see Ding & Yin 2012), to maintain sufficient energy
production sources for self-repair. The prospect of replacing damaged and
dysfunctional mitochondria with healthy exogenous mitochondria has already
been attempted with promising results, though no such intervention has been
attempted in models of spinal cord injury.
1.5 Hypothesis of Dissertation
As described above, contusion SCI is a complex and phasic event that
results in permanent damage. Mitochondria are implicated in many aspects of
the pathophysiological progression, and are therefore a therapeutic target after
injury. Pioneering work in our lab characterizing mitochondrial dysfunction after
SCI led to the discovery that preservation of mitochondrial function correlates
with tissue sparing and better long-term hindlimb recovery after injury (Patel et al
2012, Patel et al 2014). As such, our lab has been actively investigating other
methodologies of mitochondrial therapeutics. Early publications describing
successful mitochondrial transplantation in models of cardiac tissue ex vivo or
lung tissue injury in vivo (Islam et al 2012, McCully et al 2009) caught our
attention as an exciting and novel therapeutic strategy. With the existing
experience in our lab of performing microglial cell transplantation into the spinal
cord after injury (Rabchevsky & Streit 1997) and extensive knowledge of
mitochondrial bioenergetics after SCI, it was a logical step forward to branch out
into the field of mitochondrial transplantation.
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While the published mitochondrial transplantation approaches showed
promise in alleviating tissue damage and mitochondrial dysfunction in different
organ systems and pathologies such as cardiac infarction and lung damage, no
studies have investigated the potential benefits of supplementing healthy
mitochondria into the injured spinal cord. As such, the hypothesis of this
dissertation is isolated mitochondria can be successfully transplanted into injured
spinal cord tissue and increase overall host mitochondrial bioenergetics and cell
survival, resulting in tissue sparing and improved functional recovery. To test our
hypothesis, we first characterized and optimized techniques for isolating
transgenically-labeled mitochondria from cultured cells for transplantation
(Chapter 4). We then performed experiments to find the optimal dosage of
mitochondria transplantation to maximally restore cellular bioenergetics following
acute contusion SCI (Chapter 5.3.1). Next, we characterized both time and celltype dependent incorporation of tGFP-labeled mitochondria after injury (Chapter
5.3.2). Finally, we assessed tissue sparing and functional recovery benefits
afforded by mitochondrial transplantation (Chapter 5.3.3).

Note:
Portions of this chapter were adapted and reprinted by permission from
Elsevier: Jenna L. Gollihue and Alexander G. Rabchevsky. (2017) Prospects for
Therapeutic Mitochondrial Transplantation. Mitochondrion. 2017 May 19 DOI:
10.1016/j.mito.2017.05.007
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CHAPTER 2
History of Mitochondrial Transplantation
2.1 Methods of Transplantation
While mitochondrial replacement therapy has been proven successful in
embryonic genetic therapies (see Chapter 1.1.1), there is a dire need to develop
complementary approaches for treating adults who suffer from mtDNA defects
and mitochondrial dysfunctions. The transplantation of mitochondria isolated from
one source into different recipient cells has been successful in various models
and multiple studies have shown incorporation of exogenous mitochondria via
direct injection, co-incubation, and cell-mediated transfer, both in vitro and in
vivo. This chapter investigates the techniques used for transplantation of
mitochondria into a host cell/tissue, methods used to verify successful transfer,
and the benefits that transplantation has afforded various models of
mitochondrial dysfunction.

2.1.1 In vitro Transplantation
As early as 1982, the possibility of isolated mitochondrial transplantation
into mouse adrenal and embryonal carcinoma cell cultures was shown (Clark &
Shay 1982). Chloramphenicol- and efrapeptin-resistant mitochondria were
isolated from mammalian cells and co-incubated with cells lacking resistance to
the mitochondrial-targeting antibiotics. The isolated mitochondria labeled with
rhodamine 123 were not only endocytosed by the cells as visualized by
fluorescence microscopy, but they also conferred resistance indicating
successful incorporation of the exogenous mitochondria. This resistance was
present in 12 passages of the cells as the mtDNA was retained. Damaging the
resistant mitochondria with UV light before co-incubation rendered them
incapable of conferring resistance to co-incubated cells. Moreover, resistance
could not be conferred between species (mouse into human), introducing a
caveat in mitochondrial transplantations- that various cell types may have
different propensities to take up mitochondria originating from different sources.
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Another group that capitalized on conferred resistance via mitochondria
transplantation showed that direct injection of isolated mitochondria into cultured
cells is a viable technique for replacing endogenous mtDNA (King & Attardi
1988). Using ethidium bromide, mtDNA was reduced in 143B human
osteosarcoma cells to 3% of control levels. Mitochondria were then isolated from
chloramphenicol-resistant CAP23 cells and microinjected into mtDNA-depleted
143B cells. Subsequent addition of chloramphenicol to the recipient cells failed to
kill them, indicating successful incorporation of CAP23 mitochondria. Further, the
cells contained CAP23 mtDNA at five weeks after injection while the nuclear
DNA was only that of 143B cells, indicating the transfer of only mtDNA.
Direct microinjection of isolated mitochondria into cultured cells was
thought to be impractical based on the size of mitochondria compared to the
gauge of injection needles (Yang & Koob 2012), despite that previous studies
used needles with tip diameter of 1 um or less (King & Attardi 1988). To
counteract this, mitochondria were first injected into oocytes to allow larger
diameter needles to be used and then a mitocytoplast containing the cell
membrane, cytoplasm, and the previously injected mitochondria was taken from
the oocyte (Yang & Koob 2012). This mitocytoplast could then be fused with
recipient lung carcinoma LL2/rho0 cells that are devoid of mtDNA so that
mitochondria were then transferred into the recipient cell cytoplasm. An important
finding in this study revealed that when a cell is in the presence of two different
species of mtDNA, recipient cells will favor the survival of syngeneic mtDNA,
similar to the findings of Clark and Shay (1982).
Others have explored direct injection techniques in which mitochondria
were isolated from rabbit heart tissue and injected into regions of ischemic rabbit
hearts ex vivo shortly before reperfusion (McCully et al 2009). Autologous
mitochondria were directly injected into heart tissue following 29 minutes of
ischemia, which resulted in decreased infarct size of the post-ischemic tissue.
Injections of frozen, non-functional mitochondria into heart tissue showed that
functional, respiratory competent mitochondria were necessary to decrease
ischemic infarct size and maintain function of cardiac tissues.
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In addition to direct transfer approaches into host cells, the possibility of
mitochondrial transfer by co-incubation has been investigated. Co-incubation of
cultured cells with isolated mitochondria results in successful incorporation of the
exogenous mitochondria into host cells, often those that had undergone some
sort of insult. Xenogenic transfer of mitochondria was evident when isolated
mitochondria were co-incubated with cells in vitro, resulting in the successful
incorporation of exogenous mitochondria (Katrangi et al 2007). It was shown that
healthy murine mitochondria were taken into compromised human mesenchymal
stem cells, resulting in their restored respiratory capabilities. The group
demonstrated transfer by fluorescently labeling and tracking isolated
mitochondria, measuring respiration changes in the cells after transfer, and
detecting exogenously-derived mtDNA using polymerase chain reaction (PCR)
techniques. These results contrast those found by Clark and Shay (1982) in
which mitochondria originating from one species were found not to transfer via
co-incubation into host cells of a different species.
Others have studied transfer of isolated mitochondria conjugated to a cellpenetrating peptide, Pep-1 (Chang et al 2013b). Pep-1 causes translocation of its
cargo in an endosomal-independent manner and has been used to deliver small
peptides and DNA sequences, but never entire organelles (for review see Morris
et al 2008). Using mitochondrial specific fluorescent dyes, Chang et al (2013)
reported that transplantation of mitochondria into recipient cells was found only
when mitochondria were conjugated with Pep-1. Conjugated mitochondria-Pep-1
were isolated and co-incubated either with cells derived from myoclonic epilepsy
with ragged-red fibers (MERRF) syndrome that had mutated mtDNA hindering
mitochondrial protein synthesis or with cells lacking mtDNA. The exogenous
mitochondria-Pep-1 co-localized with host mitochondria and resulted in the
recovery of mitochondrial membrane potential in cells, increased oxygen
consumption, increased ATP production, and decreased lactate production, all
indicating a switch from anaerobic to aerobic respiration. This is in contrast to
previous reports (Clark & Shay 1982, Katrangi et al 2007) that showed isolated
mitochondria could be taken up by host cells in vitro without Pep-1.
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In cell-to-cell transfer paradigms, it has been shown that co-culturing
human lung epithelial cells containing damaged and/or depleted mitochondria
with healthy adult human bone marrow stem cells results in donation of healthy
stem cell mitochondria and rescue of epithelial cells that contained functional
mitochondria, as indicated by increased ATP production and translation of
mitochondrial protein COXII (Spees et al 2006). Microscopy showed that the
bone marrow stem cells made cytoplasmic projections towards the epithelial
cells, shuttling mitochondria through the extensions between connected cells. In
contrast to other studies, this group showed no evidence of isolated
mitochondrial transfer into cells using co-incubation methods- when comparing
transplantation of isolated mitochondria versus cell-to-cell transplantation,
transfer was only attained in a cell-cell fashion, suggesting that movement of
exogenous mitochondria into host cells is an active process.
Nanotube formation between cells was reported through which organelles,
including mitochondria, were exchanged from one cell to another when coculturing human bone marrow mesenchymal stem cells with rat embryonic
cardiac myocytes (Plotnikov et al 2008). After co-culturing for 24 hours, the cells
formed nanotube connections and Tetramethylrhodamine Ethyl Ester (TMRE)labeled mitochondria were visualized within the nanotubes; TMRE is a
membrane potential-dependent mitochondrial dye. Further, the propensity of
each cell type to form tunneling nanotubes was higher when co-cultured with the
xenogenic cell type compared to a syngeneic cell type. By using calcein-AM, a
cell membrane permeant dye, the group was able to demonstrate the movement
of cytoplasmic contents in both directions between cultured cells using scanning
confocal microscopy, indicating that cytoplasm from both cardiomyocytes and
human mesenchymal stem cells was shared. It was also shown that physically
disrupting tunneling nanotube formation with gentle shaking inhibited this sharing
of cytosolic contents. Using MitoTracker Red and MitoTracker Green FM dyes,
each specific for one cell type, they visualized mitochondrial transfer between the
co-cultured cells. There was no detectable transfer at 3 hours but was evident
after 24 hours of co-culturing. Interestingly, mitochondria movement was
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apparent from the mesenchymal stem cells to the cardiomyocytes, but there was
no reciprocal movement and no co-localization of the MitoTracker markers,
indicating that mitochondria originating from the two different sources did not
undergo fusion at 24 hours.
Another group found that co-culturing of rat cardiomyoblasts that had
undergone oxygen glucose deprivation (OGD) with healthy mouse mesenchymal
stem cells resulted in the formation of 200-500 nm diameter nanotubes between
cells after 2 hours, and that after 24 hours these nanotubes contained the
membrane potential-dependent dye MitoTracker Red (Cselenyak et al 2010).
This indicated the presence of functionally competent mitochondria, although the
directionality of movement was not obvious using time-lapse confocal
microscopy. Importantly, such co-culturing significantly rescued the
cardiomyoblasts from OGD.
Others have reported the formation of tunneling nanotubes in cultured
cells that underwent ultraviolet radiation stress (Wang & Gerdes 2015). They
showed that PC-12 cells in the beginning stages of apoptosis formed nanotubes
that reached out to healthy, unstressed cells and that when UV-stressed cells
were co-cultured with healthy cells there was reduced cell death compared to coculturing with UV-stressed cells. EdU (5-ethynyl-2’-deoxyuridine)-labeled mtDNA
could be detected in the stressed cells, indicating transfer had occurred into the
damaged cells. They further found that mtDNA-deficient PC-12 cells lacking
electron transport function could not rescue UV-stressed cells whereas PC-12
cells with functional mitochondria did.
It is important to note that the reported successful transfer of mitochondria
from one cell type to another appears to be most prevalent when transfer
occurred from a healthy cell to a cell with dysfunctional and/or depleted
mitochondria. While there are many caveats when considering donor vs recipient
cell types in the propensity to take up mitochondria, there appear to be
mechanisms that allow damaged cells to receive mitochondria more readily than
healthy cells. For example, Cho et. al. (2012) found that cell-to-cell mitochondrial
transfer occurred via partial cell fusion, but only when the receiving cell had
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dysfunctional mitochondria. The group showed that co-culturing of human
mesenchymal stem cells with both human osteosarcoma 143B cells lacking
mtDNA and cells with severe R6G toxin-induced mitochondrial dysfunction
resulted in the transfer of mitochondria accompanied by their increased ATP and
oxygen consumption. However, transfer was not evident when recipient cells had
mtDNA mutations, leading the group to conclude that mitochondrial transfer
occurs only when mitochondrial function is severely hindered or absent (Cho et al
2012).

2.1.2 In vivo Transplantation
Phylogenetic mapping and mitochondrial transplantation methods have
been performed in a number of animal models in vivo. Interestingly, a study
investigating the phylogeny of different canine species with canine transmissible
venereal tumor (CTVT) by sequencing their mitochondrial genome (Rebbeck et
al 2011) revealed an unexpectedly high polymorphism rate in the CTVT samples
thought to be caused by transfer of mitochondria from the dogs into the
cancerous tumor cells. The group theorized that host (dog) mitochondria may be
healthier than that of the CTVT cells, encouraging transfer of mitochondria and
subsequent increase in CTVT metabolic health. This theory reflects an
endogenous mechanism of mitochondrial transfer in vivo, from one cell to
another.
The McCully group who studied direct injection of mitochondria ex vivo
(McCully et al 2009) also reported successful mitochondrial transplantation in
vivo using a direct injection technique (Masuzawa et al 2013). Autologous
transplantation of isolated mitochondria directly into ischemic rabbit hearts
immediately before reperfusion resulted in increased mechanical function as
soon as 10 minutes after injection, in addition to significantly higher ATP content
at 2 days post injection. Further, they showed via confocal microscopy that
cardiomyocytes can take in exogenous mitochondria as early as 2 hours after
transplantation and do not illicit an immune response. The group recently
compared direct injection mitochondrial transplantation to a more clinically
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relevant, less invasive vascular perfusion delivery method (Cowan et al 2016).
Rabbit hearts underwent focal ischemia for 30 minutes in situ followed by
reperfusion and delivery of mitochondria isolated from adult human cardiac
fibroblasts. Mitochondria were delivered either by direct injection into the
ischemic heart tissue or they were perfused through the coronary artery. They
noted that a large amount of mitochondria were found in the interstitial spaces,
but some mitochondria were co-localized within cardiomyocytes. Vascular
delivery of mitochondria resulted in a larger dispersal area, while direct injection
resulted in a higher concentration in smaller regions of tissue. Importantly, this
study showed that both direct injection and vascular delivery of mitochondria
afforded functional protection in measures of muscle contractility and decreased
infarct size after ischemia-reperfusion injury. The group then aimed to show
these results in a larger, more clinically relevant animal model. Kaza et al (2016)
studied the autologous transplant of mitochondria isolated from the pectoralis
major muscle into a porcine model of ischemia reperfusion (Kaza et al 2016).
Regional ischemia injury was performed, blocking blood flow for 24 min, after
which isolated mitochondria were given to the heart, with reperfusion of the heart
following immediately after mitochondrial delivery. The animals then survived for
4 weeks. Results from this study are important as they show that there was no
increase in inflammatory or immune reactivity when mitochondria were delivered.
There was also significantly larger infarct size in vehicle injected animals
compared to mitochondria treated animals. Further, injected mitochondria were
still present at the 4 week time point.
In addition to direct injections in vivo, cell-to-cell transfer of mitochondria
has also been reported in vivo. One study instilled mouse bone marrow derived
stromal cells (mBMSC) into acutely injured mouse lungs which resulted in
connexin pore-dependent attachment of the mBMSC to the injured lung
epithelium (Islam et al 2012). This attachment was followed by nanotube
formation and delivery of mitochondria-containing vesicles into the injured tissue,
leading to increased ATP production and cell survival after injury. The group
determined that connexin pore and gap junction channel formation was
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necessary for such transfer since blocking connexin pore formation inhibited gap
junction channel formation, which was then found to inhibit cytosolic mixing
between the two cells. When dynamin, a GTPase responsible for endocytosis in
the eukaryotic cell, was inhibited mitochondrial delivery was blocked leading the
group to posit endocytosis to be the mechanism responsible for mitochondrial
transfer. Again, it is important to note that the mitochondria were transferred to
damaged cells or tissues.
Recent compelling studies have shown that endogenous mitochondrial
transfer occurs between resident astrocytes and neurons after stroke injury
(Hayakawa et al 2016). The investigators stimulated astrocytes in vitro to release
mitochondria by upregulating the CD38 protein, and found that the addition of
these astrocyte-derived mitochondria in a model of neuronal cell injury in vitro
was successful in increasing neuronal ATP production and cell survival, and that
these mitochondria were incorporated into the neuronal cells. They further
studied this in vivo by directly injecting astrocyte-derived mitochondria into the
injury site 3 days after inducing cerebral ischemia in mice and found these
mitochondria were taken into neurons. The endogenous transfer of mitochondria
was seen in these transgenic mice with labeled astrocytic mitochondria that were
found within neurons 24 hours after ischemic stroke, and cell survival signals
such as phosphorylated AKT were increased after this transfer (Hayakawa et al
2016).
Direct injection of isolated mitochondria has been explored in a 6-OHDA
rat model of Parkinson’s Disease (PD) (Chang et al 2013a). Transgenicallylabeled GFP-mitochondria were conjugated to Pep-1, a cell penetrating peptide,
and injected in a dose dependent manner into the medial forebrain bundle. The
group found that GFP labeled mitochondria were evident at 12 weeks post
injection using fluorescent microscopy, however, they did not detect foreign
mtDNA at these time points. Importantly, they also noted mitochondrial
aggregation at the highest dosage used (2.1µg) compared to the lowest dosage
(0.525 µg), which was less aggregated and more extensively dispersed. They
hypothesized that the aggregation at higher concentrations led to decreased
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penetration of mitochondria into host tissues; this is supported by their findings
which delineate the lower dosage treatments as having higher efficacy for
different outcome measures of recovery including cell survival and behavior. Both
the low and middle dosage group (1.05µg) resulted in significantly higher cell
body numbers in the substantia nigra compared to vehicle injected animals.
Additionally, these two lower dosage groups gave significantly higher
mitochondrial complex I, III, and V activity compared to vehicle. Functional
recovery was analyzed using apomorphine-induced rotation assessment and
showed conjugated mitochondria/Pep-1 injection at the two lower dosages
improved rotational scores closer to baseline compared to vehicle injected
animals.
In a later study, the same group utilized xenogenic transfer in PD rats
(Chang et al 2016). When mitochondria with or without Pep-1 conjugation were
injected into the medial forebrain bundle, oxidation of substantia nigra cell DNA
was decreased compared to vehicle injection. They simultaneously performed
allogeneic transplantation using transgenically-labeled GFP mitochondria
isolated from PC-12 cells. 3 months after transplantation, locomotion comparing
distance, speed, and amount of movement were analyzed for each animal. After
onset of PD by using 6-OHDA, there is significantly decreased locomotor activity.
Locomotor scores of 6-OHDA animals were significantly increased when
transplanting either allogeneic or xenogenic mitochondria, but only when
conjugated with Pep-1; there was not such locomotor recovery when non- Pep-1
conjugated mitochondria were injected. Interestingly, locomotor scores were
higher in the allogeneic Pep-1/mitochondria group compared to the xenogenic
Pep-1/mitochondria group, suggesting there may be differences when using
mitochondria from sources that are unlike the recipient strain or species. Pep-1
conjugated mitochondrial transplant also resulted in significantly increased
neuronal survival and tyrosine hydroxylase immunoreactivity, and increased
amount of complex I compared to vehicle injection. Importantly, GFP
immunofluorescence was apparent in the substantia nigra dopaminergic neurons
3 months after Pep-1 conjugated GFP-mitochondria administration. It should also
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be noted that 6-OHDA injury increased inflammatory cytokines such as IL-1a, IL1b, IL-10, IL-5, and IL-18, and that Pep-1 conjugated mitochondrial delivery
significantly decreased these levels.
2.2 Tracking Exogenous Mitochondria after Transplantation
Various methods have been utilized to verify that exogenous mitochondria
are successfully transplanted into host cells. One common procedure is to
transplant exogenous mitochondria of one species animal into a host cell of a
different species, followed by PCR on the host cell mtDNA showing that the
exogenous mtDNA is present (Islam et al 2012, Kitani et al 2014b, Yang & Koob
2012). PCR is also performed to show transfer of mtDNA into cells lacking
mtDNA (Spees et al 2006) or transfer of mitochondria containing a specific
sequence for chloramphenicol resistance (King & Attardi 1988). Alternatively,
species-specific mitochondrial antibodies are used to detect exogenous
mitochondria (Masuzawa et al 2013). Mitochondria can be fluorescently labeled
pre-injection to visualize after uptake into the host cells by either transfection
methods (Chang et al 2013b, Islam et al 2012, Kitani et al 2014b, Spees et al
2006, Wang & Gerdes 2015, Yang & Koob 2012), using mitochondrial-specific
dyes such as MitoTrackers or rhodamine derivatives (Chang et al 2013b, Clark
& Shay 1982, Cselenyak et al 2010, Katrangi et al 2007, Masuzawa et al 2013,
McCully et al 2009, Plotnikov et al 2008), or transgenic mice in which a subset of
mitochondria are fluorescently labeled (Hayakawa et al 2016). Another method
labels mitochondria using pHrodo Red, a pH-sensitive label that indicates proton
levels. Using this, increased fluorescence of cardiomyocytes in vitro could be
measured, indicating mitochondrial internalization that could be quantified as a
number of mitochondria per nucleus (Pacak et al 2015).
2.3 Mitochondria Transplantation Increases Health of Host Cells and
Tissues
Many different outcome measures are being used to show that
transplanted mitochondria have beneficial effects on host tissues. Energy
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production, mitochondrial protein translation, and enzyme activities have all been
reported to be increased after transplantation. One group found a three-fold
increase in ATP levels and a decrease in lactate levels in cells rescued by cell-tocell mitochondrial transfer, indicating that the host cells with depleted mtDNA
were able to switch from anaerobic respiration to aerobic respiration after
receiving mitochondria (Spees et al 2006). Further, the host cells that contained
extensive mtDNA damage could again translate mitochondrial proteins, namely
COXII, after incorporating exogenous mitochondria. Others showed that
mitochondrial transplantation into damaged lung epithelia resulted in increased
ATP production approaching control levels, not only in the cells that received
exogenous mitochondria, but also in juxtaposition alveoli (Islam et al 2012). The
increase in ATP to normal levels rescued functional surfactant excretion by the
alveolar cells. Increased cellular ATP content and oxygen consumption rates
were also reported after exogenous mitochondria internalization into either
cultured cardiomyocytes or HeLa cells lacking mtDNA, and PCR confirmed
replacement with exogenous mtDNA in the cells (Pacak et al 2015).
Mitochondrial function and ROS production have also been used to
assess the benefits of mitochondrial transplantation. For instance, flow cytometry
and the fluorescent dyes rhodamine 123 and JCI have been used to determine
changes in mitochondrial membrane potential in culture using MERRF cells
(Chang et al 2013b). They also measured oxygen consumption rates as well as
ATP levels, cell viability, amount of fusion and fission proteins, caspase-3/-7
activity, mtDNA copy number, mitochondrial mass, and mitochondrial calcium
uptake. ATP production has also been assessed using fluorometric analyses.
TBARS (thiobarbituric acid-reactive substances) has been used to show
differences in oxidative damage and TdT-mediated dUTP nick-end labeling
(TUNEL) assays have been used to investigate apoptosis (McCully et al 2009).
This latter group also employed Mito-Tracker Orange CMTMRos label to show
that labeled mitochondria maintained a viable membrane potential and their
oxygen consumption rates showed that they were respiration competent.
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2.4 Mechanisms for Mitochondrial Incorporation
Cell-to-cell fusion has been disputed as a necessary mechanism of
mitochondrial transfer. When co-culturing human mesenchymal stem cells with
human alveolar epithelial cells lacking mitochondrial DNA, transfer of
mitochondrial but not nuclear DNA was reported (Spees et al 2006). Further, the
addition of platelets or isolated mitochondria to cultured cells lacking mtDNA did
not result in mtDNA transfer, indicating the incorporation of exogenous
mitochondria is not a passive process. In fact, the mesenchymal cells made
cytoplasmic extensions towards alveolar cells lacking mtDNA, after which the
depleted cells began dividing after being rescued by mitochondrial transfer. It
was not shown whether mitochondrial transfer was achieved through nanotube
formation or budding of mitochondria-filled vesicles from the donor cells.
However, other groups have demonstrated that co-incubation of cells with
purified isolated mitochondria results in the uptake of exogenous mitochondria
into cells (Clark & Shay 1982, Katrangi et al 2007). This indicates an uncertainty
as to whether mitochondria can be passively endocytosed in cell culture. There
may be a difference among cell types in the ability to incorporate exogenous
materials, as was demonstrated in an earlier study examining incorporation of
nuclear DNA among different cell types (Wigler et al 1980). Clark and Shay
(1982) similarly showed that different cell lines had a different propensity to
uptake co-incubated isolated mitochondria, suggesting that mitochondria are
taken up by recipient cells via different endocytic properties according to
phenotype.
Islam et al (2012) reported that physical docking of mBMSC to injured lung
epithelial cells was necessary for transfer of mitochondria to alveolar cells.
mBMSC attachment to injured cells occurred at areas of high CX43 connexin
concentration on lung epithelial cells, and specifically blocking CX43 hindered
binding and transfer of cytosolic contents from mBMSC to epithelial cells. In vitro,
mBMSC formed nanotubes with epithelial cells and released microvesicles
containing DsRed-labeled mitochondria. They concluded that gap junctional
channels are necessary for attachment, while microvesicles and nanotubes are
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needed for the movement of mitochondria. Inhibition of dynamin blocked
mitochondrial transfer, implicating that endocytosis is responsible for the
engulfment of mBMSC microvesicles (Islam et al 2012). Koyanagi et al examined
intercellular connections and whether large structures, including organelles such
as mitochondria, could be transferred between cells (Koyanagi et al 2005). They
found that when human endothelial progenitor cells were co-cultured with
cardiomyocytes containing MitoTracker-labeled mitochondria, time lapse imaging
showed formation of transient nanotubular structures and the progression of
labeled structures moving from the cardiomyocytes to the endothelial progenitor
cells. Interestingly, the reverse transport was not evident: when endothelial
progenitor cell mitochondria were labeled with MitoTracker there was not
transport to the unlabeled cardiomyocytes, indicating there may be cell-type
differences that are important to consider for mitochondria transfer. Wang et al
showed that tunneling nanotubes can be formed in vitro, providing a pathway for
mitochondrial transfer (Wang & Gerdes 2015). PC-12 cells stressed by UV
created tunneling nanotubes with a larger diameter and containing microtubules
that attached to control, unstressed cells. Fluorescence microscopy detected
tagged mitochondria located within nanotubes connecting stressed and control
cells, but no presence of mitochondria in nanotubes connecting only control,
unstressed cells. Live cell imaging techniques allowed tracking of mitochondria
from the control cell, through the nanotubes, and into the stressed cells. When
tunneling nanotube formation was inhibited using cytochalasin B, an F-actin
depolymerizing agent, they found a higher incidence of cell death with the UV
stressed/unstressed co-culture suggesting that nanotube formation was
necessary for the rescue effect. They also showed positive co-localization of
MitoTracker Red-labeled mitochondria with immunostained microtubules located
within the nanotubes. They further transgenically labeled mitochondria with
DsRed2-mito in the control cells to quantify their transfer into stressed cells.
Using cytochalasin B to inhibit the nanotubes decreased the amount of Dsred2mito in the stressed cells.
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A comparative study was performed by the McCully group to determine
the mechanism of mitochondrial internalization in vitro (Pacak et al 2015).
Chemicals were utilized to inhibit different internalization mechanisms, such as
cytochalasin D to block actin polymerization, methyl-β-cyclodextrin to block
caveola-dependent-clathrin-dependent endocytosis, nocodazole to block
tunneling nanotubes, and 5-(N-Ethyl-N-isopropyl) amiloride to block macropinocytosis. The only chemical that changed mitochondrial internalization was
cytochalasin D, indicating that actin polymerization is involved in mitochondrial
uptake into the cardiomyocyte cells, though it was not evident how the
mitochondria left the endosomes once they were internalized. The other
chemicals had no beneficial effects suggesting that clathrin-dependent
endocytosis, tunneling nanotubes, and macro-pinocytosis are not involved. This
is in accordance with their previous report that mitochondria were not colocalized with lysosomes, caveolae or autophagosomes upon internalization
(Masuzawa et al 2013). In contrast, others utilized fluorescent live imaging to
track movement of transgenically-labeled DsRed mitochondria into mesenchymal
cells and reported that macropinocytosis is necessary for mitochondrial
internalization in vitro (Kitani et al 2014b). It should be noted that various
dosages of 5-(N-Ethyl-N-isopropyl) amiloride were used in attempts to block
macro-pinocytosis in the different cell types used in each study. Recently,
mitochondrial incorporation in neurons was theorized to be integrin-mediated,
though the authors stated further investigation was necessary (Hayakawa et al
2016).
2.5 Summary
Chapter 1 discussed in detail the intricacies of mitochondrial involvement
with the secondary pathophysiological cascades after SCI. Their involvement has
made mitochondria a logical target for therapeutic intervention in the acute
stages of SCI. Currently, a multitude of treatments are being tested that aim to
maintain or increase the integrity of mitochondrial health following injury, though
replacement therapies have yet to be investigated. Chapter 2 investigated the
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history of mitochondrial transplantation, including the most recent in vivo studies.
Though these novel in vivo studies are few in number and use other types of
injury models, we believe the transplantation paradigm is translatable into our
SCI injury models. As we are the first lab to perform such a transplantation after
SCI, we had to carefully and methodically choose and characterize multiple
procedures to best test our hypotheses, which are delineated in the following
chapters.

Note:
Portions of this chapter were adapted and reprinted by permission from
Elsevier: Jenna L. Gollihue and Alexander G. Rabchevsky. (2017) Prospects for
Therapeutic Mitochondrial Transplantation. Mitochondrion. 2017 May 19 DOI:
10.1016/j.mito.2017.05.007
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CHAPTER 3
Validation and Optimization of Experimental Models

There are multiple injury models, analytical techniques, and outcome
measures that could be used to test our hypotheses. We used historical data
from our lab and from other research fields to validate our experimental
techniques. There are caveats to consider for each technique, and while these
were our first-choice methods, alternatives were considered as discussed in the
future directions section (see Chapter 6.3).
3.1 Contusion Injury and Behavioral Assessments
The SCI model used in our experiments was a severe contusion injury
(250 kDyn) at the L1/L2 spinal level using the force-controlled infinite horizon
impactor (Scheff et al 2003), and assessment of hindlimb functional recovery was
performed using the Basso, Beattie, Bresnahan (BBB) scale. Our experiments
were designed to determine if mitochondrial transplantation could afford
functional recovery after severe SCI. We hypothesized that functional recovery
would be maintained through increased cell survival including gray matter
neurons surrounding the injury site. Therefore, we considered a spinal injury level
and behavioral analysis that would elucidate functional recovery based on gray
matter sparing.
The BBB open field locomotor scale was developed using a rat model of
contusion SCI using the OSU impactor or NYU impactor at the T7-9 level to
grade different levels of hindlimb functional recovery (Basso et al 1995). The
group also later showed that recovery of hindlimb locomotor function after a
complete thoracic transection SCI is dependent upon descending tracts and that
at least 10% sparing of the ventral white matter is necessary for weight bearing
steps (Basso et al 1996). Others similarly found that in the absence of gray
matter loss, a majority of ventral white matter loss is necessary to detect
functional deficits in an ethidium bromide demyelinating injury in adult rats (Loy et
al 2002). Therefore, using the BBB to measure recovery of function after a
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thoracic SCI is a primary measure of white matter sparing of descending spinal
tracts. Recovery of BBB scores after an L1/L2 level injury, however, is a measure
of gray matter sparing; this was demonstrated when a specifically gray matter
injury utilizing spinal injections of kainic acid at T9 did not result in decreased
BBB scores, but a gray matter lesion at the L1/L2 level resulted in lasting
functional deficits without disrupting descending white matter pathways
(Magnuson et al 1999). The Magnuson group later discovered that functional
deficits as measured by the BBB were dependent upon loss of intermediate gray
matter interneurons at this level, and not ventral motor neurons of the lumbar
enlargement (Hadi et al 2000). This indicates that the behavioral recovery relied
upon the sparing of the central pattern generator (CPG) interneurons in the
intermediate gray matter that are located in lamina VII and X of the L1/L2 spinal
level and are responsible for the rhythmic pattern of hindlimb stepping (Grillner
1975, Kjaerulff & Kiehn 1996). Investigators found that a moderate-severe
contusion injury at the L2 spinal level resulted in significantly depleted locomotor
function that correlates to gray matter tissue sparing, injury level, and injury
severity (Magnuson et al 2005). They also found that the amount of spared white
matter at this level of injury did not correlate to the functional deficit, further
demonstrating gray matter loss was responsible for the low BBB scores. As our
mitochondrial transplantation experiments are hypothesized to be
neuroprotective, we chose the L1/L2 injury model to measure functional recovery
using the BBB scoring system that was sensitive to gray matter sparing.
Further, the BBB scale is a 0-21 point scale that can be split into different
segments analyzing 1) joint movements, 2) stepping and coordination, and 3)
fine details of paw movements such as toe clearance and balance. Historically
we have found that after a 250kDyne L1/L2 injury we can expect a plateau of
functional recovery at a score around 7 indicating extensive joint movements with
no hindlimb weight bearing or stepping (Patel et al 2012). Increases in recovery
by mitochondrial transplantation may increase the scores to the walking and
patterned stepping scores. Restoration of function via the CPGs will result in
more differences in the upper two thirds of the BBB scale, giving greater
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separation of animals that are stepping. Attempts to modify the scale for post hoc
analysis have been published, placing more emphasis on certain parts of the
scale that are more translational, or making the scale more ordinal by decreasing
emphasis on scores that are rarely assigned (Ferguson et al 2004). We reported
these post hoc analyses in addition to our BBB testing to further differentiate
recovery between treatment groups (Chapter 5.3.3).
3.2 Cultured Cells as the Source of Transplanted Mitochondria
From very early stages of our experiments, a major goal was to
demonstrate that transplanted mitochondria can be successfully incorporated into
host cells in vivo. For this purpose, we chose to transgenically label mitochondria
in cell culture, allowing us to tag the mitochondria indelibly before their
transplantation to track them in situ. PC-12-Adh cells were chosen as the cell line
to be transfected with the pTurboGFP-mito vector. PC-12 cells originate from the
adrenal gland of a Rattus norvegicus pheochromocytoma tumor and are
neuronal-like in their development. Further, we chose to transplant mitochondria
between like species based on studies that showed mitochondrial transplantation
in vitro was more efficient when the same species of donor mitochondria were
used (Clark & Shay 1982, Yang & Koob 2012). For instance, they showed that
isolated murine mitochondria were more apt to be incorporated into cultured
murine cells, but were not able to incorporate into human cells.
3.3 Stable Selection and Purification of tGFP PC-12 Cells
When first performing these experiments, we used a pTurbo-GFP-mito
vector (evrogen cat # FP517 Farmingdale, NY) that contains a neomycinresistant cassette to transform naïve PC-12 cells. We performed a G418 dose
response selection curve, and determined that 400 µg/mL was necessary to kill
PC-12 cells that do not have a neomycin resistance cassette. While under
constant selection, individual turbo green fluorescent protein (tGFP) positive cells
colonies were manually picked from the plates to grow in separate dishes, a
technique commonly performed to give a pool of stably transfected cells.
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However, we soon noticed that the transfection rate was not 100%, and the cells
that were tGFP+ had varying degrees of fluorescence. We then decided to
change the antibiotic resistant cassette of the vector to puromycin instead of
neomycin and repeat our selection process in the hopes that we could obtain a
colony with high tGFP expression rates.
To create our vector, the coding sequence for tGFP and the mitochondrial
targeting sequence was removed from the original pTurbo-GFP-mito vector and
inserted into a pIRESpuro3 vector (for details see 4.2.1). The resulting plasmid
contained the mitochondrial targeting sequence, tGFP coding sequence, and
puromycin resistance sequence. PC-12 cells were transfected with the resultant
DNA and the cells were propagated under puromycin selection (concentration for
selection curve determined to be 3µg/mL puromycin), first very sparsely.
Fluorescent microscopy was used to verify tGFP+ cell colonies, which were then
physically selected and re-plated as described. The result was a colony of cells
that had close to 100% tGFP-expression at high levels that did not seem to
disappear with generations further removed from initial transfection. However, it
is important to note that these cells grew more slowly than unlabeled PC-12 cells,
and they had overall lower respiration rates (see Chapter 4.3.4). Regardless, the
tGFP mitochondria had an indelible marker that is critical for tracking purposes.
Because we are genetically altering cells and possibly affecting the function of
mitochondria destined for transplantation, we had to first characterize the
differences between our labeled mitochondria and unlabeled mitochondria. For
this, we delved into a series of experiments, which is discussed in detail in
Chapter 4.
3.4 Muscle Tissue as the Source of Donated Mitochondria
While tGFP-labeled mitochondria are optimal for visualization after
transplantation, they respire much more slowly and may have inherently lower
metabolic requirements compared to mitochondria isolated from naïve spinal
cord tissue. Historically, state III oxygen consumption rates (OCR) of spinal cord
mitochondria isolated from naïve SD rats is typically close to 600 pmol
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oxygen/min (Patel et al 2014). Typical state III OCR of cell-derived mitochondria
labeled with tGFP is closer to 300 pmol oxygen/min (see Chapter 4.3.4). As
such, we chose to also evaluate the transplantation of mitochondria that had a
higher metabolic potential more similar to mitochondria residing in the spinal
cord. We therefore tested muscle mitochondria that were isolated from naïve
Sprague Dawley rats, and transplanted into a different rat that had received SCI.
While this transplantation is syngeneic, and not autologous, it does serve the
purpose of transplanting high respiration-competent mitochondria into the spinal
cord. In the future, muscle mitochondria transplantation may be clinically
relevant- after a patient undergoes a SCI, it may be possible to isolate one’s own
mitochondria from a muscle biopsy providing for an autologous transplantation.
3.5 Injection Sites
Our mitochondrial injections were performed in the injury penumbra
surrounding the primary contusion injury site. The primary injury site is necrotic,
while the penumbra contains at-risk tissue that may be salvaged by mitochondrial
transplantation therapy (see Chapter 1.2). The heterogeneous cell types of the
spinal cord are all susceptible to oxidative damage and mitochondrial
compromise after SCI, and we hypothesized that mitochondria would be able to
incorporate into a variety of cell types in the spinal cord. Affording
neuroprotection was a main goal of these experiments, regardless if this is
possible directly through transplantation of mitochondria into neurons or indirectly
through mitochondrial incorporation into various cell types in the injury penumbra
making the environment more favorable for cell survival. Therefore, our injections
were made into the medial lateral gray matter near the white matter interface so
that injected mitochondria had the opportunity to incorporate into various cell
types that are typically found in both the white and gray matter. This also places
the injection bolus near lamina VII/X which includes the CPG interneurons critical
for patterned locomotor stepping (Figure 3.1).
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Figure 3.1. Location of mitochondria injections into the injured spinal cord.
A. Laminectomy was made at thoracic level T12, exposing the L1/L2 spinal level.
A 250 kDyne injury was performed, followed within 30 minutes by mitochondrial
injections (green). Four injections were made into the injury penumbra,
surrounding the injury site at the L1/L2 spinal level. B. Injections were targeted to
the medio-lateral gray matter. This allowed for the dispersion of exogenous
mitochondria into nearby white matter as well as gray matter. Importantly, this
placed tGFP mitochondria in close proximity of CPG interneurons (boxed area),
which are located within Lamina VII (yellow) and Lamina X (purple).
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3.6 Using the Seahorse Flux Analyzer for Respiration Measurements
Function of the mitochondrial electron transport system has been
examined using substrates and inhibitors to manipulate different complexes of
the ETC and measuring the subsequent oxygen consumption rates. This has
historically been done using the popular Clarke-type oxytherm electrode, though
a relatively new method that uses the same concept is the Seahorse Flux
Analyzer XFe 24. We chose to use the Seahorse for our OCR analysis of
mitochondria for its ease of use and higher throughput of samples.
The Seahorse Flux Analyzer XFe 24 is an automated system that was
initially developed to assay cultured cells, but techniques were developed to use
this device to measure OCR of isolated mitochondria with as little as 5 µg
mitochondria protein per well necessary for analysis (Rogers et al 2011). They
noted that the optimal concentration of mitochondria to assay is that which will
give an increased and sustained OCR with addition of ADP, with a significant
decrease after the addition of oligomycin. We have optimized our concentration
of isolated mitochondria to be 5- 7.5 µg per well. This allows us to easily run each
sample in triplicate, with leftover mitochondria that can be frozen and used for
other assays. The oxytherm, on the other hand, requires a relatively large
amount of protein per sample, about 80 µg/ sample run.
The time required for a sample run is much lower for the automated
Seahorse (about 30 minutes for one plate containing 7 samples in technical
triplicate) compared to the oxytherm (15-20 minutes per sample). After the
process of mitochondrial isolation, samples are left on ice until they can be
analyzed. The order of sample analysis using the oxytherm may influence
results, with those run later having been isolated and on ice for much longer,
possibly compromising the mitochondria compared to those run first in order.
One benefit that the oxytherm offers is that you can watch and manipulate
the trace in real time. For instance, if you have a bad reading in the oxytherm,
you can immediately re-start the trace if you have enough sample. There have
been mechanical failures in which the seahorse plate got stuck in the reader, or
had bad baseline readings ruining all the samples for the day. While there is a
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surplus of sample, the plates need to be incubated overnight- so that you do not
have a replacement plate if needed. Attempting to prepare for the worst and
incubating an extra plate for each experiment can get very costly, as plates and
substrates are expensive.
State V.1 should be the maximal respiration rate after addition of the ETC
uncoupler protonophore, carbonilcyanide p-trifluoromethoxyphenylhydrazone
(FCCP). However, while this is always the case in the oxytherm, it is not always
the case with the seahorse. On multiple experimental days, the seahorse tended
to give lower state V.1 readings compared to state III. One of the theories is that
FCCP is interacting with the plastic of the seahorse plate, so that it is not fully
interacting with the mitochondria (Sauerbeck et al 2011). While we assume that
this interaction is similar in each plate, we have seen plates with very high
maximal V.1 rates, and other plates with the same experimental groups have
state V.1 lower than state III. This is an important caveat to consider, and for this
reason we emphasize state III OCR results when analyzing our results.
3.7 Removing Contamination from Culture-Derived Mitochondria
Many different iterations of mitochondria isolations were performed to
increase the yield and health of mitochondria isolated from cell culture.
Modifications were made from our usual protocol of mitochondrial isolation from
spinal cord tissue, including addition of drill press homogenizations and three
rounds of nitrogen bombing (detailed isolation protocol in Chapter 4.2.2). In our
first mitochondrial transplantation studies, we had difficulty pulling the 100 µg
(33.3 µg/µL) dosage into injection needles. We could successfully pull 50 µg
(16.6 µg/µL) dosage into the needle- though this still often proved to be difficult
with clogging that resulted in bubble formation in the needle. We knew that the
clogging issue was specific to cell culture-derived mitochondria, as preliminary
feasibility studies used 200 µg (66.6 µg/uL) of spinal cord-derived mitochondria
without problems. At this point we assumed that 50 µg was the highest feasible
concentration using cell-derived mitochondria, and carried out initial experiments
using this dosage including acute bioenergetics and long term behavioral and
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histological studies. Preliminary studies indicated that 50 µg tGFP mitochondria
injection/cord resulted in significantly maintained state III OCR (Figure 3.2).

Figure 3.2. Mitochondrial respiration following SCI and tGFP mitochondrial
transplant. tGFP-labeled mitochondria were isolated and injected immediately
after L1/L2 spinal cord injury. 24 hours later, mitochondria were isolated and
analyzed for mitochondrial respiration. State III OCR was maintained with 50 µg
tGFP mitochondrial transplantation. Bars are means ± SEM. *p<0.05 vs Sham
Laminectomy; #p<0.05 vs Vehicle; + p<0.05 vs contusion only. (one-way ANOVA
for each state, Tukey’s multiple comparison). N= 4-5/group in triplicate.
During long term transplantation studies, we noted a conspicuous layer of
white film on isolated culture-derived mitochondria after ficoll purification steps.
Gentle removal of this layer, followed by an additional resuspension and
centrifugation step resulted in mitochondria that could be pulled into the needle at
a dosage of 150 µg (or 50 µg/µL). At this time, it is not known what comprised the
non-mitochondrial fraction that was removed, though all subsequent studies
utilized these extra purification steps.
3.8 Conclusions
Using historical data and preliminary studies, we determined the optimal
parameters to use for our injury and injections, as well as important outcome
measures that were used in the ensuing experiments. As these techniques are
being used in a novel paradigm of transplantation, they come with their specific
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set of caveats that are discussed further in Chapter 6. The studies described in
the subsequent chapters provide a foundation for mitochondrial transplantation
after SCI, while possible refinements in future studies can continually modify and
enhance our mitochondrial transplantation paradigm.

44

CHAPTER 4
Optimization of Mitochondrial Isolation Techniques for
Intraspinal Transplantation Procedures
4.1 Introduction
Mitochondria are widely referred to as the powerhouse of the cell. They
sustain life by providing the cell with energy in the form of ATP via a process
known as oxidative phosphorylation, and are crucial regulators of calcium
buffering and apoptosis (Nunnari & Suomalainen 2012). Since mitochondria are
vital to maintain normal cellular functions, their dysfunction can have widespread
and devastating effects. Mitochondrial dysfunction has long been associated with
neuronal trauma and ischemia/reperfusion damage to central nervous system
tissues (Azbill et al 1997, Fiskum 2000, Sullivan et al 2005, Visavadiya et al
2015). Promising pharmacotherapies have been developed to target
mitochondrial dysfunction using antioxidants (Bains & Hall 2012, Gilgun-Sherki et
al 2002, Jin et al 2014, Patel et al 2014, Smith et al 2008), ETS uncouplers
(Cunha et al 2011, Jin et al 2004, Patel et al 2009b, Rodriguez-Jimnez et al
2012, Sullivan et al 2004), and alternative biofuels (Patel et al 2010, Petruzzella
et al 1992) to feed into the electron transport system. In the burgeoning field of
organelle transplantation, a novel paradigm has emerged to transplant
exogenous, well-coupled mitochondria to replace those that are nonfunctional.
As evidenced with earlier experiments, not only can this approach supplement
the original pool of mitochondria with more endogenous antioxidant systems and
improve energy producing capabilities, but it can also replace those mitochondria
that are too damaged to function (Chang et al 2016, Hayakawa et al 2016, Islam
et al 2012, Katrangi et al 2007, Masuzawa et al 2013, Pacak et al 2015).
Mitochondrial transplantation has been shown to have beneficial effects in
different injury models in vitro using co-incubation methods (Chang et al 2013b,
Clark & Shay 1982, Elliott et al 2012, Katrangi et al 2007), direct injection
techniques (King & Attardi 1988) or co-cultured cell delivery approaches
(Cselenyak et al 2010, Plotnikov et al 2008, Spees et al 2006, Wang & Gerdes
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2015, Yang & Koob 2012); as well as in vivo using direct injections (Masuzawa et
al 2013) or cell-to-cell transfer (Islam et al 2012). In the emerging field of
mitochondrial medicine (for reviews see Armstrong 2007, Luft 1994),
mitochondrial transplantation has a unique set of caveats that require careful
consideration. Multiple labs have shown that exogenous mitochondria can be
integrated into host cells (Chang et al 2013b, Clark & Shay 1982, Cselenyak et al
2010, Islam et al 2012, Katrangi et al 2007, Kitani et al 2014a, Masuzawa et al
2013, Pacak et al 2015, Spees et al 2006). Relevant to the current study,
verification of mitochondrial incorporation into host tissues has been performed
using various techniques including quantifying transplanted mitochondrial DNA
(Islam et al 2012, Spees et al 2006, Yang & Koob 2012) or visualizing
mitochondria with transgenic labeling or post-isolation fluorescence tagging
(Chang et al 2013b, Clark & Shay 1982, Kitani et al 2014a, Lin et al 2013,
Masuzawa et al 2013, McCully et al 2009, Plotnikov et al 2008). More recently, it
has been reported that mitochondrial particles are transferred from astrocytes
into nearby damaged neurons after ischemic stroke in mice, resulting in
neuroprotection (Hayakawa et al 2016). This group also showed that injecting
isolated mitochondria particles labeled with MitoTracker Red CMXRos into the
mouse brain allows for tracking of mitochondria in the CNS in situ.
Using fluorescent mitochondrial labels does not come without its caveats.
Different mitochondrial dyes have been utilized when tracking mitochondria in
vitro (Chang et al 2013b, McCully et al 2009, Plotnikov et al 2008). Transgenic
labeling of mitochondria in vitro provides a stable alternative to labeling with more
photosensitive MitoTracker dyes (Rizzuto et al 1996, Shitara et al 2001). While
MitoTracker Green FM is a dye whose fluorescence intensity is altered with
changing membrane potentials (Keij et al 2000), it is reported that the
MitoTracker dyes can inhibit mitochondrial respiration (Buckman et al 2001). The
latter group reported that upon mitochondrial damage, such as uncoupling using
FCCP, MitoTracker dyes were released into the cell cytoplasm, indicating that
these dyes are not irreversibly bound to the mitochondria. MitoTracker Green FM
is reported to be cytotoxic in Hela cells even at low concentrations of 250 nM
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(Han et al 2013), and MitoTracker Red CMXRos is toxic to human 143B
osteosarcoma cells (Minamikawa et al 1999). CMXRos is a photosensitizer that
causes chemical damage when subjected to laser scanning, such as used in
confocal imaging.
To address the fidelity of using fluorescent trackers to label exogenous
mitochondria, we investigated the use of transgenically-labeled mitochondria
isolated from cell culture compared to traditionally labeled MitoTracker
mitochondria to ascertain which could provide a non-toxic, indelible tag that
allows for long-term visualization of transplanted mitochondria in vitro. Our
results showed that the tGFP label did not dissociate from isolated transgenic
mitochondria, but the MitoTracker Green FM label detached from mitochondria.
We then used time-lapse confocal imaging to reveal the incorporation of
exogenous tGFP mitochondria into PC-12 cells after brief co-incubation. After we
established optimal isolation protocols to obtain well-coupled and easily
identifiable mitochondria for characterizing transplantation into cell cultures, we
addressed technical hurdles for transplanting mitochondria in vivo.
Immunohistochemical evidence shows that these transgenically-labeled
mitochondria can be injected into the spinal cord with host cellular uptake within
24 hours post injection. In summary, we show successful transplantation of
exogenous, transgenically labeled mitochondria both into PC-12 cells in vitro and
within various host cells in the rat spinal cord in situ. These experiments
delineate a superior method of using transgenic cell lines for the purpose of
isolating well coupled mitochondria that have a permanent fluorescent label that
allows real time tracking of transplanted mitochondria. This lays the foundation to
apply these techniques of mitochondrial transplantation after SCI to discern cell
type incorporation and the effects on overall bioenergetics and tissue sparing.
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4.2 Materials and Methods
4.2.1 Transgenic Labeling of PC-12 Cells
The section of the plasmid vector pTurbo-GFP-mito (evrogen cat # FP517
Farmingdale, NY) containing the sequence coding for both tGFP and the
mitochondrial targeting sequence was removed and inserted into a pIRESpuro3
vector. Briefly, the restriction enzymes NheI-HF and NotI-HF were used to digest
both vectors. NheI cuts the pTurbo-GFP-mito vector at the 591 position, and
NotI cuts at the 1406 position. Within these cuts are the mitochondrial targeting
sequence and the turbo-GFP coding sequence. This insert was then gel purified
and ligated with the PIRESpuro3 vector using a rapid DNA ligation kit (Roche).
The resulting plasmid contained CMV promoter, the mitochondrial targeting
sequence, tGFP coding sequence, and puromycin resistance sequence.
OneShotStbl3 E. coli (Invitrogen cat no C7373-03 Carlsbad, CA) were then
transformed with the resulting plasmid. Briefly, the plasmid was diluted to 1ng/µL
and used according to manufacturer protocol for E. coli transformation. One
colony from the resulting plate was then selected for plasmid DNA purification
using a Miniprep kit (Qiagen 27106 Valencia, CA) according to manufacturer’s
protocol. PC-12 Adh (ATCC CRL-1721.1 Manassas, VA) cells used in these
experiments were grown at 37°C with 95% air, 5% CO2 in complete growth
media consisting of F-12K Medium (ATCC cat # 30-2004 Manassas, VA) with
2.5% fetal bovine serum (Atlanta Biologicals # S1111OH, Atlanta, GA), 15%
horse serum (Gibco # 26050-070), and 1.1% penicillin streptomycin (Corning #
30-002-CI, Tewksbury, MA). Cells were passaged every 3-4 days. Transfection
was carried out using LipoJet In Vitro DNA and siRNA Transfection kit (SignaGen
Laboratories Rockville, MD) according to manufacturer’s protocol for transfecting
adherent cells. At 24 hours after transfection, selective media (3 µg/mL
puromycin in complete media) was applied to the cells. Cells were stably
transfected by continual growth in selective media for the remainder of the
studies.
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4.2.2 Mitochondrial Isolation from Cell Culture
Isolation of mitochondria from cell culture was carried out by using
techniques for isolating mitochondria from spinal cords (Patel et al 2014), with
modifications for removing PC-12 Adh cells from culture plates and
homogenization with additional nitrogen bomb steps to ensure cellular disruption.
Briefly, cells were removed from 15cm culture plates at 95% confluence by
trypsinization (0.25% Trypsin EDTA) or manual cell scraping, as described for
experiments comparing cell removal techniques. Cells were concentrated by
centrifugation at 500 x g for 5 min at 4°C and resuspended in 2 mL isolation
buffer (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, pH
adjusted to 7.2 with KOH) containing 1 mM ethylene glycol tetraacetic acid
(EGTA). The solution was centrifuged at 1.8 rcf for 3min, 4°C. The resulting pellet
was then resuspended and mechanically homogenized using a drill press with 10
gentle passes of the pestle into and out of the solution. The cells were then
nitrogen bombed at 1500 psi, 10 min, 4°C to further release mitochondria from
cells and increase yield. Mechanical homogenization was then repeated before
the solution was again centrifuged at 1.8 rcf, 3 min, 4°C. The supernatant
containing mitochondria was removed and saved in an Eppendorf tube to be
combined at later step. To further increase mitochondrial yield, the pellet was
resuspended in isolation buffer, and mechanical homogenization and nitrogen
bombing steps were repeated. The solution was again centrifuged at 1.8 rcf, 3
min, 4°C, after which the supernatant containing mitochondria was saved and the
pellet was again resuspended and underwent mechanical homogenization,
nitrogen bombing, and centrifugation at 1.8rcf for 3min, 4°C. Finally, the 3
resulting supernatant portions that had been saved from previous steps were
centrifuged at 13,000 rcf for 10 min at 4°C, and the pellets were then
resuspended in isolation buffer, combined into one sample, and purified using
ficoll gradient (7.5%/10%) centrifugation at 32,000 rpm for 30 min, 4°C. After
centrifugation, mitochondria remain in a pellet at the bottom of the tube.
Importantly, we found that there is an inconspicuous layer of non-mitochondrial
particles lying on top of the pellet that must be aspirated gently prior to removing
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the rest of the supernatant. The purified mitochondrial pellet was resuspended
600µL isolation buffer without EGTA and centrifuged at 10,000 rcf, 10 min, 4°C
resulting in the final pellet which was then resuspended in 20 µL isolation buffer
without EGTA. 2 µL of this was used in the Pierce BCA protein assay kit (Thermo
Scientific cat# 23227 Rockford, IL) with the Biotek Synergy HT plate reader
(Winooski, VT) measuring absorbance at 560 nm to determine mitochondrial
protein concentration.

4.2.3 MitoTracker Green Labeling and Filter Testing
Mitochondria were isolated from naïve, unlabeled PC-12 Adh cell cultures
(see previous section 4.2.2). After centrifugation at 10,000 rcf, 10min, 4°C, the
mitochondria were labeled with MitoTracker Green FM (MTG, Invitrogen cat#
M7514) according to manufacturer’s protocol. Briefly, mitochondria were
incubated with 1 uM MTG for 5 min at room temperature, covered from light. The
solution was centrifuged at 10,000 rcf, 10 min, 4°C to wash any remaining
unbound MTG. The mitochondrial pellet was then resuspended in isolation buffer
with EGTA, drawn into a 1mL syringe, slowly passed through a 0.2 µm pore
Nalgene filter (Thermo Scientific cat # 723-2520) placed at the end of the
syringe, and then seeded onto 35 mm plates containing unlabeled PC-12 Adh
cells. The cells were placed in a 37°C incubator for 1 hour, after which they were
imaged using a Nikon confocal microscope (see 4.2.7). In tandem, a filter test
was performed on isolated tGFP mitochondria, which were drawn into a separate
syringe, passed through a filter and seeded onto naïve cells for imaging.

4.2.4 Transmission Electron Microscopy
For transmission electron microscopy (TEM), tGFP-labeled mitochondria
were isolated as described above. After 10,000 rcf centrifugation, the
mitochondrial pellet was fixed in 3% glutaraldehyde in sodium cacodylate buffer
overnight at 4°C. The pellet was then rinsed in 0.2M sodium cacodylate buffer 3
times for 5 minutes each at 4°C. The pellet was then placed in 2% osmium
tetroxide for 1 hour at 4°C, followed by washing in distilled water 5 times for 5
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min each at 4°C. The pellet was then placed in 2% uranyl acetate overnight at
4°C. The sample was rinsed in distilled water 5 times for 5 min each at room
temperature, followed by sequential ethyl alcohol dehydrations in 30, 50, 70, and
90% ethyl alcohol (EtOH) for 10 min each at room temperature. This was
followed by three washes in 100% EtOH for 15 min each wash at room
temperature. The pellet was then washed in resin (23.1% ERL 4221 (3,4Epoxycyclohexylmethyl-3’,4’-epoxycyclohexane carboxylate) Electron
Microscopy Sciences Hatfield PA), 18.5% DER (Diglycidyl ether of polypropylene
glycol, Electron Microscopy Sciences Hatfield PA), 57.7% NSA (Nonenyl succinic
anhydride, Electron Microscopy Sciences Hatfield PA), 0.69% DMAE
(Dimethylaminoethanol, Electron Microscopy Sciences Hatfield PA) 3 times, each
for 1 hour at room temperature with gentle spinning. The pellet was then cut into
smaller sections, placed in fresh resin in molded blocks, and incubated at 60°F
for 48 hours. Blocks were then trimmed and cut at 90 nm thickness using Ultracut
UCT (Leica Microsystems, Buffalo Grove IL). Sections were placed onto copper
grids and allowed to dry at room temp, covered to protect from dust
accumulation, overnight. The mounted grids were then processed using lead
citrate. Briefly, each grid was placed on top of a drop of 0.5% aqueous lead
citrate at room temperature in a petri dish containing sodium hydroxide pellets to
absorb carbon dioxide. Grids were left on the droplet for 3 minutes, then moved
to a new droplet of distilled water, in turn “washing” the grid. The grid was moved
to a fresh droplet of water every 5 min, for a total of 5 washes then dabbed with a
Kimwipe to remove the excess water and allowed to dry. Grids were then imaged
at 60kV on a Philips TECNAI 12 BT transmission electron microscope. Captured
images represent the inner portion of the mitochondria pellet.

4.2.5 Assaying Respiration of Isolated Mitochondria
Mitochondria, whether labeled or not, were assayed for OCR immediately
after isolation using the Seahorse Bioscience XFe Flux Analyzer as described
previously (Sauerbeck et al 2011, Patel et al 2014). Briefly, isolated mitochondria
were applied into cell plate cartridges that were then centrifuged to concentrate
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mitochondria to the bottom of each well. Then, automatically 5mM pyruvate/ 2.5
mM malate/ 1mM ADP, 1µg/uL oligomycin, 3 µM FCCP, and 100nM
rotenone/10mM succinate were sequentially added to each well. Oxygen levels
were measured after each substrate/inhibitor addition over time to obtain OCR in
each instance of manipulating different complexes of the electron transport
system.

4.2.6 Co-incubation of PC-12 Cells with Transgenically-Labeled tGFP
Mitochondria
Transgenically-labeled tGFP mitochondria were isolated from cell culture
and then applied to confluent naïve (unlabeled) PC-12 Adh cells. tGFP
mitochondria were isolated as described above (section 4.2.2) and diluted to
desired concentrations using complete media at 37°C. Naïve PC-12 cells were
plated 24 hours prior in 35mm dishes (MatTek corp. Part no. P35GC-1.5-14-C
Ashland, MA) with glass coverslip bottoms for imaging purposes. The media on
naïve PC-12 cells was replaced with mitochondrial-supplemented media at
concentrations of 5, 10, or 20 µg per 2mL of media, which was left on the cells for
1 or 2 hours dependent on the experimental design at 37°C on a gently rocking
platform. The mitochondria-enriched media was then aspirated and the cells
were rinsed once, followed by replacement with fresh complete media at 37°C
and imaging.

4.2.7 Imaging of PC-12 Adh Cells After Mitochondrial Transplantation
Cells were evaluated using a confocal Nikon Ti-e inverted microscope
(Nikon Instruments Melville NY) for high magnification and live imaging purposes
or an American Microscopy Group (AMG) Evos fluorescent microscope for low
magnification images to verify transfection efficiency of tGFP. For live imaging,
the cell plates were placed in an incubation chamber situated above an inverted
laser, set to 5% CO2 and 37°C. Cells were imaged using wavelengths for tGFP
using excitation laser 488-20 nm (Nikon) or using the green fluorescent protein
(GFP) filter cube (EVOS).
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4.2.8 Quantification of tGFP Transplantation in vitro
tGFP-labeled mitochondria at three different dosages (5 µg, 10 µg or 20
µg) were applied to and incubated with unlabeled PC-12 Adh cells (Passage 31,
80% confluent in 35 mm dish) for 2 hours before washing and imaging (section
4.2.7). In each of 3 separate experimental runs performed on separate days,
each dosage was applied to 3 different culture dishes, and 4 random nonoverlapping fields of view in each dish were captured using Nikon confocal
microscopy representing the region of interest (ROI). These images were taken
on live, non-fixed cells. After capturing the ROI, the image was thresholded
above background fluorescence, and quantification of the number of green
fluorescent objects was calculated using Nikon NIS software (Nikon Instruments).

4.2.9 Microinjection of tGFP Mitochondria in vivo
Adult female Sprague Dawley rats (250g, Harlan, n=13) underwent a T12
laminectomy to expose the L1/L2 spinal level (Patel et al 2012). Isolated tGFP
mitochondria were injected into the mediolateral gray matter at 4 circumferential
sites of the spinal cord separated by 2mM in the rostral caudal direction using a
glass micropipette needle (World Precision Instruments, Sarasota, FL cat no.
4878) pulled and beveled to a 20-30 µm inner diameter pore opening. One cohort
of naïve animals was used to determine tGFP co-localization with other
mitochondrial markers (n=2). Each injection site consisted of 750 nL of 12.5µg
tGFP mitochondria suspended in vehicle (isolation buffer with 5mM pyruvate, 2.5
mM malate and 10mM succinate); hence a total of 50µg tGFP mitochondria in
3µL vehicle was injected per cord. Animals survived 24 hours after injections and
then spinal cords were processed for histological assessment. A separate cohort
of animals was used to determine cell-type co-localization after SCI (n=11). Each
injection site consisted of 750 nL of either vehicle (n=3) (isolation buffer with
5mM pyruvate, 2.5 mM malate and 10mM succinate) or 25µg tGFP mitochondria
(n=8) suspended in vehicle; hence a total of 100µg tGFP mitochondria in 3µL
vehicle was injected per cord. Animals survived 24 (n=6) or 48 (n=5) hours after
injections and then spinal cords were processed for histological assessments.
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4.2.10 Immunohistochemistry and Image Analysis
At 24 hours after injections animals were overdosed with 0.2 mL FatalPlus solution (Vortech Pharma Ltd., Dearborn, MI) followed by transcardial
perfusion first with 0.1M phosphate buffered saline (PBS), then 4%
paraformaldehyde in PBS. A 1.5cm segment of spinal cord centered on theL1/L2
injection sites was dissected, cryoprotected in 20% sucrose/PBS, embedded in
gum tragacanth, cryopreserved, and serially cryosectioned coronally at 25µM,
keeping every section as we have reported (Patel et al 2010, Rabchevsky et al
2002). Antibodies used for fluorescent imaging and co-localization comparisons
included rabbit anti-tGFP (0.13µg/mL, Evrogen # Ab513), mouse anti-COXIV
(2µL/mL, Cell Signal #11967), mouse anti-TOMM20 (5µg/mL, abcam #
ab56783), mouse anti-RECA1 (5µg/mL, abcam # ab9774), mouse anti-Ox42
(5µg/mL, abcam # ab78457), goat anti-rabbit 488 (4µg/mL, Invitrogen # A11008),
goat anti-mouse Biotin (7.5µg/mL, Vector # BA-9200), and Streptavidin Texas
red (3.3µg/mL, Vector # SA-5006). Images were obtained using Nikon Eclipse Ti
Confocal microscope and NIS elements software (Nikon Instruments).

4.2.11 Statistical Analyses
Mander’s overlap analyses were carried out using NIS software (Nikon
Instruments), in which the percentage of overlap between pixels which were both
TRITC + and FITC + was calculated within the injection site ROI in tissue
sections. Changes in OCR and respiratory control ratio (RCR) were analyzed
using a one-way analysis of variance (ANOVA) for each respiration state. For
passage OCR comparisons, we first found no differences within the groups of the
passage OCR using one-way ANOVA. Because there were no differences, the
passages were combined to do a broad comparison between treatment groups.
The treatment groups (naïve vs tGFP) were then compared using Student’s T
test. Dose-response incorporation studies in vitro were analyzed using a one-way
ANOVA with Tukey’s multiple comparisons. All analyses were performed using
Graphpad Prism 6 (Graphpad Software, Inc., La Jolla, CA). Significance was set
to p < 0.05.
54

4.3 Results
4.3.1 Transgenic Labeling with pTurboGFP-mito Vector
The pTurboGFP-mito vector encodes tGFP as a fusion protein with the
mitochondrial targeting sequence of subunit VIII of cytochrome c oxidase
complex. When transfected into PC-12 cells, this plasmid targets the protein to
the inner mitochondrial membrane (Matz et al 1999, Rizzuto et al 1995, Rizzuto
et al 1989). By exploiting the puromycin resistance cassette of the vector,
puromycin was used to select for and amplify cells that expressed tGFP (Figure
4.1).

Figure 4.1. tGFP transfected PC-12 Adh cells. Representative images show
PC-12 cells expressing tGFP fluorescent protein under A. bright-field or B. Green
Fluorescent Protein filters. Cells were under constant selection using puromycin
(passage 19). High transfection efficiency is evident, though it should be noted
that there are varying degrees of signal intensity. C. High magnification of a tGFP
transfected cell showing perinuclear mitochondrial networks throughout the
cytoplasm. A and B taken on AMG scope, scale bar = 50µM. Image C taken on
Nikon confocal Ti-e microscope, 488nm excitation laser, scale bar= 10µM.
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4.3.2 Transmission Electron Microscopy
The morphological features of tGFP-labeled mitochondria under TEM
showed typical healthy structures such as prominent cristae and intact outer and
inner mitochondrial membranes (Figure 4.2), as we have reported (Patel et al
2009a). Verifying the structural integrity of the labeled mitochondria to be
transplanted is important, but to ensure that isolated tGFP mitochondria were
functioning properly we assessed their respiration rates to confirm the integrity of
the electron transport system; notably in comparison to mitochondria labeled with
a fluorescent dye.

Figure 4.2. TEM images of tGFP mitochondria. TEM shows that the tGFPlabeled mitochondria have dense cristae (yellow arrows) and intact membranes
(white arrows), indicative of healthy mitochondria. B. is a higher magnification of
boxed insert shown in A. Scale bars = 1 um (A), 200 nm (B).

4.3.3 Comparing Fidelity of Mitochondrial Labels
There are concerns about both the fidelity of MTG to irreversibly label
targeted mitochondria and the potential to affect the function of isolated
mitochondria (Buckman et al 2001). To compare the fidelity of the MTG label
versus the transgenic tGFP label, we performed an experiment in which labeled,
isolated mitochondria were gently pushed through a 0.2 µM filter which does not
allow the mitochondria (0.4 – 1 µM) to pass through, but does allow for unbound
MTG or tGFP to pass through. We found that while the filtered MTG/mitochondria
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solution resulted in positive green fluorescence labeling of naive cells (Figure
4.3A), there was no fluorescent labeling with the filtered tGFP/mitochondria
solution (Figure 4.3B). This indicates that using MTG in mitochondria
transplantation experiments may render ambiguous results since the dye can
label endogenous mitochondria as well. Therefore, transgenic labeling of
mitochondria in cultured cells affords an alternative method of labeling
mitochondria in an indelible manner.

Figure 4.3. MTG label dissociates from mitochondria, leading to nonspecific labeling. A. MTG labeling (green) of PC-12 cells after MTG
mitochondria solution passage through 0.02 um filter. B. Absence of tGFP
fluorescence after passing the tGFP mitochondria solution through 0.02um filter,
indicating no leakage of the label. Scale bars= 50µM.

4.3.4 Testing Respiration of Isolated, Transgenically-Labeled Mitochondria
Prior to comparing transgenic versus MTG labeling of mitochondria on
bioenergetic integrity, we tested transgenically labeled tGFP mitochondria for
functionality to ensure the integrity of the electron transport chain. Isolated
mitochondria were assayed using the Seahorse Bioscience Flux Analyzer to
determine the OCR and RCR, as described in section 4.2.5. Mitochondrial
respiration rates at the different states gives insight into the function of different
complexes of the mitochondrial electron transport system. The following methods
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are published in our lab (Patel et al., 2014). For further reference, Brand and
Nicholls have published a review of mitochondrial assessment techniques and
theories (Brand & Nicholls 2011). Briefly- addition of pyruvate, malate, and ADP
creates movement of electrons through the electron transport system, creating
ATP and consuming oxygen in the process. OCR at this point is referred to as
state III respiration- it includes the flow of electrons through the electron transport
chain from complex I through complex IV, including coupling to the ATP synthase
complex to give a complete picture of the electron transport system integrity. This
is a measurement of oxygen consumption that corresponds to ATP production.
Oligomycin is then added, resulting in state IV respiration- where the ATP
synthase complex is inhibited so that any oxygen consumption is caused by
leakage of electrons from the electron transport chain. Subsequent addition of
FCCP, a protonophore, causes collapse of the membrane potential across the
inner mitochondrial membrane, and uncouples the ATP synthase complex from
the electron transport chain. Referred to as state V.1 respiration, proton pumping
across the membrane is at a maximal rate, and is reflected by a high rate of
oxygen consumption. Final addition of rotenone (a complex I inhibitor) and
succinate (feeding electrons into complex II) elicits state V.2 respiration. Oxygen
consumption in this state is caused by electrons entering the electron transport
chain through complex II. The ratio of state III divided by state IV respiration
gives the RCR- a ratiometric measurement that is indicative of mitochondrial
integrity as it incorporates respiration from both the entirety of the electron
transport chain as well as leakage of electrons. For example, respiratory
competent mitochondria with low leakage will have a high OCR after pyruvate,
malate, and ADP addition, but a very low OCR following addition of oligomycin,
thus resulting in a higher RCR value.
We first compared mitochondria isolated from cells at various passage
numbers to ensure that there were no alterations in mitochondrial functionality
with age or cell passage numbers. Simultaneously, respiration rates of tGFPlabeled mitochondria were also compared to respiration rates of naïve, unlabeled
PC-12 mitochondria (Figure 4.4).
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Figure 4.4. OCR of isolated tGFP-labeled mitochondria or naïve nonlabeled mitochondria at different passage generations. One-way ANOVA
was performed for each state of respiration within treatment groups. With no
significant differences among passage number OCR values using a one-way
ANOVA, the groups were collapsed (indicated by the horizontal bars) and
compared using Student’s T tests to determine overall group effects. RCR were
analyzed using a one-way ANOVA for each cell group, with Tukey’s multiple
comparisons. Bars are means ± SEM. *p<0.0001 tGFP vs Naïve; #p<0.05 vs
tGFP P19. n= 3/group performed in triplicate.
There were no passage-dependent differences in respiration rates within
cell lines, indicating that the passage generation of the cells did not significantly
affect respiration; though there was a trend for decreased state III and V.1 OCR
with increased passages of the tGFP mitochondria group. Therefore, group
passage OCR values were collapsed to compare differences between naïve and
tGFP mitochondria at each state. Results showed significant differences in
respiration when comparing tGFP to naive groups (State III- P < 0.0001; State
V.1- P <0.0001) (Figure 4.4), indicating that tGFP mitochondria respire at lower
rates than naïve mitochondria, perhaps producing less ATP. Additionally, there
were significant differences in RCR values [F (2, 6) = 8.388, P=0.0183]; post hoc
analyses showed tGFP mitochondria from lower passage numbers had
significantly higher RCR values. While this is important to note, it is not yet
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known what optimal respiration rates are for mitochondria to be transplanted
since ATP production may be different among cell types. Therefore, in
subsequent experiments we utilized tGFP mitochondria from low passage
numbers.
Respiration rates of tGFP-labeled mitochondria were then compared to
MTG-labeled mitochondria. Results show that regardless of the label, there were
no significant differences in OCR at any state (State III- [F (2, 6) = 3.652, P=
0.0917]; State IV- [F (2, 6) = 3.098, P= 0.1190]; State V.1- [F (2, 6) = 2.010, P=
0.2147]; State V.2- [F (2, 6) = 1.277, P= 0.3450]), or RCR values among groups
[F (2, 6) = 0.1853, P= 0.8355] (Figure 4.5). The electron transport system does
not appear hindered by either the MTG or tGFP label as the RCR for each group
was above 5. While tGFP mitochondria were found again to respire at overall
lower rates, they remained well-coupled. It should be noted that, per
manufacturer’s protocol, MTG is reconstituted in Dimethyl sulfoxide (DMSO) to a
final concentration of 1% DMSO in solution, which may have effects on the lipid
membrane of mitochondria causing partial mitochondrial ETS uncoupling and
increased OCR.

Figure 4.5. tGFP vs MTG mitochondrial respiration. Mitochondria were
isolated from either transgenic tGFP PC-12 cells or naïve PC-12 cells that were
then labeled using MTG, then assayed for respiration using the Seahorse Flux
Analyzer. Bars are means ± SEM. (One-way ANOVA for each state) n=3/group,
performed in triplicate.
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After isolating well-coupled transgenically-labeled mitochondria from cell
culture, we optimized techniques for increasing both bioenergetics and
mitochondrial yield. In order to perform in vivo transplantation experiments, a
sufficient yield of respiratory-competent mitochondria is needed to elicit
responses following their supplementation. Using isolation methods with or
without ficoll, we have found that we can obtain a higher yield of crude
mitochondria versus purified mitochondria. However, when the health of cell
culture-derived mitochondria in the crude vs purified fractions was tested, we
found that purified mitochondria give much higher respiration rates (data not
shown). Our initial use of trypsin as a means to permeabilize the cell membranes
and release mitochondria resulted in a higher yield of mitochondria. Importantly,
however, we found in preliminary studies that intraspinal transplantation of
mitochondria isolated with trypsin caused tissue damage due to residual trypsin
remaining in the pellet (data not shown), even after washing and centrifugation.
Therefore, while the isolated mitochondria appear well-coupled, trace amounts of
trypsin in the suspension can be detrimental to tissues in vivo. Therefore,
subsequent studies using mitochondria derived from cell culture were isolated
using manual scraping with the ficoll purification step.
During in vivo transplantation experiments, isolated mitochondria may be
exposed to room temperature (RT) for up to 30 minutes while in the
microinjection needle. An experiment was performed on tGFP mitochondria to
test the effects of temperature and substrate supplementation on respiration
(Figure 4.6). The mitochondria were resuspended in isolation buffer and either
left at RT or on ice for 30 minutes, and either with or without substrate
supplementation (5mM pyruvate/malate and 10mM succinate).
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Figure 4.6. Mitochondrial respiration changes with temperature and
substrate addition. Mitochondrial respiration was highest when left on ice, with
state III and V.1 decreasing significantly at RT. Addition of substrates (subs) at
RT helped maintain state III respiration. Bars are means ± SEM. *p<0.05 vs Ice;
#p<0.05 vs Ice + subs (One-way ANOVA for each state, Tukey’s multiple
comparison) n=3/group in triplicate.
Mitochondria that were kept on ice in centrifuge tubes had higher
respiration rates compared to mitochondria left at RT. State III OCR changed
significantly [F (3, 8) = 7.407, P= 0.0107] and post hoc analysis revealed
significantly decreased OCR in samples that were left at room temperature
without substrates compared to those on ice, with or without substrates. Addition
of 5mM pyruvate malate and 10mM succinate substrates to mitochondria held at
RT partially restored state III OCR towards the respiration of mitochondria held
on ice. This indicates that substrate addition helps to maintain mitochondrial
bioenergetics in our injection paradigm.
State V.1 respiration was significantly different among groups [F (3, 8) =
22.79, P= 0.0003]; post hoc analyses showed lower respiration in all samples
compared to the naive sample on ice. There were no differences in State IV [F
(3, 8) = 2.561, P= 0.1279], State V.2 [F (3, 8) = 2.059, P= 0.1842], or RCR [F (3,
8) = 0.5777, P= 0.6458] among the groups.
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4.3.5 tGFP Mitochondrial Transplantation in vitro
We tested whether isolated transgenically-labeled tGFP mitochondria
could be incorporated into PC-12 cells by co-incubation. The tGFP mitochondria
were isolated from cell culture and 10µg was mixed with 2mL fresh complete
media and added to 35 mm culture dishes that were 80% confluent with naïve
PC-12 cells. After one hour, cells were live-imaged and showed positive tGFP
labeling within somas (Figure 4.7).

Figure 4.7. Transplanted tGFP mitochondria are taken into naïve PC-12 Adh
cells. After 10 µg tGFP mitochondria were incubated with unlabeled PC-12 cells
for one hour, live-imaging showed positive tGFP labeling within soma. The
bottom panel shows the X plane, and the right panel shows the Y plane. Cross
hairs indicate one instance of punctate tGFP mitochondria within a cell. Image
was taken using Nikon Ti confocal microscope. Scale bar = 25 µm.
We next applied increasing concentrations of tGFP mitochondria to naïve
PC-12 cells. After two hours of co-incubation, the cells were washed of any
remaining extracellular mitochondria and live-imaged (Figure 4.8A). Upon
visualization, there appeared to be much more instances of tGFP labeling in the
higher dosage groups, with no labeling in the control group (Figure 4.8A). These
differences in fluorescence were compared to assess the dose-dependent
incorporation of tGFP mitochondria. Images of the ROIs (Figure 4.8B) were
captured and thresholded to a non-transplanted plate to remove non-specific
background fluorescence for quantification. Our results showed that there was a
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significant dose-dependent difference between different groups [F (3, 8) = 5.430,
P= 0.0248]; post-hoc analysis showed a significantly higher amount of tGFP
immunofluorescence within PC-12 Adh cells administered 20µg tGFP
mitochondria compared to naive with decreasing amounts of fluorescence in the
lower dosage groups (Figure 4.8C).

Figure 4.8. tGFP mitochondria are taken up by PC-12 Adh cells in a dosedependent manner. A. Representative DIC/FITC images of individual ROI in cell
cultures from each dosage showing varying amounts of tGFP mitochondria within
cells. B. Schematic depiction of four random non-overlapping ROIs chosen per
plate analyzed for each dosage, replicated in three plates. C. Quantification of
ROI densities of tGFP for each dosage administered showed that the 20µg
transplant group had the highest number of mitochondria taken up. Bars are
means ± SEM. *p <0.05 vs control group using one-way ANOVA with Tukey’s
multiple comparisons. n=3/dosage performed in triplicate, scale bar = 50µM,
applies to all images.
To further confirm that mitochondria were successfully incorporated into
cultured cells, time-lapse experiments were performed. After 10 µg of isolated
tGFP-labeled mitochondria were incubated with naïve PC-12 cells for 2 hours as
described earlier, the cells were imaged over a 12 hour period during which
positive intracellular tGFP fluorescence was evident (Figure 4.9). Remarkably,
cells could be seen replicating during this time, segregating transplanted
mitochondria between daughter cells.
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Figure 4.9. Movement of exogenous tGFP mitochondria within PC-12 cells.
After 10 µg tGFP mitochondria was added to naïve PC-12 cells and incubated at
37°C on a gently rolling platform for 2 hours, they were washed off and replaced
with complete media before time lapse images were taken over a 12-hour period.
Images represent beginning of imaging A separated by 100 minutes for each
time frame (B-F). Mitochondria can be visualized moving within cells (yellow
arrow). As a cell divides (white asterisk on mother cell in A and B, then on each
daughter cell in C-F, with division occurring at white line in C), transplanted
mitochondria can be seen throughout the division process, and are retained in
the daughter cells (white arrow). Images were taken using Nikon Ti confocal
microscope. Scale bar = 20µM.

4.3.6 In vivo Transplantation
Using the optimal isolation methods, mitochondrial transplantation was
performed in vivo to determine if transgenically-labeled, cell culture-derived
exogenous mitochondria can be incorporated into living spinal cord tissues. tGFP
mitochondria were isolated and injected into the medial lateral gray matter of the
rat spinal cord at the L1/L2 spinal level. 24 hours after transplantation animals
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were euthanized and spinal cords processed for histology. An anti-tGFP antibody
was used in tandem with antibodies specific to mitochondrial proteins to
determine cell type co-localization (Figure 4.10).

Figure 4.10. tGFP labeled mitochondria injected into the spinal cord colocalize with mitochondrial markers. tGFP mitochondria were isolated from
PC-12 cells and injected into the rat spinal cord. Antibodies against tGFP and the
inner (A) (COXIV) and outer (B) (TOMM20) mitochondrial membranes show that
the injected green fluorescence is intact mitochondria. Images taken on Nikon Ti
confocal microscope. White boxes indicate region of injection and co-localization
analyses. Scale bar= 100µM.
COXIV antibody targets the inner mitochondrial membrane, while
TOMM20 antibody targets the outer mitochondrial membrane. When visualized
with tGFP which also localizes to the inner membrane, COX IV co-localization
indicates that the tGFP signal is indeed mitochondria. Further, the exogenous
mitochondria appear intact as the tGFP tag localizes to the inner membrane and
TOMM20 labels the outer membrane; positive co-localization indicates grafted
mitochondria with both inner and outer membranes intact (Figure 4.10). When
quantifying the co-localization of the tGFP positive and Texas Red positive pixels
in the injection region (indicated by white boxes), the Mander’s overlap value for
tGFP and COXIV was 0.843 and for tGFP and TOMM20 was 0.855. This
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indicates that within the region of injection, the tGFP mitochondria are colocalized with mitochondrial markers.
Cell type co-localization was evident within macrophages and endothelial
cells at both 24 and 48 hours after injection (Figure 4.11). Positive signal overlap
(yellow) of green (tGFP) signal within cell membranes (red) indicate colocalization. Exogenous tGFP mitochondria were found to be within both
microglia/macrophages and endothelial cells of the spinal cord at both 24 and 48
hours after injection (Figure 4.11). There may be a cell-specific mode for
mitochondrial incorporation. For example, there is much evidence of punctate
tGFP+ signal within the cell membrane of macrophages (Fig. 4.11 A and B),
though it is not known if the mitochondria underwent phagocytosis or whether
they were passively incorporated into the cytoplasm. Additionally, tGFP
mitochondria were found within endothelial cells at both time points (Fig. 4.11 C
and D). There was positive tGFP signal directly associated with the membranes
of some endothelial cells that appeared perinuclear, which may indicate the
mitochondria are being taken into perivascular pericytes (Figure 4.11 C, tGFP+
signal closely associated with endothelial membrane). Further studies will utilize
markers for pericytes to determine if exogenous mitochondria are being taken
into these cells, and we will comprehensively characterize cell-type incorporation
over time.
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Figure 4.11. Exogenous tGFP mitochondria are incorporated into different
cell types in situ. tGFP mitochondria were injected into the naïve spinal cord.
Representative z-stack images were taken from spinal cords at the 24 (A, C) or
48 hour (B,D) time points after injection. OX42 = microglia/macrophages, RECA
= endothelial cells. Scale bars = 10µM. Images were taken with Nikon Ti confocal
microscope.
4.4 Discussion
The results of our feasibility study demonstrate that transgenically-labeled
tGFP mitochondria are a viable option for visually tracking transplanted
mitochondria both in vitro and in situ. It is possible to label the inner mitochondrial
membrane of cultured cells with tGFP with high transfection efficiency and
isolated mitochondria have intact inner and outer mitochondrial membranes, as
well as dense cristae as seen in TEM images. We also found that
supplementation of isolated mitochondria with pyruvate malate and succinate is
beneficial for maintaining state III respiration at room temperature for prolonged
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periods of time often required for transplantation procedures in vivo. Further, we
demonstrate that the transgenic tGFP label is an indelible marker of transplanted
mitochondria, and contrary to previous studies (Katrangi et al 2007), we found
that MTG did not stay irreversibly bound to exogenous mitochondria; this may
result in host labeling and inaccurate conclusions of successful transplantation.
Others have also found MTG fluorescence intensity to be at least partially
dependent upon membrane potential (Keij et al 2000).
The bioenergetics of mitochondria isolated from cultured cells did not
change across multiple passages, but there was an overall decreased respiration
rate of transgenically-labeled mitochondria when compared to unlabeled
mitochondria. This may be partially contributed to the stable transfection attained
by puromycin selection. While the transgenic cells have a puromycin resistance
sequence, they grew more slowly than naive cells at the same passage numbers.
We noted that the cell doubling time for unlabeled cells is about 24 hours,
whereas the doubling time for transgenic cells was closer to 72 hours. We did not
note any higher levels of die-off or cell death while the transgenic cells were
under selection. At lower cell passage generations, the isolated mitochondria
remained well-coupled with comparable RCR to naïve mitochondria. In contrast,
MTG-labeled mitochondria showed higher respiration than tGFP-labeled
mitochondria, although this increase was not significant. Importantly, naïve,
MTG-labeled and tGFP-labeled mitochondria had healthy RCRs indicating that
the electron transport chain is well coupled to the ATP synthase complex.
Differences in respiration of MTG labeled mitochondria vs naive unlabeled
mitochondria has been documented (Buckman et al 2001), where it was
concluded that MTG alters ETC activity such as uncoupling the ETC from ATP
synthesis.
Use of transgenically-labeled mitochondria opens the possibilities for cell
type co-localization/double labeling and tracking experiments to evaluate
incorporation of exogenous mitochondria distinguishable from host cells.
Transgenic labeling of mitochondria in vitro can supply a pool of stably
transfected mitochondria that affords the opportunity to visualize the movement
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and integration of exogenous mitochondria within host cells and/or tissues. This
can be especially important in future studies to determine the fusion and fission
properties of exogenous mitochondria in the context of their successful
integration into the host mitochondrial networks after transplantation. Further, this
labeling strategy could be useful for visualizing mitochondria in paradigms of
transplantation after cytotoxic insult to cultured cells to determine beneficial
effects afforded by mitochondrial supplementation.
Upon co-incubation of tGFP mitochondria with naïve PC-12 cells, we
showed that exogenous mitochondria were taken into cells within hours and
could be seen moving within cells. This reflects previous reports that
supplemented mitochondria, labeled in various manners, are taken into cultured
cells upon co-incubation (Chang et al 2013a, Clark & Shay 1982, Katrangi et al
2007, Kitani et al 2014b). Our results showed concentration-dependent tGFP
mitochondria incorporation into naïve cells, and time lapse imaging over 12 hours
after co-incubation showed tGFP mitochondria moving within cells. We also
performed in vivo transplantation to test incorporation in spinal cord tissues in
situ. Co-labeling of TOMM20 and COXIV showed that the tGFP+ signals
represent exogenous mitochondria, and subsequent immunohistochemistry
indicated that transplanted tGFP mitochondria were co-localized predominantly
with both microglia/macrophages and endothelial cells. Further analyses are
quantifying the incorporation propensity into these cells, as well as other cell
types of the spinal cord including neurons, oligodendrocytes, and astrocytes.
Mitochondrial uptake into cells similar to our results has been reported, but it is
yet unknown what the mechanism of incorporation is- whether the process is
passive or active, as multiple studies have found evidence for different
mechanisms not always supporting each other. For instance, some have shown
that different cell lines are more likely than others to incorporate exogenous
mitochondria upon co-incubation, which was theorized to be due to differential
endocytic properties of cell types (Clark & Shay 1982). Others have shown
xenogenic transfer of exogenous mitochondria in culture upon co-incubation
(Katrangi et al 2007). It has been posited alternatively that mitochondria cannot
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be taken into recipient cells via passive endocytosis (Pacak et al 2015). This
group utilized chemicals to block different methods of internalization and found
that only cytochalasin D, which blocks actin polymerization, inhibited
mitochondrial uptake. They also blocked clathrin-dependent endocytosis,
tunneling nanotubes, and macropinocytosis, but found none of these inhibited
mitochondrial uptake. However, others reports that macropinocytosis is
necessary for mitochondrial internalization utilizing the same blocker of
macropinocytosis the Pacak study used (Kitani et al 2014b). Different cell types
were used in the two studies, which may support the findings of Clark and Shay
(1982) that cell types can behave differently. While these studies all support that
exogenous mitochondria can be taken into host cells in culture, there is not yet
consensus on mechanisms by which this happens.
In summary, by using transgenic mitochondrial labeling and time-lapse
imaging, it is possible to visualize mitochondrial uptake into cells in real time in
vitro, allowing further investigation into the exact mechanisms of incorporation.
Importantly, we present data showing that transgenic labeling is indelible without
affecting mitochondrial integrity so that they may be effectively tracked and
visualized after transplantation in both cultured cells and tissues in situ. We found
the transgenic tGFP tag 1) permanently labels mitochondria with no evidence of
dissociation, 2) does not affect mitochondrial integrity, and 3) is easily identified
using both fluorescent microscopy alone or with enhanced antibody labeling. Our
transgenically-labelled mitochondria did have lower overall respiration rates
compared to unlabeled mitochondria, which is a caveat that must be considered
for future transplantation experiments. Depending upon the purpose of the
experiment, there is a caveat that using tGFP mitochondria may respire more
slowly, but they have a reliable marker for visualization.
Our next set of experiments utilized these isolation protocols for
transplantation of exogenous mitochondria into the injured spinal cord to
determine the effects mitochondria transplantation have on tissues in vivo where
there is a complex environment including different cell types, potential immune
responses, as well as further technical hurdles to consider.
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Note:
Portions of this chapter were adapted and reprinted by permission from
Elsevier: Gollihue J.L., Patel S.P., Mashburn C., Eldahan K.C., Sullivan P.G. and
Rabchevsky A.G. (2017) Optimization of mitochondrial isolation techniques for
intraspinal transplantation procedures. Journal of Neuroscience Methods
Epub 2017 May 23 DOI: 10.1016/j.jneumeth.2017.05.023
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CHAPTER 5
Mitochondrial Transplantation in vivo: Bioenergetics, Incorporation, and
Functional Recovery

5.1 Introduction
Contusion spinal cord injury can result in lifelong debilitation and has a
profound impact on day to day activities of individuals living with SCI. In the event
of an injury, the primary injury site comprises necrotic tissue that can cause
secondary injury cascades, including glutamate excitotoxicity, decreased ATP
production, increased lipid and protein oxidation, and resulting apoptosis and
necrosis (see Chapter 1.2 for details). It is widely accepted that mitochondrial
dysfunction is intimately related to detrimental secondary pathophysiology
resulting from SCI. Similar to SCI, mitochondrial dysfunction has been found to
be pivotal to disease and injury progression in other injury models including
traumatic brain injury, cardiac ischemia, stroke, Parkinson’s disease, and
Alzheimer’s disease (Aygok et al 2008, Bolanos et al 2009, Ide et al 2001,
Krajewski et al 1999, Lin & Beal 2006, McCully et al 2009, Mizuno et al 1989,
Sullivan et al 2007, Swerdlow & Khan 2004, Winklhofer & Haass 2010, Xiong et
al 1997).
As such, mitochondrial medicine is a developing field of therapeutics
aimed at improving mitochondrial health and function for a variety of
physiological disease and injury states. Several groups have shown that using
different methods of targeting mitochondria dysfunction results in
neuroprotection, tissue sparing, and functional recovery. Antioxidants are used to
decrease ROS and RNS damage caused by dysfunctional mitochondria in
models of nephrotoxicity, TBI, SCI, PD, neurodegeneration, and oxidative stress
(Ahmed et al 2014, Bains & Hall 2012, Hall et al 2010, Jin et al 2014, Patel et al
2014, Robb et al 2008, Sheu et al 2006, Smith et al 2008, Ungvari et al 2009,
Xiong & Hall 2009). Mild uncoupling of the ETS resulting in increased ATP
production has also been shown to be a potential therapy for mitochondrial
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dysfunction after SCI, quinolinic acid neurological injury, and models of
neurological insult in vitro (Brand & Esteves 2005, Jin et al 2004, Maragos et al
2003, Patel et al 2009b, Rodriguez-Jimnez et al 2012, Sullivan et al 2004).
Mitochondrial substrate precursors such as acetyl L-carnitine (ALC) and Nacetylcysteine amide (NACA) have been used to improve mitochondrial function
after TBI, SCI, age-related cognitive function, and PD (Carta & Calvani 1991,
Laird et al 2013, Liu et al 2002, Patel et al 2012, Patel et al 2010, Petruzzella et
al 1992, Puca et al 1990). All of these therapies attempt to increase functional
neuroprotection by intervening in mitochondrial dysfunction in one form of
another.
Gaining credence is a new therapy of mitochondrial transplantation that
has emerged as a possible treatment option to restore mitochondrial function
after injury, consequently improving long term functional outcome (McCully et al
2017). Transplanted mitochondria may exert beneficial effects by increasing ATP
production and calcium buffering capacity, decreasing overall ROS production,
providing more antioxidants, and providing a new pool of mtDNA-see Chapter 2.
Though this therapy is relatively new, transplantation has been shown to be an
important player in recovery after ischemic injury to cardiac tissue (Cowan et al
2016, Masuzawa et al 2013, McCully et al 2009, Pacak et al 2015). It has also
been shown recently that astrocytes inherently donate their mitochondria to
nearby neurons after stroke injury in vivo, and that astrocytes can be induced to
release mitochondria after injury resulting in neuroprotection (Hayakawa et al
2016). Further, they showed that blocking astrocyte donation of mitochondria
using CD38 siRNA inhibited mitochondrial transfer and resulted in neuronal cell
death. This shows both the importance and possibility of mitochondrial transfer
into damaged cells resulting in cell survival. Intravenous injections of isolated
fluorescently-labeled mitochondria in a mouse model of Parkinson’s Disease
resulted in increased ATP production, increased Complex I activity, decreased
ROS, and increased behavioral rotarod scores compared to vehicle injected
animals (Shi et al 2017). In a rat model of Parkinson’s Disease, injections of Pep1 conjugated isolated mitochondria into the medial forebrain bundle increased
74

locomotor scores and dopaminergic neuronal sparing (Chang et al 2016). We
have previously shown that exogenous transgenically-labeled mitochondria can
be taken into cells of the injured rat spinal cord and are visible at 24 and 48 hours
post injury (Gollihue et al 2017).
In the current studies, we investigated the therapeutic effects of immediate
mitochondrial transplantation after traumatic SCI. We hypothesized that
supplementing the injured spinal cord with a pool of healthy, well-coupled
mitochondria could provide a new source of increased energy production,
decreased oxidation, and dampened effects of glutamate excitotoxicity resulting
in increased tissue bioenergetics. Further, we theorized that exogenous
mitochondria would be successfully incorporated into a variety of cell types.
Lastly, we posited that these beneficial effects in the short term would result in
long term benefits, such as hindlimb functional recovery and tissue sparing.
5.2 Methods
5.2.1 Transgenic Labeling of PC-12 Cells
PC-12 cells were transgenically labeled with a mitochondrial-targeting
tGFP, as detailed in Chapter 4.2.1. Following transfection, cells were kept under
constant selection using media containing 3 µg/mL puromycin in complete media.

5.2.2 Mitochondrial Isolation from Cell Culture
Purified mitochondria were isolated from transfected tGFP-PC-12 cells as
described in detail in Chapter 4.2.2. Briefly, when cells were 95% confluent they
were manually removed from culture plates using a cell scraper. Mitochondria
were isolated using multiple centrifugation and resuspension steps to yield
purified mitochondria. Importantly, after ficoll purification the non-mitochondrial
layer was gently aspirated off the final pellet, ensuring the sample did not have
contamination that would make it difficult to pull into the injection needle (see
Chapter 3.7).
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5.2.3 Mitochondrial Isolation from Soleus Muscle
Immediately following CO2 asphyxiation and decapitation, the soleus
muscle was dissected from naïve Sprague Dawley rats (n=6, see Table 5.1). The
animal was placed on its stomach, with the hindlimb stretched backwards. 70%
EtOH was sprayed on the hindlimb, and scissors were used to blunt dissect the
skin away from the underlying calf muscle. The skin was then cut away from the
muscle on the lateral sides, followed by cutting the Achille’s tendon. The muscle
was pulled up and away from the leg, exposing the underlying soleus muscle.
The tendons were cut at both insertion sites, and the soleus muscle was
removed and placed in 2mL of isolation buffer (215 mM mannitol,
75 mM sucrose, 0.1% BSA, 20 mM HEPES, and pH adjusted to 7.2 with KOH)
containing 1 mM EGTA and trypsin. The muscle was chopped into smaller pieces
using scissors to increase surface area exposed to the isolation buffer and
trypsin. The sample was then mechanically homogenized taking care not to
introduce air bubbles. Protease inhibitor was added to halt trypsin activity,
followed by centrifugation at 1500 rcf, 4°C, 5min. The supernatant was removed
and spun at 13,000 rcf for 10min, 4°C after which the pellet was resuspended in
isolation buffer and purified using ficoll gradient (7.5%/10%) centrifugation at
32,000 rpm for 30 min, 4°C.The pellet was removed and resuspended in 0.6 mL
isolation buffer without EGTA, and spun at 10,000 rcf for 10min, 4°C.The
resulting pellet contain purified mitochondria, which was resuspended in isolation
buffer without EGTA for Pierce BCA protein assay and microinjection into spinal
cord.

5.2.4 Spinal Cord Injury and Microinjection Surgical Procedures
Adult (12 weeks old, 225-250g) female naïve Sprague Dawley rats
(Harlan) underwent intraperitoneal injections of anesthesia (80mg/kg ketamine
and 10mg/kg xylazine, Butler Animal Health Supply) followed by lacrilube
opthalmic ointment applied to both eyes before surgery to prevent drying. The
surgical site along the dorsal spine is shaven with an electric hair trimmer and
cleaned with both 70% ethanol and betadine solutions. Animals then had a T12
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laminectomy to expose the L1/L2 spinal level (Patel et al 2012). Sham animals
received a laminectomy only, whereas injured animals received a severe 250
kDyn contusion injury using a force controlled Infinite Horizon impactor
computerized injury device (Precision Systems and Instrumentation, LLL,
Lexington KY (Scheff et al 2003)). Injured animals were split into three cohortsthe first cohort received vehicle injection, the second received cell-derived tGFP
mitochondria, and the third received muscle-derived mitochondria. Injections
were made immediately after injury into the mediolateral gray matter at 4
circumferential sites of the injured cord separated by 2mM in the rostral caudal
direction (see Figure 3.1) using a glass micropipette needle (World Precision
Instruments, Sarasota, FL cat no. 4878) pulled and beveled to a 20-30 µm inner
diameter pore opening. Each injection consisted of 750 nL of either vehicle
(isolation buffer with 5mM pyruvate, 2.5 mM malate and 10mM succinate) or
mitochondria suspended in vehicle (for a total of 50, 100 or 150 µg); hence a total
of 3µL volume was injected per spinal cord. Muscle incisions were closed using
silk sutures and skin incisions were closed using wound clips, followed by
application of hydrogen peroxide and betadine. Immediately following surgery,
animals were single housed in a clean cage on top of a towel on a 37C heating
pad, and monitored until recovery from anesthesia. Yohimbine 1−2 mg/kg s.c.
(Lloyd Laboratories) was used to counteract the effects of xylazine.
Buprenorphine HCl (0.02−0.05 mg/kg s.c, Butler Animal Health Supply) was
administered subcutaneously immediately after surgery to alleviate pain, and
then every 8 hours for 3 days following operation. The antibiotic cefazolin (33.3
mg/kg, s.c, Butler Animal Health Supply) was given twice daily for 5 days
post−operatively to decrease incidence of infection. The animals were housed
individually until staple removal, with the addition of aspen chew sticks and
plastic toys for environmental stimulation. Cages were lined with absorbent pads
for the duration of buprenorphine use, as pica has been observed in these
animals. After discontinuation of buprenorphine, pine bedding was used.
Additional parenteral fluids (Lactated Ringer’s solution) were provided as needed
for 24−72 h post-surgery to compensate for dehydration brought on by
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anesthesia. Bladder expression was performed 2 times per day until adequate
spontaneous voiding returned to avoid urinary tract infections. Skin wound clips
were removed 10−14 days post−injury under isoflurane anesthesia. Animals
survived either 1) 24 hours for mitochondrial respiration analyses (n=45), 2) 24h,
48h, or 7 days for histological analyses (n=15), or 3) 6 weeks for long term
behavioral and tissue sparing analyses (n=36)- see Table 5.1 for division of
animal cohorts.
Table 5.1. Separation of animal cohorts by outcome measure. Animals were
separated into cohorts for different timepoints and different outcome measures.
Depending on the outcome measure, cell derived tGFP or muscle derived
mitochondria were transplanted. It should be noted that in addition to these
animals, 6 rats were used as donors for leg muscle-derived mitochondria, and 7
animals from long term studies were removed from the study for various reasons
(see Section 5.3.3).
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5.2.5 Behavioral Analyses
5.2.5.1 Overground Locomotor Rating Scale (BBB)
The BBB locomotor rating scale was used to analyze the hindlimb
functional recovery of animals after contusion SCI. Assessments were performed
according to published protocol (Basso et al 1995). Animals underwent contusion
injury, followed by BBB assessment at 2, 7, 14, 21, 28, 35, and 42 days post
injury. Testing was performed at the same time in the same room on each testing
day to reduce variation. The scores for the right and left leg were averaged for
each time point.
5.2.5.2 von Frey Filament
Mechanical tactile sensitivity and allodynia was measured using von Frey
filament (Stoelting, Inc, Wood Dale, IL). Briefly, eight monofilaments increasing in
logarithmic stiffness were used to incrementally stimulate the plantar hindpaw.
As described previously, a modified up-down method was used to determine the
50% withdrawal threshold (Chaplan et al 1994). An intermediate force von Frey
filament (#4.31, 2.0g force) was first applied to the glabrous skin until the filament
was slightly bent. If the animal immediately withdrew the hindpaw in response,
this was designated a positive response and the next filament tested was of a
lesser force. When there was not an immediate withdrawal of the hindpaw, the
next filament applied was of a greater force. The thresholds for both hindpaws
were averaged and reported.

5.2.6 Mitochondrial Isolation from Spinal Cords
For bioenergetics assays, animals were CO2 asphyxiated and decapitated
24 hours after injury and injections. A 1cm segment of spinal cord surrounding
the injury site and including all of the injection sites was quickly dissected and
total mitochondria were isolated as described previously (Patel et al 2012,
Sullivan et al 2007). Briefly, the spinal cord was placed in a homogenization tube
with 2mL isolation buffer containing EGTA ((215 mM mannitol, 75 mM sucrose,
0.1% BSA, 20 mM HEPES, and pH adjusted to 7.2 with KOH) containing 1 mM
EGTA), and physically homogenized with 6 quick rotations of the pestle, without
79

introducing bubbles into the solution. The sample was poured into a 2mL
Eppendorf tube and centrifuged at 1400 rcf for 3 min, 4°C. The supernatants
containing mitochondria were poured into a separate Eppendorf tube which was
filled up to 2mL with isolation buffer containing EGTA. To increase yield, the
pellet was resuspended in 500uL isolation buffer containing EGTA and again
centrifuged at 1400 rcf for 3 min 4°C. The supernatants containing mitochondria
were again poured into separate tubes and filled to 2mL with isolation buffer
containing EGTA. The supernatant tubes were centrifuged at 13000 rcf for 10
min at 4°C. The resulting supernatant was discarded, and 350 uL isolation buffer
containing EGTA was used to resuspend each pellet containing mitochondria.
The samples underwent nitrogen bombing at 1200 PSI for 10 min at 4°C. The
samples were placed on top of a ficoll gradient (7.5%/10%) and centrifuged at
32000 rpm for 30 min 4°C. The supernatant was removed leaving a purified
mitochondrial pellet. The pellet was resuspended in 450 uL isolation buffer
without EGTA and centrifuged 10,000 rcf for 10 min 4°C to remove remaining
EGTA from the sample. The pellet was resuspended in isolation buffer without
EGTA. BCA protein assay was performed to determine protein content.

5.2.7 Assaying Respiration of Isolated Mitochondria
Mitochondria were assayed for OCR immediately after isolation using the
Seahorse Bioscience XFe Flux Analyzer as described previously (Patel et al
2014, Sauerbeck et al 2011) and described in detail in Chapter 4.2.5. Briefly,
mitochondrial respiration was assessed using Seahorse Bioscience eXF24 Flux
Analyzer at 37°C using respiration buffer: 215 mM mannitol, 75 mM sucrose, 2
mM MgCl2, 2.5 mM inorganic phosphates, 0.1% BSA, 20 mM HEPES, pH 7.2.
After isolation, purified mitochondria were added to the respiration buffer and
centrifuged in cell plate cartridges to concentrate mitochondria to the bottom of
each well. Then, 5mM pyruvate/ 2.5 mM malate/ 1mM ADP, 1µg/uL oligomycin, 3
µM FCCP, and 100nM rotenone/10mM succinate were sequentially added to
each well. Oxygen levels were measured after each substrate/inhibitor addition to
calculate each state of mitochondrial respiration.
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5.2.8 Mitochondrial Complex I Assay
Function of the ETC complex I was assayed as we have previously
described (Patel et al 2009b). Immediately after mitochondria were isolated, 20
µL was stored at -80C. At the time of the assay, the samples were thawed at
room temperature, then diluted to 1 µg/µL using 10 mM phosphate buffer (pH
7.4) and vortexed to mix. The samples then underwent three cycles of
freeze/thawing. This was followed by 3 cycles of sonication consisting of 0.5
seconds sonication/0.5 seconds of rest for 10 seconds total/cycle. The samples
were placed on ice between cycles to prevent overheating. 6 µg protein was
added to buffer containing 45.45mM phosphate buffer, 1mM KCN, and 150uM
NADH so that the total amount/well was 100uL. Each sample was run in wells
both with and without 10uM Rotenone. 50uM CoQ10 was added using the
BioTek Synergy HT plate reader (Vinooski, VT) and changes in NADH
fluorescence (excitation 360nm/emission 460nm) were measured at 1 min
intervals and reported as nmol/min/mg protein. The reduced form of NADH emits
light at these wavelengths, while the oxidized form does not.

5.2.9 Spinal Cord Processing for Histological Analyses
Rats survived to their terminal time point after injection (24 hours, 48
hours, 7 days, or 6 weeks). They were overdosed with 0.2 mL Fatal-Plus
containing sodium pentobarbital (Vortech Pharma Ltd., Dearborn, MI) followed by
transcardial perfusion with150 mL of 0.1M PBS, then with 250mL 4%
paraformaldehyde (PFA) in phosphate buffered saline. A 3cm segment of spinal
cord centered on the L1/L2 injury site was dissected, and post-fixed up to 4 hours
with 4% PFA followed by washing overnight in 2M phosphate buffer. The cords
were cryoprotected in 20% sucrose/PBS at 4°C until the cords sank in the
solution, then embedded in tragacanth blocks and serially cryosectioned
coronally at 20µM (Rabchevsky et al 2001). For the 24 hour, 48 hour, and 7 day
cohorts in which more sections were necessary for planned histological analyses,
every other section was mounted. Ten slide series were collected so that
adjacent spinal cord sections on any given slide were spaced equally 400 µM
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apart. For long term studies with a 6 week time point in which lesion volume
analysis was performed, every 5th section was mounted onto a slide. Ten slide
series were collected with adjacent sections on a slide separated by 1000 µM.

5.2.10 Immunohistochemistry and Fluorescent Imaging
Antibodies used for fluorescent imaging and co-localization studies
included rabbit anti-tGFP (0.13µg/mL, Evrogen # Ab513), mouse anti-RECA1
(5µg/mL, abcam # ab9774), mouse anti-GFAP (2µg/mL, abcam # ab10062),
mouse anti-CC1 (0.5µg/mL, Cal Biochem #OP80), mouse anti-NeuN (5µg/mL,
Millipore # MAB377), mouse anti-Ox42 (5µg/mL, abcam # ab78457), phosphorPDGF Receptor β (5uL/mL Cell Signaling mAb #3166), goat anti-rabbit 488
(4µg/mL, Invitrogen # A11008), goat anti-mouse Biotin (7.5µg/mL, Vector # BA9200), and Streptavidin Texas red (3.3µg/mL, Vector # SA-5006). Images were
obtained using Nikon Eclipse Ti Confocal microscope and NIS elements software
(Nikon Instruments).

5.2.11 Quantification of tGFP Volume and Spread Over Time
A set of tissue section slides for each time point were used to analyze the
tGFP mitochondria volume and spread over time after injection. Anti-tGFP
antibody was used to label injected mitochondria, as described above. Each
spinal tissue section was then analyzed under the Nikon confocal microscope for
the presence of distinct tGFP labeling. When a discreet tGFP injection bolus was
present, ND2 software was used to measure the area of the bolus. Each of the
four injection epicenters per spinal cord was verified by finding the largest area of
discreet bolus. Every section both rostral and caudal of the injection epicenter
that contained a discreet tGFP bolus was measured for bolus area. After defining
the boundaries of the injection bolus, the tissue thickness and periodicity of the
sectioning paradigm was used to calculate the total bolus volume of each cord
that included all four injections. The rostral-caudal length through the cord that
punctate tGFP labeling was evident, regardless of an apparent discreet injection
bolus, was also calculated.
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5.2.12 Quantification of Brain Macrophage Response
For the 24 hour, 48 hour, and 7 day animal cohorts, we analyzed the
macrophage density at each injection epicenter. Once the injection site was
located, a score of 0-3 was assigned for each injection epicenter. 0 indicates no
abnormal density in macrophages, similar to staining evident in naïve tissues. A
score of 1 indicated there was some increased infiltration/activation of brain
macrophages. This included a change in morphology of the macrophages from
the inactivated state with long cellular processes to an activated state in which
processes were withdrawn and the shape of the macrophage was larger and
more spherical. A score of 2 represented an increase in activated brain
macrophages within the confines of the injection site, usually within a dense
bolus. 3 was the highest score, and represented an injection site in which there
was a brain macrophage response with a high density that exceeded the original
injection bolus size.

5.2.13 Cell-type Co-localization Over Time
Cell-type co-localization of tGFP mitochondria was quantified for different
cell types in the 24 and 48 hours and 7 day cords. Separate sets of slides were
labeled for either microglia, endothelial cells, oligodendrocytes, astrocytes,
pericytes or neurons, and co-labeled with antibodies against tGFP as described
above in 5.2.11. Eight sections total per spinal cord were quantified using the left
side injections of each spinal cord including the injection epicenter, one section
(400um) from the injection epicenter towards the injury, one section (400um)
from the injection epicenter away from the injury site, and the first section away
from the injection epicenter that no longer contained a visible bolus (see Figure
5.8A for counting schematic). The region of interest counted for each section was
the left dorsal quadrant of the cord, drawing a vertical line from the central canal
to the dorsal surface, and a horizontal line from the central canal to the lateral
surface (see Figure 5.8B for depiction of ROI). Slides were visualized under an
Olympus BX51 microscope at 100X magnification (10x eye piece) using a
FITC/TRITC combination filter to simultaneously visualize the green and red
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channels. Positive co-localization was defined by the yellow overlap of signal, or
the green punctate signal contained within the cell membrane of the cell-type
marker. Cells were verified using the DAPI filter to ensure that the nucleus was
within the focal plane. Counts were performed within the ROI of a total of 8 spinal
cord sections of each animal for 1) each time a specific cell was co-localized with
the tGFP signal and 2) total cell counts for the specific cell type. Quantification of
co-localization was reported as a percentage of the total number of a specific cell
type within the ROI divided by the number of that specific cell type within the ROI
that also stained positive for tGFP.

5.2.14 Tissue Sparing Analyses
Tissue sections were stained for eriochrome cyanine-cresyl violet (ECCV)
to differentiate white matter and gray matter as previously described
(Rabchevsky et al 2002, Rabchevsky et al 2001). Sections were imaged using a
Nikon microscope (Nikon Corporation, Tokyo,Japan) and Scion Imaging analysis
software (Scion Corporation, Frederick,MD, USA) was used to delineate injured
versus spared tissue in each section. ROIs were manually drawn around the
entire cord, spared gray matter, and injured tissue which allowed extrapolation of
the spared white matter area. Eleven sections equally spaced apart by 1000 µm
and centered on the injury epicenter were analyzed to get the volume of
damaged versus spared tissue using the Cavalieri method (Michel & Cruz-Orive
1988).

5.2.15 Stereology
Analysis was performed to determine sparing of the neurons in the medial
portion of lamina VII and lamina X of the L1/L2 spinal cord in the 6 week injured
cohorts. Stereological counts of neurons were performed using a method
previously published (Patel et al 2012). We used an Olympus BX51 microscope
to image sections and the Bioquant image analysis program to analyze our
tissues (Nova Prime, V6.70.10, Bioquant Image Analysis Corp., Nashville, TN).
Briefly, a region of interest was drawn over lamina VII and X, containing putative
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CPG interneurons. A counting grid was placed over this region, with each
counting frame measuring 125 X 125 µm. Disectors were set to 50 X 50 µm, and
section thickness was set at 10µm, with a 2µm guard zone on both the top and
bottom of the tissue to keep from double-counting cells across sections. NeuN
positive cells were then counted under 40X magnification (10x eyepiece). The
criteria for being counted required the neuron cell body to be contained within the
disector and the nucleus was in focus within the set 10µm counting thickness, as
verified by Hoechst staining (Hou et al 2008). The coefficient of error (CE) was
calculated for each group (vehicle- 0.116, tGFP mitochondria- 0.1126, and
muscle mitochondria – 0.1456) to determine intra-animal variation. The interanimal variation, or coefficient of variance (CV), was also calculated (vehicle0.7007, tGFP mitochondria- 0.6506, and muscle mitochondria- 0.5145). The
number of neurons in each section was extrapolated using a previously
published equation (McCullers et al 2002).

5.2.16 Statistical Analyses
Changes in OCR and RCR for acute bioenergetic studies were analyzed
using a one-way ANOVA for each respiration state or RCR, with Tukey’s multiple
comparisons post hoc test. Complex I functional assays, injected tGFP bolus
volume and rostral-caudal length, and tissue sparing analyses were analyzed
using one-way ANOVA with Tukey’s multiple comparisons test when appropriate.
Cell type incorporation was analyzed using a one-way ANOVA for each cell type,
number of co-localization instances, and for percentage co-localization within
each time point, with Tukey’s multiple comparison test. Brain macrophage
density analyses were performed using Mann-Whitney U test for each time point
analyzed. Rostral-caudal location of cell-type colocalization, von Frey tests, BBB
scoring and neuronal stereology counts were analyzed using a repeated
measures two-way ANOVA with Tukey’s multiple comparisons when warranted.
All analyses were carried out using Graphpad Prism 6 (Graphpad Software, Inc.,
La Jolla, CA). Significance was set to p < 0.05.
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5.3 Results
5.3.1 Acute Mitochondrial Bioenergetics
We transplanted mitochondria into the injured spinal cord in a dosedependent manner. Vehicle or one of three dosages of transgenically-labeled
tGFP-mitochondria were microinjected into the injured spinal cord at 50, 100, or
150 µg and 24 hours later the spinal cord was dissected and assessed for
mitochondrial bioenergetics. Mitochondria isolated from this portion of spinal cord
includes both endogenous mitochondria and exogenous transplanted
mitochondria. When assayed for mitochondrial bioenergetics in terms of OCR,
there were significant differences in state III [F (4, 27) = 6.269, P= .0011] and
state V.1 [F (4, 27) = 11.80, P= <0.0001] respiration. Post hoc analyses indicated
significantly maintained state III (89% of sham) and state V.I (73% of sham) OCR
in the 100µg tGFP-injected group compared to significantly impaired rates in
vehicle injected groups (Figure 5.1). There were no significant differences in
RCR among tGFP mitochondria injected, vehicle injected, or sham laminectomy
animals indicating that mitochondria in each group are well-coupled.

Figure 5.1. Culture-derived tGFP mitochondrial transplantation after SCI
maintains OCR. SCI caused significant decreases in mitochondrial respiration at
state III, IV, and V.1, which was partially maintained with mitochondrial
transplantation. State III and V.1 OCR were maintained near sham levels after
100µg tGFP mitochondrial transplantation. Bars are means ± SEM. *p<0.05 vs
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Sham; #p<0.05 vs Vehicle. (One-way ANOVA for each state, Tukey’s multiple
comparison) n=6-7/group.
The use of tGFP-labeled mitochondria allows for visualization and tracking
of transplanted mitochondria in situ, which is important for determining cell-type
incorporation and temporal uptake of exogenous mitochondria. However,
cultured cells can have a lower energy demand, resulting in mitochondria that are
well coupled but respire at lower rates (see Chapter 4.3.4). We were concerned
that these lower respiring mitochondria may not have enough energy producing
capability to be optimally beneficial to the injured cord, so we also tested the
injection of muscle-derived mitochondria. We chose to inject muscle
mitochondria at the 100 µg dosage to compare to the optimal dosage found in
our tGFP mitochondrial transplant study (see Figure 5.1). Further, we
hypothesized that because muscle mitochondria respire at higher rates than
tGFP mitochondria, a lower dosage of 50 µg muscle mitochondria could possibly
give the same OCR increases as tGFP mitochondria.
Muscle mitochondria were isolated from the soleus muscle of a separate
naïve rat and injected into the injured spinal cord. Following transplantation, we
found significant differences in state III OCR [F (3, 8) = 12.23, P= 0.0023] and
post hoc analyses revealed significant increases with either 50 µg (83% of sham
levels) or 100 µg (88% sham levels) mitochondria injection compared to vehicle
injected groups (Figure 5.2). There were also significant differences in state IV [F
(3, 8) = 8.940, P= 0.0062] and state V.1 respiration [F (3, 8) = 12.64, P= 0.0021].
Post hoc analyses showed significantly increased state IV OCR with 100 µg
muscle mitochondria compared to vehicle and significant decreases in state V.1
respiration after injury compared to sham levels which was not rescued through
mitochondrial transplantation. There were no significant differences in RCR
among muscle injected, vehicle injected, or sham laminectomy animals indicating
that the mitochondria in each group are well coupled.
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Figure 5.2. Muscle-derived mitochondrial transplantation after SCI
maintains OCR. State III and IV OCR were maintained with 100 µg musclederived mitochondrial transplantation. State V.1 OCR deficits after injury were not
rescued with transplantation. Bars are means ± SEM. *p<0.05 vs Sham; #p<0.05
vs Vehicle. (one-way ANOVA for each state, Tukey’s multiple comparison). n=24/group in triplicate.
Using isolated mitochondrial samples obtained from the same animal
cohorts used in acute OCR studies we assessed the function of complex I, the
NADH Coenzyme Q oxidoreductase enzyme of the ETS (Figure 5.3).

Figure 5.3. Complex I function following SCI and mitochondrial
transplantation. Using the same mitochondrial samples used in OCR studies,
we analyzed the function of mitochondrial ETC complex I. A. Complex I function
was maintained near sham levels with 100 µg and 150 µg tGFP mitochondria
compared to vehicle injection. n= 6-7/group. B. Complex I function significantly
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increases after 100 µg muscle mitochondria transplantation compared to vehicle
injections. n= 2-4/group. Bars are means ± SEM. #p<0.05 vs Sham
Laminectomy; *p<0.05 vs Vehicle. (One-way ANOVA, Tukey’s multiple
comparison).
Mitochondrial transplantation maintained complex I function near sham
levels. Similar to our OCR outcome measures, there were significant differences
in complex I function in tGFP mitochondria injected experiments [F (4, 26) =
5.432, P= 0.0026] and muscle mitochondria injected experiments [F (3, 9) =
21.51, P= 0.0002]. Post hoc analyses showed that transplantation of 100 µg
tGFP or muscle mitochondrial significantly maintains complex I function
compared to vehicle. Interestingly, 150 µg tGFP mitochondria also significantly
increased complex I function, though it did not significantly increase state III OCR
compared to vehicle.
Our results show the state III OCR of the 100 µg mitochondria injected
animals of either mitochondrial origin was comparable to sham indicating rescue
of oxidative phosphorylation function in the injured spinal cord to almost 90% of
sham levels. We have shown historically that maintaining state III respiration
towards sham levels corresponds to maintained long term behavioral recovery
(Patel et al 2012). Thus, we chose to use the 100 µg dosage to investigate the
effects of mitochondrial transplantation on both cell-type incorporation and long
term recovery.

5.3.2 Characterization of Transplanted tGFP Mitochondria in situ
We characterized the uptake of exogenous tGFP mitochondria into
resident cells of the injured spinal cord. Analysis of multiple time points after
injury gave a time course picture of exogenous mitochondrial incorporation within
tissues after 24 hours, 48 hours, and 7 days post injection. Injection sites
contained a bolus at the injection epicenter, with scattered punctate labeling
further from the injection site (Figure 5.4A). Earlier time points had a very
discreet injection bolus (Figure 5.4B,C) in addition to scattered punctate tGFP
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mitochondria (Figure 5.4D) within the cord. By the 7 day time point, these
discreet injection boluses had almost completely disappeared, save for a few
instances, and only dispersed tGFP mitochondrial stippling was present. We
analyzed the spread of 100 µg dosage injected tGFP mitochondria in two ways.
The first was a measure of the rostral-caudal distribution of all 4 injection
boluses. There were significant differences in bolus length among time points [F
(2, 9) = 22.46, P= 0.0003] (Figure 5.4E); post hoc analyses revealed a significant
decrease in bolus length of the 7 day group compared to 24 and 48 hour time
points. The measured length of the bolus had insignificantly increased length in
the 48 hour group compared to 24 hour group. We further measured the rostralcaudal length that instances of punctate mitochondria were visible, and found
that there were no significant differences among groups [F (2, 9) = 2.996,
P=0.1006] (Figure 5.4F). Interestingly, this may indicate that tGFP mitochondrial
dispersal is quite uniform across time points, and the bolus disappears at a
different rate than the punctate instances of tGFP mitochondria. The second
analysis was a measure of total volume of the injection boluses throughout the
spinal cord (Figure 5.4G). The tGFP mitochondria injection bolus volume was
significantly different among time points [F (2, 9) = 15.61, P= 0.0012]; post hoc
analysis indicated the volume was similar for 24 hour and 48 hour time points but
was significantly different at the 7 day time point.
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Figure 5.4. Quantification of transplanted tGFP mitochondria volume and
spread. A. Injection schematics depicting bilateral injections into the spinal cord.
Cross section shows a portion of the injection bolus is boxed in red, and
representation of the punctate area analyzed is boxed in yellow. Longitudinal
section indicates four peri-contusion injection sites (black stars) with injection
bolus as solid green oval. Punctate tGFP labeling is represented by the shaded
green oval. B. Representative image of bilateral tGFP injections. For volumetric
measurements, the discreet bolus was circled (yellow) to give an area for each
section which was used to calculate the subvolume of each section measured. C.
High magnification image of tGFP located within the bolus of (B) as delineated in
red box in (A). D. High magnification image of punctate tGFP-labeled
mitochondria in (B) that were not part of the discreet bolus, as delineated in
yellow box in (A). E. Rostral-caudal length of tGFP bolus was significantly
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decreased at 7 days compared to 24 hour and 48 hour groups. F. Length in the
rostral-caudal direction that any visible evidence of punctate mitochondria was
apparent. G. Analysis of bolus volume was achieved by measuring the area of
each bolus (circled in yellow in image B) and multiplying the subvolume by the
total thickness of all sections with a bolus present to get total volume of
bolus/cord. tGFP injection bolus was similar at the 24 and 48 hour time points,
and significantly decreased at 7 days post injection. Scale Bars- B= 200µm, C
and D =10µm. Bars are means ± SEM. *p<0.05 vs 24 hrs; #p<0.05 vs 48 hrs.
(One-way ANOVA, Tukey’s multiple comparison) n=4/group.
All of the tGFP injection sites (4/animal) for the 24 and 48 hour groups
were visible using fluorescent microscopy. By 7 days post injection, the injection
sites had almost disappeared so that only 3 total injections across all four
animals in the group could be visually verified. Some instances of a remaining
injection bolus were still evident and the rostral-caudal spread of punctate tGFP
stippling was similar to 24 and 48 hour time points.
We set out to characterize the cell-type co-localization with tGFP
mitochondria. We looked at multiple different resident spinal cord cell types when
performing our analyses, including neurons, macrophages, endothelial cells,
astrocytes, pericytes, and oligodendrocytes (Figure 5.5).
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Figure 5.5. Resident cell types of the spinal cord within the tGFP
mitochondria injection bolus. The top box shows an injection bolus into the
dorsal horn of the spinal cord at 24 hours post injection. Adjacent slide series
(separated by 40uM) were stained with specific cell type markers and images
represent different cell types within the same injection site. Green lines delineate
the margins of the injection bolus, the white dotted lines outline the dorsal horn
gray matter. Within the injection bolus, there appeared to be a loss of neurons
and oligodendrocytes. There was a noticeably increased density of brain
macrophages in the area of the injection bolus. Additionally, there were
endothelial cells and pericytes evident within the injection bolus. While there
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were not astrocytes within the bolus, they were prevalent in the area surrounding
the injection. NeuN= neurons, OX42 = macrophages, RECA = endothelial cells,
GFAP = astrocytes, PDGFR-B= pericytes, CC1 = oligodendrocytes, tGFP =
exogenous tGFP mitochondria, DAPI = cell nucleus. Scale bars= 100um.
When examining the different cell types within the injection epicenter
bolus, we noted an almost complete absence of neurons within the bolus, while
there was an influx and high density of macrophages. The concentration of
mitochondria or volume of the injections could be inherently damaging the spinal
cord tissue. When comparing vehicle injected and tGFP mitochondria injected
animals, we typically saw that there was increased density of brain macrophages
at the mitochondria injection sites compared to vehicle (Figure 5.6A), indicating
the tGFP mitochondria could be causing an inflammatory response more so than
vehicle injection alone. Semi-quantitative analyses were performed to evaluate
the brain macrophage densities within the injection epicenters at different time
points (Figure 5.6B). Mann-Whitney U test showed a significant effect between
vehicle injected and tGFP mitochondria injected groups at 24 hours [P= 0.0012],
48 hours [P= 0.0002], and 7 days post injection [P= 0.0196].
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Figure 5.6. Brain macrophage activation at the mitochondria injection sites.
A. Brain macrophage infiltration was compared between naïve, injured/vehicle
injected, and injured/tGFP mitochondria injected animals at 24 hours post
injection. There is an obvious high density of brain macrophages within the tGFP
injection site compared to a vehicle injection site. B. At each of the injection
epicenters, the macrophage density was given a semi-quantitative score of 0-3.
For 0, there was no abnormal response (similar to A naïve), while a score of 3
indicated extensive activation of brain macrophages. There was a significant
increase in the macrophage response when tGFP mitochondria were injected
compared to vehicle injections at all time points. Bars are for visual
representation of means ± SEM. *p<0.05 vs vehicle; (Mann-Whitney U test for
each time point) n=4 vehicle injection sites per time point, n=16 tGFP injection
sites per time point. OX42 = macrophages, DAPI = cell nucleus. Scale bars=
200um.
One of our goals was to discern which cell types of the spinal cord had
higher propensities to incorporating exogenous mitochondria, so we first
characterized positive co-localization. Representative images show positive co-
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localization of various cell types both away from and within the bolus of tGFP
injection (Figure 5.7). The left column represents instances of co-localization
within the dense tGFP bolus, while the right column represents instances of colocalization that were seen away from the bolus where only stippling was
present. For our purposes, co-localization was defined in two different ways. The
first criterion of positive incorporation was when tGFP labeling was present within
the cytoplasm of the cell, as evident by green tGFP labeling within the confines of
the red cell membrane marker juxtapositioned to the nucleus (DAPI). This was
most often the case when using OX42 staining for macrophages, which labels
the cell membrane of macrophages. The second criterion of positive
incorporation was when the tGFP labeling was present and overlapped with the
cell specific marker. GFAP labels the cytoplasm of astrocytes, thus both the
incorporated tGFP signal and GFAP signal overlapped. If either of these
definitions was met, this was counted as a positive instance of co-localization.
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Figure 5.7. Representative images of cell type-specific tGFP co-localization.
Images show instances of positive co-localization with different cell types at 24
hours post injury. Z-stack images were captured, with the bottom panel of each
image representing the x plane and the right panel of each image representing
the y plane. ‘Within Bolus’ (left column) indicates images that were taken in the
area of dense tGFP mitochondria, while ‘Away from Bolus’ (right column)
indicates images that were taken in areas of more sparse punctate tGFP
mitochondria. Crosshairs in each picture are placed over an instance of tGFP
colocalization with that specific cell type. OX42 = macrophages, RECA =
endothelial cells, PDGFR-B= pericytes, GFAP = astrocytes, CC1 =
oligodendrocytes, tGFP = exogenous tGFP mitochondria, DAPI = cell nucleus.
Scale bars= 10um.
We found instances of cell-type specific colocalization with tGFP
mitochondria for various cell types including brain macrophages, endothelial
cells, pericytes, astrocytes, and oligodendrocytes at 24 hours post
transplantation. Colocalization was evident for all cell types both within the
injection bolus site as well as more distal from the injection epicenter, where
sparse punctate tGFP was present. However, no colocalization of tGFP
mitochondria within neurons was evident when we looked either within the bolus
or distal to the bolus site. For better visualization purposes, representative high
magnification images were taken to show instances of colocalization 24 hours
after transplantation (Figure 5.8).
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Figure 5.8. High magnification images showing positive colocalization.
Images show instances of cell-type specific colocalization of tGFP mitochondria
either macrophages (Ox42), endothelial cells (RECA), or pericytes (PDGFR-B).
White arrows point to instances of tGFP mitochondria colocalization within the
cell. Tissues were processed 24 hours post tGFP mitochondria transplantation.
OX42 = macrophages, RECA = endothelial cells, PDGFR-B= pericytes, tGFP =
exogenous tGFP mitochondria, DAPI = cell nucleus. Scale bar = 10um.
We quantified the propensity of tGFP mitochondria to be incorporated into
different cell types across time. Tissue sections were analyzed per hemi cord as
depicted in the schematic (Figure 5.9A) including the 2 injection epicenters, one
section both rostral and caudal of the injection epicenters, and the first section
distal to the injection epicenter that did not have a bolus present, but had
punctate tGFP signal present. From each of these sections we quantified the
percentage of a specific labeled cell type within the dorsolateral cross section
ROI (Figure 5.9B) that were co-localized with tGFP mitochondria to compare
their affinities for exogenous mitochondrial uptake.
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Figure 5.9. Counting schematic for cell-type co-localization with tGFP
mitochondria. A. 8 sections were analyzed for the left side of each injected
cord. This includes both injection epicenters (red box), the next section 400 um
rostral and 400 um caudal of the injection epicenters (blue box), and the first
section distal from the injection epicenter that no longer has an injection bolus
but punctate tGFP mitochondria were present (dashed black box). Injection
epicenters are denoted by the black stars, injection boluses are depicted as solid
green ovals, and punctate tGFP stippling is represented by faded light green
shading. We found the caudal injection sites to be closer to the injury epicenter
than the rostral injections sites. This is due to the location of the T12
laminectomy, which reveals the L1/L2 spinal level at the caudal side of the
laminectomy. The location of the injury epicenter is therefore at the caudal side of
the laminectomy window, and closer to the subsequent caudal injection sites. B.
For each section analyzed, the ROI for cell counts was defined by drawing a
horizontal line from the central canal to the lateral side and a vertical line from the
central canal to the dorsal surface (red). Both the total labeled specific cell types
and instances of co-localization were counted within this left dorsolateral
quadrant.
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Comparisons were made to determine which cell type was overall more
likely to incorporate mitochondria. The cell type counts for each of the 8 sections
(analyzed as described in Figure 5.9) were summed to give a total number of
that cell type per spinal cord (Figure 5.10A, red). Likewise, the co-localization
instances from each of the 8 sections analyzed were totaled (Figure 5.10A,
green). One-way ANOVAs were performed to evaluate differences among total
cells counted of a specific type, and showed significant differences at 24 hours [F
(4, 15) = 72.59, P<0.0001], 48 hours [F (4, 15) = 87.46, P<0.0001], and 7 days [F
(4, 15) = 37.32, P<0.0001]. Post hoc analyses revealed that total macrophages
counted were significantly higher than all other cell types at each time point. Oneway ANOVA showed significant differences among the number of co-localized
cells among cell types at 24 hours [F (4, 15) = 10.62, P=0.0003], 48 hours [F (4,
15) = 45.55, P<0.0001], and 7 days [F (4, 15) = 5.159, P=0.0081]. Post hoc
analyses showed that co-localization numbers were significantly higher in
macrophages than other cell types. It should be noted that brain macrophages
infiltrate the injury site and therefore there is a higher number of total
macrophages in the ROI compared to other cell types (Figure 5.10A). This
potentially puts the macrophages at an optimal location for interactions with the
tGFP mitochondria. Consequently, we additionally report the percentage of cells
that are also co-localized with tGFP (Figure 5.10B). One-way ANOVA revealed
significant differences among cell type co-localization percentages at 24 hours [F
(4, 15) = 6.384, P=0.0033] and 48 hours [F (4, 15) = 5.854, P=0.0048]. Tukey’s
multiple comparisons showed both macrophages and pericytes co-localized with
tGFP at a significantly higher rate than oligodendrocytes at 24 and 48 hours post
injection, which had the lowest colocalization percentages at any time point.
There was also colocalization of tGFP mitochondria with endothelial cells and
astrocytes at each time point.
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Figure 5.10. Cell-type co-localization of tGFP mitochondria across three
time points. A. Cell type incorporation was compared for each cell type at a
given time point. Total numbers of a given cell type were counted (red), as well
as the number of cells co-localized with tGFP (green) per ROI. B. Co-localization
was calculated as a percentage of total cells. Macrophages and pericytes had
significantly higher co-localization percentages compared to oligodendrocytes at
24 and 48 hours. There were no differences in percentage of co-localization
among the cell types at 7 days. OX42 = macrophages, RECA = endothelial cells,
PDGFR-B= pericytes, GFAP = astrocytes, CC1 = oligodendrocytes, tGFP =
exogenous tGFP mitochondria. *p<0.05 vs macrophages, # p<0.05 vs
endothelial cells, @ p<0.05 vs pericytes, $ p<0.05 vs astrocytes; (One-way
ANOVA, Tukey’s multiple comparison) n=4/group. Bars are means ± SEM.
The differences in cell type incorporation may be due to the different
endocytic and phagocytic properties of each cell type. Additionally, we did not
see any evidence of incorporation in neurons, though there was evidence of
uptake in all other cell types examined in the injury penumbra. In fact, there was
a profound loss of neurons in the gray matter where the injection epicenter was
located (Figure 5.5). This may be due to many factors, including the
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mitochondrial concentration and volume of injection into this area. Disturbance of
the tissue by the injection compounded by the activated brain macrophages may
be responsible for neuronal death at the injection site. However, if other cell
types in the injury penumbra can be rescued using mitochondrial transplantation,
the injury environment may be more favorable for overall cell survival, including
neurons. Macrophages can be either pro inflammatory or anti-inflammatory, and
are responsible for phagocytosing debris and foreign substances as well as
having a part in mediating immune response. Astrocytes are important support
cells for neurons, help maintain the blood brain barrier, and carry out functions in
ion homeostasis of the extracellular space. Oligodendrocytes play an imperative
role in insulating axons to increase signal transmission efficiency. Endothelial
cells supply blood and oxygen to tissues, and pericytes wrap around endothelial
cells for contraction of vessels and regulation of blood flow. Each of these cell
types have important functions in maintaining homeostasis within the spinal cord
tissue, and salvaging these cells could be as beneficial for functional recovery as
neuronal cell survival after SCI.
The injection epicenter contained a dense bolus of tGFP mitochondria,
and based on the high concentration in this area it may be difficult for
mitochondria to have access to various cells for incorporation. Alternatively,
sections that are further from the injection epicenter showed dispersed tGFP
mitochondria and may have differential uptake as higher concentrations of
mitochondria have been shown to aggregate with less extensive distribution into
nearby tissues (Chang et al 2013a). We therefore mapped the propensity of colocalization in relation to the injection epicenters where there is a higher
possibility for aggregation. We quantified the cell-type incorporation, as described
above, and analyzed this across the rostral-caudal distribution of the 8 sections
analyzed for each spinal cord (Figure 5.11). Two-way ANOVAs were performed
and showed differences in cell-type colocalization for macrophages [F (2, 9) =
8.123, P = 0.0096], endothelial cells [F (2, 9) = 10.69, P = 0.0042],
oligodendrocytes [F (2, 9) = 9.575, P = 0.0059], astrocytes [F (2, 9) = 22.54, P =
0.0003], and pericytes [F (2, 9) = 928.3, P < 0.0001]. We found that there were
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differences in colocalization percentages dependent upon the location in relation
to the injection epicenter, especially at the 24 hour time point. At 24 hours,
macrophages had higher incorporation percentages one section rostral of each
injection site compared to the most caudal section analyzed. Endothelial cells
had higher co-localization percentages closer to the injection epicenters
compared to the distal sections. This indicates there could be spatial-dependent
incorporation in addition to cell-type dependent incorporation.

104

Figure 5.11. Rostral-caudal cell-type incorporation of tGFP mitochondria
over time. Co-localization was quantified within ROIs across 8 different sections
(numbered 1-8) in relation to injection epicenters. Top panel schematic of
counted sections corresponds to the rostral-caudal counts of co-localization
percentages. There were differences in colocalization percentages among
location sites when analyzed within cell types. *p<0.05 vs section 8, #p<0.05 vs
section 1, @p<0.05 vs section 3, $ p<0.05 vs section 5; (Two-way repeated
measures ANOVA, Tukey’s multiple comparison) n=4/group. Bars= mean ±
SEM.

5.3.3 Behavioral Recovery and Tissue Sparing after Mitochondrial
Transplantation
We tested the effects of mitochondrial transplantation after SCI on
hindlimb functional recovery and tissue sparing. Anesthetized animals underwent
a severe contusion injury at the L1/L2 spinal level, followed immediately by 4
injections for a total of 100 µg tGFP-labeled or muscle-derived mitochondria into
the injury penumbra (see Figure 3.1 for injection schematic).
The starting numbers per experimental group was n=12 per group.
Throughout the course of the 6 week long study, there was an attrition of animals
due to various causes. As animals were randomly assigned to groups, and we
were blinded to the groups throughout the study, this resulted in uneven numbers
per group at the terminal timepoint. 3 animals died from anesthesia during
surgical procedures, 3 animals were removed from the study and euthanized due
to extensive autophagia of the hindlimbs, and one animal was removed from the
study due to its high 2-day BBB score (more than 2 SD from the mean, indicating
a bad contusion injury). This resulted in final groups of Vehicle injection n= 10,
tGFP mitochondria injection n=11, muscle mitochondria injection n=8.
Animals were tested for mechanical sensitivity of hindpaws using the von
Frey hair test, and hindlimb motor recovery using the overground locomotor BBB
scale. Results show that 3 weeks after injury, mechanical hypersensitivity was
increased in each group, as filaments with less force elicited responses in the
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hindpaws (Figure 5.12). At 6 weeks post injury, hindpaw sensitivity approached
baseline levels in all groups, but was somewhat decreased in the mitochondria
transplant groups. Two-way ANOVAs showed no differences among treatment
groups [F (2, 26) = 1.370, P= P = 0.2718]. However, there were significant
differences among time points [F (2, 52) = 17.64, P<0.0001]. Post hoc analyses
showed each treatment group was significantly decreased at 3 weeks compared
to their baseline levels. Vehicle injected animals scored closer to their baseline
levels at 6 weeks, but both mitochondrial transplant groups were still more
hypersensitive at 6 weeks compared to their baseline levels.

Figure 5.12. Mechanical hypersensitivity following SCI and mitochondrial
transplantation. At three weeks post injury, each group had significantly
decreased mechanical thresholds compared to baseline levels, though there
were no differences among groups. At 6 weeks post injury, the vehicle injected
and tGFP mitochondria injected animals began to return towards baseline levels,
while the muscle mitochondria transplanted group remained significantly lower
than baseline. Two-way ANOVA showed no significant treatment effect
differences between groups at any given time point, though there were significant
time-dependent differences across groups. Bars are means ± SEM. $ p<0.05
vehicle vs baseline vehicle; *p<0.05 tGFP mito vs baseline tGFP mito; #p<0.05
muscle mito vs baseline muscle mito (Two-way repeated measures ANOVA,
Tukey’s multiple comparison) n=8-11/group.
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Two-way ANOVAs revealed that there were no significant differences in
the BBB analysis among treatment groups [F (2, 26) = 0.01894, P = 0.9812]
(Figure 5.13A). All animals recovered some functional recovery compared to
scores at 2 day post injury, which is consistent with vehicle recovery scores we
have reported with this injury type (Patel et al 2012). The BBB scale can be
separated into three categories- the first third of the scale (score 0-7) evaluates
movements of the three joints of the hindlimbs, the next part of the scale (score
8-13) evaluates stepping and coordination, and the highest part of the scale (1421) evaluates fine movements of the paw during coordinated stepping. A score of
7 indicates extensive movements of all joints in the hindlimb, 8 indicates plantar
placement of the hindpaw, and a score of 9 indicates the animal is beginning to
make weight supported plantar placements of the paw or is stepping on the
dorsal face of the hindpaw. A score of 10 indicates the animal is making weight
supported plantar steps. The animals in these studies plateaued at an average
score of ~8, which is indicative of plantar placing of the hindlimb that is not weight
bearing (Basso et al 1995). This level of recovery correlates to historical data
using this injury severity and spinal level, indicating there was no overt damage/
effect of volumes of injections. We further performed a post hoc analyses on the
BBB scores that transforms the scale to make it more ordinal and translational
(Ferguson et al 2004) and again found no differences among groups [F (2, 26) =
0.01319, P = 0.9869] (Figure 5.13B). It is important to note that while we did not
see improvements in functional recovery with either type of mitochondrial
transplantation, there was no loss of function.
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Figure 5.13. Functional hindlimb recovery following SCI and mitochondrial
transplantation. A. BBB scores for all animals was decreased after SCI, with
gradual increases over time after injury. B. Transformed scores of original BBB
scores. There were no significant differences among animal groups at any time
point using either analysis. Bars are means ± SEM. (Two-way ANOVA, Tukey’s
multiple comparison) n=8-11/group.
Following terminal behavioral analyses, animals were euthanized and
spinal cords were processed for tissue sparing analysis. Total lesion volume,
percent sparing at the injury epicenter, and gray and white matter sparing were
similar between both treatment groups, supporting our behavioral findings
(Figure 5.14). There were no significant differences between groups of lesion
volume [F (2, 26) = 1.913, P=0.1679] (Figure 5.14A) or percent sparing at injury
epicenter [F (2, 26) = 0.8532, P=0.4376] (Figure 5.14B). Mitochondria injections
were targeted to the medial lateral gray matter, allowing for possible
mitochondrial integration into either gray matter or white matter. We therefore
compared tissue sparing of either gray or white matter volume to determine if
transplanted mitochondria differentially spare different tissue types (Figure 5.14C
and D respectively). Again, we saw no treatment effects among groups in either
gray matter tissue sparing [F (2, 26) = 1.586, P=0.2240] or white matter tissue
sparing [F (2, 26) = 0.03762, P=0.9631].
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Figure 5.14. Tissue sparing analyses 6 weeks after injury and mitochondrial
transplantation. Tissue sparing and lesion volumes were compared among
vehicle, tGFP Mito injected, and Muscle Mito injected injured rats. At 6 weeks
post injury and injection, total lesion volume and percentage sparing at the injury
epicenter was assessed. Additionally, tissue sparing was analyzed for gray
matter and for white matter to determine if there were tissue-type differences in
sparing. There were no differences among groups in any of the measures
assessed. Bars are means ± SEM. (One-way ANOVA, Tukey’s multiple
comparison) n=8-11/group.
There were no differences in tissue sparing among groups and this
reflects what we might expect given the functional BBB scores after severe injury
at L1/L2 (Magnuson et al 2005). We were also interested in determining if
mitochondrial transplantation resulted in sparing of putative CPG interneurons,
which represent only a portion of the gray matter sparing analyses. To more
specifically investigate if mitochondrial transplantation salvaged these
interneurons, we performed stereology of putative CPG neurons after injury and
transplantation (Figure 5.15). We defined the ROI for neuronal counts to include
lamina X and the central portion of lamina VII (Figure 5.15A).
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Figure 5.15. Neuronal counts in the upper lumbar spinal cord after injury. A.
ECCV stained section of the spinal cord representing the ROI analyzed including
Lamina X and part of Lamina VII, which include putative CPG neurons. B.
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Representative images showing neurons in the ROI (dashed box) at 4mm rostral
and -1mm caudal of the injury epicenter. There appeared to be more NeuN
staining within the ROI of the mitochondria injected animals at 1mm caudal to the
injury compared to either vehicle or muscle mitochondria injected groups. C.
Stereological counts were performed across 11 equally spaced spinal cord
sections, centered on the injury epicenter (epi). Each point on the graph is then
an extrapolated estimate of the number of NeuN positive cells per 1mm length of
spinal cord section analyzed. NeuN positive cells were significantly higher in
tGFP mitochondria injected groups compared to the other cohorts at 1mm caudal
of injury epicenter, and significantly higher in tGFP mitochondria groups
compared to muscle mitochondria groups at 2 mm caudal of the injury epicenter.
Bars are means ± SEM. cc= central canal. * p<0.05 tGFP mito vs muscle mito; #
p<0.05 tGFP mito vs vehicle, (2-way ANOVA, Tukey’s multiple comparison) n=811/group.
There were significant differences in neuronal sparing among groups [F
(2, 286) = 3.658, P=0.0270]. Post hoc analyses showed that there were
significantly more neurons in the ROI of tGFP mitochondria injected groups
compared to vehicle or muscle mitochondria injected groups at 1 mm caudal of
the injury epicenter. While there was more neuronal sparing at these regions,
there was no corresponding functional recovery. This may be due to the fact that
the putative CPG interneurons were not spared with mitochondrial treatment
(Figure 5.15C, epicenter). Without these neurons there is a loss of rhythmic
output to rhythmic elements which project on ventral motor neurons of the lumbar
enlargement. If neuronal sparing of putative CPG interneurons had occurred
rostral of the injury in the T13 spinal level, there may have been BBB
improvements as was seen in previous publications (Magnuson et al 2005, Patel
et al 2012). However, our studies showed neuronal sparing in levels caudal of
the injury in the absence of putative CPG interneuron sparing. Our results are in
agreement with Magnuson et al (2005) who showed that a kainic acid depletion
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of putative CPGs in gray matter with concurrent caudal gray matter sparing did
not result in improved BBB scores.
5.4 Discussion and Future Directions
We showed for the first time that mitochondrial transplantation into the
injured spinal cord results in increased bioenergetics at 24 hours post
transplantation using either cell culture-derived tGFP-labeled mitochondria or
muscle-derived mitochondria. Cell culture derived mitochondria are optimal for
post-transplant visualization; however, we have shown that these mitochondria
respire at a lower rate than naïve spinal cord-derived mitochondria. To assess
whether different sources of isolated mitochondria with inherent differences in
respiration rates alter the effects of transplantation on acute bioenergetics, we
compared culture derived to muscle derived mitochondria. When comparing the
two sources of mitochondria on acute bioenergetics 24 hours after SCI, we found
both to significantly maintain state III respiration at the 100 µg dosage compared
to vehicle. As we have shown previously that maintaining state III respiration
near sham levels corresponds to improved long term tissue sparing and
functional recovery (Patel et al 2012), we used both sources of mitochondria at
the 100 µg dosage to evaluate the effects of mitochondrial transplantation on
long term histological and behavioral outcome measures.
We evaluated the time course of exogenous tGFP mitochondrial
incorporation into host cells and saw evidence as early as 24 hours post
injection. Discreet tGFP mitochondria boluses were evident, though these
decreased significantly in volume and rostral-caudal spread by 7 days post
injection, and completely disappeared by 6 weeks. By 7 days post injury, the
injection sites were barely evident as the exogenous tGFP mitochondria had
dissipated within the tissues. A discreet bolus injection was not always visible in
the 7 day cohort, but instances of small, punctate tGFP signal were visualized
and calculated to have similar rostral-caudal distribution to earlier time points.
We also evaluated the propensity of different cell types to incorporate
exogenous mitochondria and found that brain macrophages and pericytes had
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the highest propensity to colocalize with tGFP mitochondria, with lowest amount
of incorporation into oligodendrocytes. We cannot at this time discern if the tGFP
mitochondria were functionally incorporated within the macrophages or if they
were phagocytosed. While mitochondria were incorporated into a variety of cell
types, it is important to note that they were conspicuously absent in neurons.
When the same transplantation paradigm was used in long term studies,
we did not see a restoration of functional recovery, tactile sensation, or tissue
sparing. Von Frey testing showed a significantly decreased hindlimb mechanical
sensitivity thresholds in each group after injury, with some recovery towards
baseline at later stages. The vehicle injected group recovered closer to baseline
(pre-injury) levels, which may indicate slight hypersensitivity in the transplantation
groups. BBB hindlimb locomotor scores for each group showed functional loss 2
days after contusion SCI, with some recovery that plateaued at day 35 post
injury. This is consistent with spontaneous recovery with this injury severity at the
L1/L2 spinal level that we have reported (Patel et al 2012). Lesion volume
analyses were consistent with the behavioral outcome measures showing no
group differences between lesion volume or percent tissue sparing at the injury
epicenter. We further analyzed sparing of the spinal cord white matter or the gray
matter and again found no differences. Stereological counts showed significantly
higher numbers of NeuN positive cells when tGFP mitochondria were injected
compared to vehicle or muscle derived mitochondria, though this was only
evident 1 to 2mm caudal to the injury epicenter. While these differences were
significant, they were not so different that they resulted in changes in behavioral
recovery. The injury was performed at the L1/L2 spinal level, whereas the
neuronal sparing differences were seen more caudal. This spinal level may not
contain the putative CPG interneurons, so functional locomotor differences may
be more dependent upon ventral horn motor neurons at these spinal levels,
which were not targeted by our mitochondrial injections. This data is intriguing as
it shows that neuronal sparing may be possible through mitochondrial
transplantation, though there may be a threshold of neuronal sparing needed to
achieve measurable functional recovery. Additionally, caudal injection sites that
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target the ventral motor neurons, in addition to the CPGs may provide more
potential locomotor recovery. Potential means for increasing the efficiency of
mitochondrial transplant are discussed in Chapter 6. Importantly, these findings
show that acute bioenergetic recovery may not be the best criteria for advancing
experiments to long term functional recovery in mitochondrial transplant
paradigms. Instead, exploration of other markers of recovery at the acute time
points of 24 and 48 hours that do correlate into functional hindlimb recovery is
necessary. One such outcome measure could be tissue sparing analyses at
more acute time points such as 48 hours and 7 days post injury. These would be
expected to correlate to long term tissue sparing analyses.
Our findings indicate the feasibility of mitochondrial transplantation into
injured tissue with restored acute bioenergetics. There are multiple caveats to
consider when trying to interpret why our short term outcome measures did not
correspond to long term functional outcome measures. First, we noted an
increased density of brain macrophages in the injection and injury sites. The
volume of vehicle or mitochondria injected may disturb the intact spinal cord
tissue causing injury and subsequent infiltration of brain macrophages. Further,
mitochondria are a source of DAMPS (see Chapter 1.2.1.3) that may elicit a
stronger immune response compared to vehicle alone. Thus, mitochondria
injection could cause an influx of macrophages, increasing the overall number of
healthy cells in that area. The mitochondria assayed for bioenergetic analyses
includes both endogenous host mitochondria as well as injected mitochondria. If
macrophage infiltration resulted in a higher density of healthy cells, then
mitochondria from these macrophages would also be included in our OCR
assays. However, if there truly was an overt immune response, we would expect
this to be reflected in our long term studies. There was no decrease in functional
recovery when mitochondria were injected, which means if there was an immune
response it did not exacerbate long term functional deficits.
There was evidence for more mitochondrial integration at shorter time
points of 24 or 48 hours compared to 7 days post injury. If mitochondria are being
taken into cells but not successfully incorporated as part of the endogenous
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mitochondrial network, they may only exert beneficial effects at acute time points
correlating to our OCR assays. As the exogenous mitochondria undergo
mitophagy, a mitochondrial-specific form of autophagy, the OCR increases and
benefits may disappear. This can be evaluated in future studies by measuring
mitochondrial respiration at different time points after injury to determine exactly
how long the improved bioenergetics effects are present.
There may be a possibility that mitochondria are exerting their effects
extracellularly. The McCully lab noted functional benefits of cardiac tissue
mechanics after ischemia/reperfusion injury was followed by direct mitochondrial
injection (Masuzawa et al 2013, McCully et al 2009). Similar to our studies, they
noted a low incorporation rate and theorized that the benefits seen could possibly
be contributed by extracellular functions of the transplanted mitochondria. If
mitochondria can function extracellularly, it can be hypothesized that this would
be short lived before the immune response and debris-clearing mechanisms are
enacted to remove the mitochondria. This may explain short-term effects in the
absence of long term effects.
There are probably various reasons for the scarcity of tGFP label at 7
days and 6 weeks after injection- 1) It is likely that a certain amount of the
injected mitochondria that are not taken into cells will be phagocytosed,
especially at the injection site bolus as the density of mitochondria may be too
high to be incorporated into the surrounding host cells; 2) tGFP mitochondria
within the extracellular spaces will diffuse through the tissue away from the
injection site with time, especially in the white matter where there is greater
longitudinal diffusion; 3) When tGFP mitochondria are successfully incorporated
within cells, they may fuse and divide with host cell mitochondria leading to a
wider dispersal of fluorescent tGFP indicator within the cell. However, others
reported evidence of fluorescently-labeled mitochondria at chronic time points.
Using direct injection technique of mitochondria transplantation, one group
showed the presence of exogenous mitochondria using fluorescent microscopy
as late as 4 weeks after injection of human mitochondria into a porcine model of
cardiac ischemia using an antibody against human mitochondria (Kaza et al
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2016). Another group directly injected GFP-labeled mitochondria conjugated with
the peptide carrier protein Pep-1 into the rat brain of a Parkinson’s Disease
model, and found instances of GFP as long as 12 weeks after injection (Chang et
al 2013a).
While advances have been made in mitochondrial transplantation
therapies, many caveats need to be addressed to make this therapeutic
technique beneficial in models of SCI. Similar to previously published studies, we
show that mitochondrial transplantation has beneficial short term effects.
Increasing incorporation efficiency is the first step we can take to make our
transplantation approach more successful in achieving our recovery goals after
SCI. Alternative transplantation techniques for increasing incorporation rates or
functionality of exogenous mitochondria are discussed in detail in Chapter 6.
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CHAPTER 6
Overall Conclusions, Discussions, and Future Directions

6.1 Conclusions
We have learned much in our studies to aid in the progression of
mitochondrial transplantation as a therapy after a rat model of SCI. We
characterized transgenic labeling of mitochondria in culture to serve as a donor
of exogenous mitochondria both in vitro and in vivo for easy visualization. We
saw similar acute bioenergetic results in vivo when performing either allogeneic
transplantation of transgenically-labeled mitochondria or syngeneic musclederived mitochondrial transplantation (Figure 5.1 and 5.2). This opens the
possibility to transplant from either source depending on the needs of the study.
Transgenic mitochondria may serve an important purpose for tracking
studies, while muscle mitochondria transplantation may have importance in dose
response studies as higher mitochondrial yields can be obtained from muscle
tissue and higher concentrations can be successfully injected after SCI. Tracking
tGFP-labeled mitochondria incorporation into host tissues of the injured spinal
cord showed integration into specific cell types occurred at different percentages.
Discreet injection boluses were evident at 24 and 48 hours post injection, though
they significantly decreased by 7 days and were completely gone by 6 weeks.
There was a cell-type dependent incorporation efficiency. At 24 and 48
hours post injection, macrophages and pericytes had the highest percentage of
tGFP mitochondria incorporation (Figure 5.10). Macrophages may be taking
mitochondria into their cytoplasm, but it is also possible that these tGFP
mitochondria are in the process of being phagocytosed. Different measures can
be taken to determine whether this is a functional incorporation, which are
discussed in section 6.3.5. Pericytes are found within the vascular basement
membrane and are closely associated with endothelial cells. They have many
similarities to macrophages, including originating from the mesoderm,
possessing lysosomes, similar cell surface markers, and prostaglandin secretion117

for review on CNS tissue pericytes (see (McCully et al 2017). Perhaps
unsurprisingly then is that pericytes are also known to be inherently phagocytic
which may explain their higher tendency to pick up exogenous mitochondria.
Other cell types incorporated tGFP mitochondria, though at lower rates.
Oligodendrocytes took in the least amount of mitochondria, though this could
possibly be due to the location of the injection sites which were more targeted to
the gray matter. Injections targeted to the white matter may give
oligodendrocytes more opportunities for interacting with tGFP mitochondria, and
thus possibly more incorporation. There was no evidence of tGFP incorporation
within neurons at any time point.
There were no differences among treatment groups in lesion volume at
the 6 week time point, and both gray matter and white matter tissue sparing were
similar across the groups. Long term behavioral recovery was not apparent using
our transplantation paradigm, though possible explanations and counteractive
measures are presented later in this chapter. Some differences in neuron sparing
in the CPGs were apparent, though this occurred caudal of the injury site and did
not result in hindlimb recovery. Similar to our findings, changes in tissue
bioenergetics, cell survival, and cellular mechanics have been reported in other
studies, though it should be noted that few behavioral outcome measures have
been either tested or reported after mitochondrial transplantation in vivo
(Hayakawa et al 2016, Kaza et al 2016, Pacak et al 2015). However, one group
has examined mitochondrial transplantation in a rat model of Parkinson’s disease
and saw significantly improved locomotion behavior (Chang et al 2013a, Chang
et al 2016) see Chapter 2.1.2 for details. Alternative approaches that may
increase mitochondrial incorporation to promote further behavioral and functional
recovery are discussed in detail later in this chapter.
6.2 Discussion
Great strides have been made in the field of mitochondrial replacement
and transplantation therapies, and many techniques have proven to be
beneficial, although there are still very important questions that must be
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addressed before such therapies can be used widely and safely. There is
discordance among labs as to the mechanisms of mitochondrial incorporation
into host cells. While some argue that it may be endocytosis, others indicate the
mechanism is much more complicated. Is the formation of nanotubes between
cells necessary or is it the connection supplied by gap junctions or connexin
pores? Are the connections seen in vitro formed in vivo? Some reported
mitochondrial uptake upon co-incubation with cells in vitro (Clark & Shay 1982,
Katrangi et al 2007) or into host cells after direct injection in vivo (Kaza et al
2016, McCully et al 2009), while others found no such incorporation after coincubation in vitro (Spees et al 2006). One group showed conjugation of
mitochondria with Pep-1, a cell penetrating peptide that increases incorporation,
was necessary to incite mitochondrial uptake (Chang et al 2013a, Chang et al
2013b, Chang et al 2016). Still others found connexins or gap junctions
necessary for cells to take in extracellular mitochondria (Islam et al 2012,
Koyanagi et al 2005, Wang & Gerdes 2015). One group proposed an actindependent cellular incorporation of injected mitochondria (Pacak et al 2015). One
possible incorporation method for these organelles could be massive endocytosis
(MEND) (Lariccia et al 2011), which is a rapid internalization of large amounts of
the plasma membrane. We found that coincubation alone in vitro was sufficient
for mitochondria uptake into cultured cells. Similarly, we found direct injection of
isolated mitochondria into spinal cord tissue in vivo results in uptake, though
there is a relatively low incorporation rate (around 6% or lower of any specific cell
type within the ROI analyzed, Figure 5.10). If the incorporation mechanism were
revealed, then development of targeted techniques that take advantage of this
mechanism could increase uptake efficiency into host cells. Further, it may be
possible to exploit the uptake mechanism to specifically target certain cell types
such as neurons so that they take in mitochondria at higher rates, which would
be desirable in neuroprotection studies.
Whether there are major technical differences among the studies that
contributed to conflicting results or if there are other confounding factors remains
unclear. Contradictory findings may be due to various cell types having different
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metabolic needs or capacities for endocytosis. Additionally, the type of damage
to the host cells may be a crucial factor. Whether the cell undergoes stress,
depleted mtDNA, or damage to the ETC may dictate whether the cell can
endocytose mitochondria as multiple studies have reported that only
compromised cells can take in exogenous mitochondria (Cho et al 2012, Katrangi
et al 2007); still others have noted the incorporation in healthy cells (Clark &
Shay 1982). We found that healthy cells in culture are capable of taking in
mitochondria upon co-culture, and injured tissues in vivo can take in exogenous
mitochondria resulting in maintained bioenergetics. Importantly, a seminal finding
is that mitochondrial transplantation from healthy cells to injured neurons in vivo
occurs naturally, which can be further enhanced by direct injection of exogenous
mitochondrial particles into injured tissues (Hayakawa et al 2016). This innate
ability of damaged neurons to incorporate extracellular mitochondria after
traumatic injury may open a new avenue for neuroprotective strategies.
The origin of donated mitochondria may also be essential to uncovering
optimal transplantation benefits. We delivered mitochondria from two different
sources- cultured cells or muscle tissue, though isolating mitochondria from cell
types commonly found in the spinal cord should also be compared. When
targeting neuronal delivery, it may be better to use mitochondria from neurons, in
the case that there are different inherent properties of mitochondria to be taken
into like cell types. Astrocytes release mitochondrial particles into the
extracellular matrix and are proven to be taken into neurons (Hayakawa et al
2016), as such we may also choose to utilize mitochondria from this source.
Future studies may compare mitochondria isolated from neurons and astrocytederived mitochondrial particles in an effort to increase incorporation efficiency
into spinal cord tissue with an emphasis on neuronal uptake. However, the
McCully group noted that using different sources of mitochondria does not alter
cardioprotection after transplantation (Kaza et al 2016, McCully et al 2009).
Additionally, we observed maintained bioenergetics at 24 hours post
transplantation of either cell culture- or leg muscle-derived mitochondria, so we
may not see differences with neuronal mitochondria transplantation.
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Furthermore, while neurons may be spared directly through targeted
mitochondrial transplantation, it may be possible to protect neurons more
indirectly by increasing the overall health of the injury environment. Sparing other
resident cell types of the spinal cord could provide a more hospitable
environment and decrease overall necrosis and apoptotic factors, thereby
decreasing extracellular-induced damage to neurons.
6.3 Alternative Approaches and Future Directions
6.3.1 Mitochondrial Delivery Methods
We used direct injection techniques for mitochondrial delivery as others
have shown it to be a feasible option (Chang et al 2013a, Masuzawa et al 2013,
McCully et al 2009). Initial proposals considered cell-mediated delivery and
liposome delivery methods as well. One pitfall of direct injection is that
mitochondria are relatively unprotected from the extracellular matrix environment
prior to cellular uptake compared to cell- or liposome- mediated delivery. As our
early experiments showed increased OCR at 24 hours when using the direct
injection method, this delivery method was used for the immunohistological and
long term studies. However, we saw a higher density of macrophages with a
concurrent loss of visible neurons in the injection epicenters that may be due to
aggregation of the injected mitochondria. To counteract this possible damage,
changing injection parameters to include more injections of lower volumes and
concentrations may increase total numbers of mitochondrial incorporation into
host cells. The same amount of mitochondria can be injected per spinal cord,
though more spread out with potentially less aggregation. Increasing the number
of injection sites could also allow for differentially targeted injections such as the
CPGs at L1/L/2, and the ventral gray matter in more caudal regions. Additionally,
based on our relatively low incorporation numbers and lack of behavioral
recovery, other delivery methods should be investigated.
There are multiple methods that may be refined to increase incorporation
after transplantation. Some have used cell-mediated delivery methods to donate
mitochondria from transplanted cells into injured cells both in vitro (Cselenyak et
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al 2010, Plotnikov et al 2008, Spees et al 2006) and in vivo (Islam et al 2012).
Using cell-delivery systems would protect mitochondria from extracellular matrix
molecules. However, the mechanism of transfer, whether it be nanotube
formation, connexin pore mediated, or gap junctions needs to be better
understood (Chapter 2.4). For instance, donor cells need to be chosen that are
compatible with targeted cells to successfully make these types of functional
connections. This may allow for targeted delivery to specific cell types,
depending on the docking and delivery mechanisms of the donor and host cells.
Another delivery method to be considered is the encapsulation of
mitochondria within liposomes. Liposomes have been used for targeted delivery
to cells, though they have been used to carry small molecules such as RNA and
not usually something as large as a mitochondrion organelle. Liposome delivery
systems have been investigated to target macromolecules to the mitochondria
(Weissig et al 2006, Yamada et al 2008, Yamada et al 2007). Modified liposomes
with surface-linked polyethylene glycol and transactivating-transduction protein
were delivered through caudal tail vein injections and found to cross the bloodspinal cord barrier to accumulate within cells at the injury site in a rat model of
contusion SCI (Gollihue & Rabchevsky 2017). Though delivering intact
mitochondria themselves to a cell is not widely published, liposomal delivery
methods of mitochondria are being investigated (Brzezinska 2012). One
consideration to make before pursuing this avenue of delivery is that liposomes
may be digested by macrophages before they can fuse with targeted cells to
deliver the mitochondria (see Ahsan et al 2002).
Vascular perfusion delivery methods of isolated mitochondria showed
beneficial effects similar to using direct mitochondrial injections into injured heart
tissue (Cowan et al 2016). This study used the coronary arteries to deliver
mitochondria to ischemic heart tissue in vivo, eliminating the need for surgical
implantation of isolated mitochondria. Cowan et al (2016) also noted that the
mitochondrial incorporation efficiency was less when using perfusion delivery
methods compared to direct injection into the heart tissue. To use a similar
approach after SCI, one could perform intrathecal injections circumventing the
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blood-spinal cord barrier to perfuse mitochondria over the pia of the injured spinal
cord. However, this would not likely target mitochondrial delivery to neurons in
the gray matter, but instead to resident cell types of the spinal white matter.
Concentrating isolated mitochondria for injections can result in
aggregation, making cellular incorporation more difficult. If delivery efficiency can
be increased, then lower concentrations may be injected with the same endpoint
number of mitochondria being taken into cells. Pep-1 is a cell penetrating peptide
that allows for fast translocation of peptides across lipid bilayers with a
hydrophobic core (Henriques et al 2010). This fast transfer could mean that
mitochondria will be exposed to the extracellular matrix for a shorter amount of
time. In a dose response study of Pep-1 conjugated mitochondrial transplant,
lower dosage groups were found to have more mitochondrial dispersion within
tissues compared to higher concentrations, which had the tendency to aggregate
(Chang et al 2013a). Future studies could use Pep-1 conjugation with different
dosages of mitochondria to evaluate changes in incorporation compared to our
data for non-conjugated mitochondria.

6.3.2 Inflammatory Response
Previously published studies investigating mitochondrial transplantation
tested for inflammatory markers and did not find increases. Masuzawa et al
(2013) did not report inflammation after direct autologous mitochondria injection,
instead they found that mitochondria transplantation resulted in significantly
decreased tumor necrosis factor alpha (TNFa), interleukin 6 (IL-6), and highsensitivity C-reactive protein (hsCRP) (Masuzawa et al 2013). Further, they
showed anti-mitochondrial antibodies were not present in blood serum samples
28 days after injections. However, there could be differences when allogeneic
mitochondria are transplanted, as was used in our studies (Chapters 4 and 5),
compared to a syngeneic or autologous mitochondrial transplant.
Mitochondrial transplantation after injury resulted in increased OCR
acutely, which is thought to be due to exogenous mitochondria supplementing or
replacing those damaged after the injury. However, this did not correspond to
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increased functional recovery. One theory to explain increased OCR at the 24
hour time point that does not correspond to long term outcome measures is that
activation and recruitment of brain macrophages to the injection site may
increase the density of healthy cells in otherwise damaged tissue. To determine if
macrophage influx is responsible for increased OCR at the acute time point, we
could assay different mitochondrial populations. After injury and transplantation,
mitochondria will be isolated from the spinal cord. Unlike our experiments
performed in Chapter 5 we will separate out the different populations of synaptic
and non-synaptic mitochondria. The non-synaptic mitochondrial population
contains mitochondria from all different cell types, including neurons,
oligodendrocytes, astrocytes, endothelial cells, resident microglia, and infiltrating
macrophages. The synaptic population, however, contains mitochondria only
from neuronal cells. This allows distinction between increases in OCR that may
be attributed to infiltrating brain macrophages (within the non-synaptic
population), and what may be attributed to increased health due to
transplantation (synaptic population). One major caveat, however, is that we did
not see any mitochondrial incorporation into neuronal cells, and thus we may not
see increases in synaptic OCR. Further, we have previously shown that synaptic
mitochondria respire at lower rates than non-synaptic mitochondria when isolated
from naïve spinal cord tissue (Patel et al 2014). Another way to test if
macrophage infiltration may be the cause of increased respiration is to use
different drugs such as a CCR2 antibody to block infiltration (see Ren & Young
2013). This will result in the same resident spinal cord cells to be assayed across
treatment groups with the aim of revealing whether increased respiration was
peripheral macrophage-dependent.
Another potential approach is to separate out the macrophages from our
spinal cord homogenate before isolation of mitochondria. For instance,
macrophage markers can be applied to the homogenate followed by
fluorescence-activated cell sorting (FACS) to remove the macrophages, leaving
behind homogenate containing the other resident cell types of the spinal cord.
Mitochondria is isolated from the remaining homogenate, and increases in OCR
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will reflect that of the resident spinal cord tissue. One caveat to this approach is
that this will also remove endogenous macrophages that were already in our
injury/injection sites, which were shown to have the highest mitochondrial
incorporation efficiency.

6.3.3 Mechanisms of Action
It was recently shown that daily intraperitoneal injections of ATP after
contusion SCI in rats significantly increased BBB scores above injury only groups
(Sun et al 2013). However, prolonged high amounts of extracellular ATP after
SCI activates P2X7 purine receptors on neurons, resulting in increased
intracellular calcium and neuronal cell death (Wang et al 2004); antagonistic
drugs that inhibit this receptor following SCI significantly improve BBB locomotor
scores (Peng et al 2009). These studies indicate that there may be functional
recovery following ATP supplementation, though extended or excessive amounts
appears to be detrimental. Mitochondria transplantation may provide an
additional source of ATP, though the benefits of transplantation seem to be
dependent upon more than just energy alone. McCully at al found that injections
of ATP or ADP did not give the same cardioprotection as mitochondria injections
(McCully et al 2009). Similarly, delivery of ATP in liposomes to damaged neurons
did not result in the same increase in cell survival when astrocyte-derived
mitochondrial particles were delivered in a mouse model of stroke (Hayakawa et
al 2016), concluding that benefits afforded by mitochondrial transplantation are
multifaceted and not just as an extra energy source. Future studies that
determine the exact mechanisms by which mitochondrial transplantation may
benefit damaged cells can immensely extend our knowledge in this novel
treatment field.

6.3.4 Time Points of Injections
The environment of the injured spinal cord may be too harsh at the acute
timepoint for transplantation. Our mitochondria injections occurred within 30
minutes of SCI. Hayakawa et al (2016) transplanted mitochondria into the mouse
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brain 3 days after stroke; given the complex inflammatory response acutely after
SCI this delayed time point may be more agreeable to mitochondrial survival and
incorporation. Confounding this further, our tGFP mitochondria may be
experiencing “donor rejection” as was seen in other transplantation paradigms
involving bone marrow stromal cells injected into the naïve brain (Coyne et al
2006). Others have shown that transplantation of fetal spinal cord tissue and
neurotrophic factors into the transected adult rat spinal cord showed axonal
regeneration and motor function recovery; this was only evident when
transplantation occurred two or four weeks after transection, but was not
apparent with acute transplantation (Coumans et al 2001). Neural precursor cell
transplantation in a rat model of compression SCI was successful in improving
hindlimb BBB scores when transplants occurred 2 weeks but not 8 weeks after
injury, indicating there may be an optimal time window for transplantation
paradigms (Gollihue & Rabchevsky 2017). Similar to (Okano et al 2003), who
found that neural stem cell transplantation at the acute time point after SCI may
not be optimal as the inflammatory response is in full swing, we propose
transplanting at later time points. For transplantation to be clinically relevant,
therapies administered 3.2 hours after injury should be investigated, as this is the
average time after SCI a patient is admitted and diagnosed (Bracken et al 1997).
Future transplantation studies may attempt this clinically relevant time point, as
well as a later time point of 3 days post SCI to correspond to published studies
using stroke injury models (Hayakawa et al 2016).

6.3.5 Quantifying Incorporation
One major hurdle in these studies is quantifying the amount of tGFP
mitochondria that are successfully taken into host cells. First, we must define
what is considered successful incorporation- are the mitochondria simply taken
into the cytoplasm, do they need to maintain their membrane potential, and do
they have to incorporate into the endogenous mitochondrial network? For our
tracking purposes, we define successful incorporation as co-localizing with the
labeled cell which was verified using confocal fluorescent microscopy. However,
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as the tGFP tag is coded for by nuclear DNA and not the mitochondrial DNA, the
tag will not be propagated after transplantation. This means that the tag will most
likely dissipate over time, making the exogenous mitochondria hard to track as
time progresses. Further, the tag will be progressively degraded as different
portions of the mitochondrial network are mitophagocytosed, a natural
occurrence that works to maintain an overall healthy membrane potential (Twig
et al 2008b). Together, these make fluorescent tracking of mitochondria difficult
at later time points.
We attempted to measure the tGFP mitochondrial presence in injured
spinal cords after 6 weeks, but only one instance of dispersed punctate tGFP
mitochondria was evident and could only be visualized at high magnification.
These studies attempt to discern the tGFP label for identification of exogenous
mitochondria, though the presence of exogenous mitochondria could be
established by utilizing a xenogenic transplantation model. Not only could we use
species-specific mitochondrial antibodies that will not dissipate over time (Kaza
et al 2016), but we could also perform quantitative real-time PCR (qRTPCR) on
the mtDNA to quantify exogenous mitochondria.
Others have measured mtDNA to demonstrate transfer in vitro. We used
PC-12-Adh cells originating from the rat Rattus norvegicus as our source of
donor mitochondria and transplanted into the Sprague Dawley strain of Rattus
norvegicus rats. We transplanted mitochondria between like-species based on
previous published studies suggesting mitochondrial uptake occurs more
prevalently when like-species are used (Clark & Shay 1982, Yang & Koob 2012).
However, the differences in the mtDNA may not be enough to discern between
host and exogenous mitochondria. Alternatively, other studies have performed
xenogenic transfer with successful incorporation. Future studies may employ
xenogenic transplant after SCI so that the host and donor mtDNA can be
differentiated and quantified using real time qRTPCR. This will allow
quantification at chronic time points that is more dependable than tGFP
immunolabeling, possibly giving more insight into the time-dependent uptake and
maintenance of transplanted mitochondria.
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Additional metrics of successful incorporation need to be investigated.
Evaluating the health of exogenous mitochondria after they have been
incorporated into cells is an important measure, such as maintenance of
membrane potential. One possible way of testing this immunohistologically is by
co-labeling the tGFP mitochondria before transplantation with MitoTrackerRed
CMXRos, a membrane-potential mitochondrial marker. Utilizing fluorescent
microscopy, the proportion of mitochondria in situ that have both the tGFP tag
and MitoTracker Red fluorescence, indicating transplanted mitochondria that
maintained membrane potential, can be evaluated. Additionally, we can define
successful incorporation as exogenous mitochondrial integration into the host cell
mitochondrial network. in vitro studies can utilize transgenic labeling of host cell
mitochondria with DsRed, then co-incubation with isolated tGFP mitochondria.
Live time-lapse imaging allows tracking of tGFP mitochondria movement within
the cell, and fusion events that result in co-localization with DsRed host
mitochondria. To test this in vivo, a transgenic rat line that has DsRed-labeled
mitochondria could be created. Upon transplantation of tGFP mitochondria after
SCI, we will be able to track the fusion, or co-localization, of tGFP mitochondria
with the endogenous DsRed-labeled mitochondrial network. Alternatively, there is
a mouse line currently available that has a yellow fluorescent protein that targets
mitochondria of neuronal cells that can be used in the same manner (JAX Labs,
Bar Harbor, ME). Using a mouse line as the recipient of PC-12 tGFP
mitochondria would further allow for qRTPCR (see previous paragraph) to
corroborate our findings of exogenous mtDNA with fluorescent microscopy
indicating the presence of exogenous tGFP mitochondria.
One method that could be extremely helpful in our characterization studies
is FACS flow cytometry. At a timepoint after transplantation, the spinal cord will
be dissected and homogenized as the first step of mitochondrial isolation. This
homogenate includes all different cell types of the spinal cord. Fluorescently
labeling one cell type at a time will allow measurement of the proportion of that
cell with and without tGFP mitochondria, thus quantifying uptake propensity.
When homogenate samples undergo mitochondrial isolation procedures, the final
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sample includes both endogenous mitochondria and tGFP mitochondria. These
mitochondria can be sorted based on whether or not they have the fluorescent
tag, and their OCR values can be compared. Comparisons can be made
between the bioenergetics within the endogenous mitochondria population of
vehicle-injected animals to mitochondria-injected animals. This allows evaluation
of whether mitochondrial transplantation benefits the health and survival of host
mitochondria. The two mitochondrial populations can be further assayed for
membrane potential, calcium buffering capacity, and fusion and fission proteins.
Once methods have been further refined to quantify incorporation of
exogenous mitochondria both in vitro and in vivo, studies can be performed to
discern possible mechanisms of isolated mitochondrial uptake. Multiple
mechanisms of incorporation have been proposed, though there is currently not a
consensus on the matter (see Chapter 2.4). It is widely accepted that
mitochondria are of bacterial origin. Moreover, there are many types of bacteria
up to 5um in size that can successfully enter into a cell where they can reside
and replicate. Therefore, we theorize that it may be possible that the mechanism
used by bacteria for host cellular infiltration is similar to that used by isolated
mitochondria for incorporation. Like bacteria, mitochondria may have proteins on
their surface that bind to receptors on host cell surfaces, initiating a zipper-like
actin-mediated phagocytosis. This zipper-like mechanism of incorporation can
utilize different receptors such as integrin for binding and signaling (for review of
bacterial invasion methods see Cossart & Sansonetti 2004). Interestingly, it was
found that neuronal internalization of mitochondria-containing particles in vivo is
dependent upon integrin-mediated Src/Syk signaling pathways (Hayakawa et al
2016). Further comparisons must be made between bacteria and mitochondria to
determine if they share a conserved cell surface protein that interacts with host
cell receptors.
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6.4 Summary of Thesis
The data and conclusions derived from the studies of this dissertation
investigate different facets of mitochondrial transplantation after traumatic SCI.
We have described the importance of healthy mitochondrial function, as well as
the involvement of dysfunctional mitochondria in the pathophysiology of SCI. This
was followed by a thorough discussion of the current state of the mitochondrial
transplantation field. Importantly, we are the first to transplant exogenous
mitochondria in a model of spinal cord injury. Different experimental techniques
were explored to best test the effects of mitochondrial transplant. Transgenicallylabeled cell culture-derived mitochondria were characterized for their use as the
exogenous mitochondrial source and were found to possess an indelible
fluorescent marker that could be tracked both in vitro and in situ. In vivo studies
showed that transplanting either culture or leg muscle-derived mitochondria
acutely maintained bioenergetics of the injured spinal cord. tGFP mitochondria
co-localized within a multitude of cell types, though at various percentages
indicating that incorporation is cell-type dependent. Co-localization was also
time-dependent, as evidence of tGFP mitochondria significantly declined at 7
days, and was all but absent at 6 weeks post injection. Hindlimb functional
recovery and tissue sparing were not improved with mitochondrial
transplantation, though multiple alternative approaches are addressed that may
increase the efficiency of incorporation and thus benefits of mitochondrial
transplantation.
While optimization of therapeutic techniques can be further refined, we
have shown feasibility for transplantation after SCI. Further systematic
characterization is necessary to fully understand the intricacies of transplantation
paradigms, but I believe that mitochondrial transplantation can be developed into
a viable option for treatment after SCI as well as other injury and disease states
in which dysfunctional mitochondria are implicated.
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Appendix 1. Abbreviations
ADP

Adenosine diphosphate

AIF

Apoptosis inducing factor

ALC

Acetyl-L-carnitine

AMPA

α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

ANOVA

Analysis of variance

ATP

Adenosine triphosphate

BBB

Basso, Beattie, Bresnahan overground locomotor scale

CAP

Chloramphenicol

CNS

Central nervous system

CPG

Central pattern generator

CTVT

Canine transmissible venereal tumor

DAMPs

Damage-associated molecular patterns

DMSO

Dimethyl sulfoxide

ECCV

Eriochrome Cyanine-Cresyl Violet

EGTA

Ethylene glycol tetraacetic acid

ETC

Electron transport chain

EtOH

Ethyl alcohol

ETS

Electron transport system

FACS

Fluorescence-activated cell sorter

FADH

Flavin adenine dinucleotide

FCCP

Carbonilcyanide p-trifluoromethoxyphenylhydrazone

hsCRP

High-sensitivity C-reactive protein

IL-6

Interleukin 6

IMM

Inner mitochondrial membrane

MEND

Massive endocytosis

MERFF

Myoclonic epilepsy with ragged-red fibers

mBMSC

Mouse bone marrow derived stromal cells

MnSOD

Manganese superoxide dismutase

MPTP

Mitochondrial membrane permeability transition pore

mtDNA

Mitochondrial DNA
131

MTG

MitoTracker Green FM

NACA

N-acetylcysteine amide

NADH

Reduced nicotinamide adenine dinucleotide

NMDA

N-methyl-D-aspartate

NSAIDs

Non-steroidal anti-inflammatory drugs

OCR

Oxygen consumption rate

OGD

Oxygen glucose deprivation

OH-

Hydroxyl radicals

PBS

Phosphate buffered saline

PCR

Polymerase chain reaction

PD

Parkinson’s Disease

PFA

Paraformaldehyde

PPARγ

Peroxisome proliferator-activated receptor gamma

qRTPCR

Quantitative real-time PCR

RCR

Respiratory control ratio

RNS

Reactive nitrogen species

ROI

Region of interest

ROS

Reactive oxygen species

RT

Room temperature

SCI

Spinal cord injury

TBARS

Thiobarbituric acid-reactive substances

TEM

Transmission electron microscopy

tGFP

Turbo green fluorescent protein

TMRE

Tetramethylrhodamine Ethyl Ester

TNF-α

Tumor necrosis factor alpha

TUNEL

TdT-mediated dUTP nick-end labeling
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